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Abstract 
During the past two decades, oligonucleotide analogues have drawn considerable 
attention as potential therapeutic and diagnostic agents. Gene silencing through "RNA 
interference" (siRNA) or the more mature "antisense" technology (AONs) have proven to 
be powerful tools for studying gene functions. Chemical modifications of these 
compounds are generally required to improve their "drug-like" properties such as potency, 
selectivity and delivery, particularly in the development of oligonucleotide-based 
therapeutics. Aptamers are another emerging class of oligonucleotide therapeutics and 
diagnostics. 
This thesis focuses on oligonucleotides containing 1-(2-deoxy-2-a-C-
hydroxymethyl-~-D-ribofuranosyl)thymine (2'-a-hm-dT, abbreviated as "H") and 2'-
deoxy-2'-fluoroarabinonucleotides (2'F-araN), and their applications. A major 
component of this work focused on the synthesis of 2'-a-hm-dT (H) and the first 
investigation of oligoribonucleotides containing this nucleoside analogue. Specifically, 
2'-CH20-phosphoramidite and 3'-O-phosphoramidite derivatives of H were synthesized 
and incorporated into both 2',5'-RNA and RNA chains. Incorporation of 3',5'-linked H 
units into a DNA, 2',5'-RNA or RNA strand led to significant destabilization of duplexes 
formed with unmodified RNA targets. 2',5'-Linked H units into 2',5'-RNA or RNA 
caused significantly less destabilization, and in fact, they were shown to stabilize the loop 
structure of sorne RNA hairpins. These results were rationalized in terms of the 
"compact" and "extended" conformations of nucleotides. 
A series of branched RNAs (Y -shaped) related to yeast pre-rnRNA splicing 
intermediates were synthesized incorporating both natural (i.e., ribose) and nonnatural 
(i.e., H, and acyclic nucleoside) branch points in order to examine the effect of sugar 
conformation and phosphodiester configuration on yeast debranching enzyme (yDBR) 
hydrolytic efficiency. The results indicate that 2'-phosphodiester scission with yDBR 
occurs only with a ribose-phosphate backbone at the branch point, whereas sorne of the 
H-containing branched RNAs were found to competitively inhibit yDBR hydrolytic 
activity. 
III 
This thesis also examines the stabilization of DNA guanine-quadruplexes (G-
quadruplexes) by replacing the deoxyribose sugar by a 2-deoxy-2-fluoroarabinose. The 
effect of this substitution was assessed in the well-known thrombin-binding DNA 
aptamer d(G2T2G2TGTG2T2G2), the telomeric DNA d(G4T4G4) sequence and a 
phosphorothioate octanucleotide PS-d(T 2G4 T 2), aIl of which are known to foid into G-
quadruplex structures. Stabilization of the G-quadruplexes was possible provided that the 
arabinose sugar was introduced at guanosine residues adopting an anti N-glycosidic bond 
conformation. Sorne of the arabinose modified thrombin-binding aptamers not only 
exhibited superior thermal stability and nuclease resistance, but also maintained high 
thrombin binding affinity. 
FinaIly, this thesis examines the ability of DNA polymerases to recognize and 
utilize 2' -deoxy-2' -fluoro- ~-D-arabinonucleoside 5' -triphosphates (2 'F -araNTPs) as 
building blocks for the synthesis of 2'-deoxy-2'-fluoro-~-D-arabinonucleic acids (2'F-
ANA). The results obtained indicate that a few DNA polymerases can synthesize 2'F-
ANA and 2'F-ANA-DNA chimeras on a DNA template. Conversely, certain enzymes 
were shown to catalyze 2'F-ANA template-directed DNA synthesis. While it was not 
possible to synthesize 2'F-ANA strands on a 2'F-ANA template, it is possible for sorne 
DNA polymerases to catalyze the formation of multiple 2'F-ANA:2'F-ANA base pairs 
within a DNA-FANA chimeric duplex. These results suggest that it should be possible to 
evolve FANA-modified aptamers via SELEX. 
IV 
Résumé 
Au cours des deux dernières décennies, une attention particulière a été portée à 
l'utilisation des oligonucléotides tant sur le plan diagnostique que thérapeutique. Par 
exemple, l'inactivation épigénétique post-transcriptionnelle comme l'ARN interférant 
(ARNi) et la technologie plus maîtrisée des oligonucléotides antisens (OA) se sont 
révélés de bons outils pour l'étude de la fonction des gènes. Des modifications chimiques 
sont généralement nécessaires pour améliorer leurs propriétés thérapeutiques, notamment 
l'efficacité, la sélectivité et la libération, en particulier dans la mise au point des thérapies 
basées sur des oligonucléotides. Les aptamères représentent une autre façon émergente 
d'utiliser les oligonucléotides sur les plans diagnostique et thérapeutique. 
Dans cette thèse, nous nous concentrons sur deux modifications chimiques 
importantes, la 1-(2-désoxy-2-a-hydroxyméthyl-~-D-ribofuranosyl)thymine (ou 2'-a-hm-
dT, abrégé H) et l'acide 2'-désoxy-2'-fluoro arabinonucléique (2'-AFAN), et leurs 
applications. Une des parties importantes de la thèse concerne la synthèse de H et la 
première investigation des oligoribonucléotides contenant cette modification chimique. 
Spécifiquement, les dérivés 2'-CH20-phosphoramidite et 3'-O-phosphoramidite de H ont 
tous deux été synthétisés et incorporés dans des chaînes de 2',5'-ARN et d'ARN. 
L'incorporation de la modification H lié en 3',5' dans les brins d'ADN, ARN ou 2',5'-
ARN déstabilisait de façon significative les duplexes formés avec un brin d'ARN 
complémentaire. Par contre, le H lié en 2',5' a un effet déstabilisant moindre sur les 
duplexes 2',5'-ARN/ARN et ARN/ARN, et peut même stabiliser les boucles de quelques 
structures d'ARN en épingle à cheveux. Ces résultats ont été rationalisés en termes de 
conformations compactes ou allongées des nucléotides. 
On a synthétisé une série de ARN s branchés (en forme de Y) qui sont similaires 
aux intermèdes de l'épissage pre-ARNm en levure, qui incorporent les points de 
branchement naturels (i.e. ARN) et modifiés (i.e. H, et nucléoside acyclique), pour 
examiner l'effet de la conformation du sucre et la configuration du phosphodiester sur 
l'efficacité de l'hydrolyse de l'enzyme du débranchement en levure (yDBR). Les 
résultats indiquent que le clivage du 2'-phosphodiester est possible seulement avec un 
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squelette naturel (ribose-phosphate) aux points de branchement. Certains des ARNs 
branchées qui contenaient H sont des inhibiteurs compétitifs de yDBR. 
Une autre partie de la présente thèse traite de la stabilisation de la structure en 
quadruplexe de guanine (G-quadruplexe) par le remplacement du sucre désoxyribose par 
2'-désoxy-2'-fluoroarabinose. Cet effet a été souligné dans un aptamère ADN de liaison 
avec la thrombine d(G2T2G2TGTG2T2G2), dans un télomère ADN d(G4T4G4) ainsi que 
dans un octanucléotide phophorothioate PS-d(T 2G4 T 2), qui possèdent tous des structures 
G-quadruplexe. On observe une stabilisation et un maintien de la conformation G-
quadruplexe tant que les unités 2'-AFAN remplacent les guanosines anti (anti-Gs). Il a 
aussi été démontré que les aptamères de liaison avec la thrombine modifiés par des unités 
2'-AF AN offrent non seulement une stabilité thermale et une résistance aux nucléas es 
supérieures, mais aussi un maintien de l'affinité de liaison avec la thrombine. 
Finalement, cette thèse examine la capacité des polymérases de reconnaître et 
utiliser les arabinonucléosides 2'-désoxy-2'-fluoro-5'-triphosphates (2'F-araNTP) comme 
précurseurs pour la synthèse de l'acide 2'-désoxy-2'-fluoroarabinonucléique (2'-AFAN). 
On a trouvé que certaines polymérases peuvent synthétiser la 2'-AF AN ou les chimères 
ADN-2'-AFAN sur un précurseur de brin en ADN. Inversement, certaines enzymes ont 
pu catalyser la synthèse de l'ADN sur un précurseur de brin en 2'-AFAN. Tandis qu'il 
n'est pas possible de synthétiser la 2'-AFAN sur un précurseur de brin en 2'-AFAN, 
certaines polymérases ont la capacité de catalyser la formation de plusieurs paires de 
bases 2'-AFAN: 2'-AFAN au sein d'un duplexe chimérique ADN: 2'-AFAN. Ces résultats 
suggèrent qu'il serait possible de créer des aptamères contenant de la 2'-AFAN par 
l'évolution in vitro (SELEX). 
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CHAPTERI 
Chapter 1 
CHAPTER 1: General Introduction 
1.1.lmportance of Nucleic Acids[1,2) 
The elucidation of the double helical structure of deoxyribonucleic acid (DNA) by 
Watson and Crick[3] signified the beginning of our understanding of life at a molecular 
level. Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) play significant roles as 
the information carrying molecules in cells. They are known to be involved in a pathway 
of information flow within cells that has been termed the Central Dogma of Molecular 
Biology. [4] Briefly, DNA is the storage medium of all genetic information and passes that 
information along through RNA, via the transcription process, to protein, via the 
translation of RNA. Transcription is the process by which an RNA molecule is 
synthesized on a DNA template by an enzyme RNA polymerase. Translation is the 
process by which an amino acid sequence (polypeptide) is assembled from an RNA 
molecule. DNA can also make copies of itself for cell propagation via the replication 
process catalyzed by DNA polymerase and faithfully transfer the genetic information 
from one generation to another. One notable exception to the central dogma is found in 
retroviruses, such as human immunodeficiency virus (HIV), where viral genetic 
information is stored as RNA and is first reverse transcribed into DNA for eventual 
integration into the host DNA. 
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2 
QI 
"tI 
.. 
o 
QI 
U 
::J 
Z 
furanose NH heterocyclic bases 1 
sugar :rl 2 / ~ ~ \ N ~N ïii 3-[0~N 1 A) Adenine ~ 
~ N ~ 
~,.,O R NJNH -o~P'o ~ -l~A Guanine 
/ '1--0_ .. / N NH2 
Phosphate )---( 
ORO \....,0 X'é -O~P---' 1 T/UNH Thymine: X=CH3 
0'1--0 -"::: ~ Uracil: X=H HN 0 
o R NH2 ~,.,O AN -o~ '0 tCÀ Cytosine 
A:T(U) 
H 
Chapter 1 
,=N 1 ' ~N-H--O X 
-v-N ~ ~ (0 
A N----H-N T " 
N""::/ #-N 
o '1. 
G:C 
H 
1 
N O----H-N 
tH h 
,J'N--( G ;N-H----N, C ) 
N=( )-N 
N-H---O "z 
1 
H 
Watson-Crick base pairing ~N 0 
3'0 R DNA:R=H,X=CH3;RNA:R=OH,X=H 
~ 
Figure 1.2: Primary structure of 2'-deoxyribonuc1eic acid (DNA) and ribonuc1eic acid 
(RNA) and the Watson-Crick base paring of complementary nuc1eoside bases (A:T(U); 
G:C) 
From a chemical point of view, the primary structure of both DNA and RNA is a 
linear polymer composed of repeating monomeric nucleotide units (Figure 1.2). A 
nuc1eotide consists of three molecular sub-units, namely a sugar, a phosphate linkage and 
a heterocyc1ic base. The term "nuc1eoside" refers to a structure comprised of one of four 
heterocyc1ic bases attached through a ,B-glycosidic linkage to a cyc1ic furanoside ribose or 
deoxyribose sugar. A nuc1eotide, there fore , is a nuc1eoside phosphorylated at the 3' 
and/or 5'-hydroxyl (-OH) group of sugar. The heterocyc1ic bases are divided into purines 
inc1uding adenine (A) and guanine (G), and pyrimidines inc1uding cytosine (C) and 
thymine (T) in DNA, while RNA substitutes uracil (U) for T. The whole nuc1eic acid 
strand is connected through a phosphodiester linkage in a defined direction, that is, 3'->5' 
connectivity (Figure 1.2). 
The biological importance of nuc1eotides in DNA is not in their local structure but 
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rather in their length and sequence, in other words as the genetic codes. Even though 
there are only four common heterocyc1ic bases, the number and sequence in which their 
corresponding nuc1eotides may be organized in DNA can vary in extraordinary ways. 
Another recent breakthrough in biological sciences has been the actually deciphering of 
these codes in the human genome. Since the veil was lifted[5] for the first time on the 
complete picture of human genome, we have had to humble ourselves in imagining how 
such a simple system is able to control the activities necessary to life in such a 
sophisticated way. There is still a long way to go in actually understanding exactly how 
these codes are related to certain biological activities, therefore, furthering the 
understanding of nuc1eic acids and their applications in biology and medicine certainly 
will benefit human well-being. 
1.2 Secondary Structure of Nucleic Acids 
DNA has been shown to adopt different structural polymorphs. The two helical types 
most commonly found in nature are called the A-form, present in low humidity 
conditions and high salt concentration, and the B-form, existing in high humidity 
conditions with low salt concentration (Figure 1.3). These two conformations of helices 
both display right-handed rotations with two antiparallel strands. The strands recognize 
each other through Watson-Crick base-pairing, where A pairs with T (or U in RNA) 
through two hydrogen bonds while G pairs with C through three hydrogen bonds (Figure 
1.2). The duplex is further stabilized by hydrophobic interactions and base stacking 
(n-n-interaction) among the flanking heterocyc1ic bases at the interior of the he1ixyl Both 
A- and B-form helices possess characteristic structure parameters as shown in Figure 1.3. 
Overall, A-DNA is wider, more compact, with more bases per tum, and more tilted from 
the helical axis as compared with B-DNA. The double helix may also be defined by the 
two types of grooves found in both A and B forms, namely the minor and major grooves. 
In A-form, the major groove is narrow and deep and the minor groove broad and 
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Figure 1.3: Global helical conformation and average structure parameters for nuc1eic 
acids of A and B form (adapted from Blackburn and Gait, 1996[21) 
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shallow; while in B-form, the major groove is wide and deep and the minor groove 
narrow and deep (Figure l.3). The DNA structure originally proposed by Watson and 
Crick[3] is a B form helix. On the other hand, RNA, which exists predominantly in a 
single stranded form in cells, pre fers an A-form conformation with a complementary 
RNA strand. The 2'-OH groups in RNA would have steric conflict with the phosphate 
linkage and the heterocyclic base if RNA were to adopt a B-form helix. Finally, RNA is 
more susceptible to hydrolysis of the phosphate linkages due to the possibility of 
neighboring group participation of the 2'-OH, which probably explains why DNA was 
chosen to store the genetic information. [6] 
1.3 Shapes of Nucleosides and Nucleotides [1] 
The overall shape of a nucleoside or nucleotide can be measured by bond lengths, bond 
angles and rotations of groups of atoms. These rotations, expressed as a torsion angles, 
are important stnce they de fine the overall conformational detail of 
nucleoside/nucleotide units (Figure lA A). According to IUPAC nomenclature, [2] torsion 
angles are expressed as Greek letters, including a, ~,y, 6, G, S in the phosphate backbone, 
Uo - U4 in the furanose ring, and X for the glycosidic linkage (Figure lA A). Since many 
of these torsion angles are interdependent, a complete description of the shape of 
nucleosides involves three principal parameters: (1) the glycosidic torsion angle X (Figure 
lA A) that determines the syn or anti disposition of the base relative to the sugar moiety 
(anti when the H6 of pyrimidines or H8 atom of purines lies above the sugar ring, such as 
anti-cytidine shown in Figure lA B; syn when these atoms are oriented in the opposite 
direction such as syn-guanosine in Figure lA B);[7,8] (2) the torsion angle y, which 
determines the orientation of C4'-C5' represented by three main rotamers, namely, +sc, ap, 
-sc (Figure lA C); and (3), more commonly discussed, the sugar pucker and its deviation 
from planarity (Figure lA D). Sugar pucker is described by the maximum out-of-plane 
pucker U max and the phase angle ofpseudorotation P (0 - 360°) which are correlated with 
the equation U max = Uo / cos P). [9,10] The value of P depends on the five endocyclic sugar 
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torsion angles Uo - U4. The conformation of the furanose ring around the pseudorotational 
cycle altemates every 18° between envelope (E) and twist (1) conformations. By 
convention, the sugar pucker is called north, or C3'-endo, at 0°:::; P :::; 36° and south, or 
C2'-endo, at 144°:::; P:::; 190°. An absolute north conformation possessing a symmetrical 
twist form 3T2 (P = 0°), its south antipode, 2T3 (P = 180°), and an east conformation °E (P 
= 90°) are shown in Figure 1.4 D. The superscripts and subscripts represent, respective1y, 
atoms displaced above or below the plane relative to other atoms in the five-membered 
ring. Atoms displaced on the same side as CS' are referred to as endo and those on the 
opposite side are termed exo.[1I,12] Sugar conformation is influenced by the substitution 
on the sugar ring, the orientation of the base (anti and syn) and other factors. 
Ideal B-DNA is C2'-endo (South) and ideal A-RNA is C3'-endo (North) (Figure 
1.2). In this thesis, chemical modifications are often discussed in terms of their influence 
on the shapes of nucleosides/nucleotides, which help to explain sorne of the interesting 
properties that these modifications have elicited (discussed in detail in Section 1.8.1). 
1.4. RNA Splicing and Intron Branched Structure 
RNA splicing is a post-transcriptional event that excises non-coding introns and links 
coding exons. [13,14] The intron excisions result in intermediate, branched ribonucleic acids 
(bRNAs) structures containing vicinal 2'-5' and 3'-5' phosphodiester linkages at the 
branch point (Figure 1.5). Branched RNA was first detected in nuclear polyadenylated 
RNA from HeLa cells by Wallace and Edmons[15] and these species were subsequently 
shown by others to be rnRNA splicing intermediatesY 6] Since then, two unique branched 
RNA configurations have been detected: loops with a tail containing a branch point (i.e., 
a "lariat" configuration) in monomolecular cis-splicing reactions, [16] or branches between 
two linear RNAs (i.e., a "Y"-like structure) in the case of bimolecular trans-splicing 
reactionsY7] Both in yeast and in mammalian cells, the branch point nucleotide is an 
adenosine,[18,19] which can have stronger base stacking ability within the branch structure 
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than other RNA branch points. This could be a possible reason why alliariat RNA introns 
conserve adenosine. [20] 
Branched RNAs are not stable in cells and are hydrolyzed by a specific enzyme 
that was first identified in HeLa cell extracts and named the RNA lariat debranching 
enzyme. [21] The enzyme is involved in the intron turnover pathway found in mammalian 
cells[21] and in yeast[22,23]. The yeast lariat debranching enzyme (yDBR) is a unique 
manganese-dependent phosphodiesterase, which selectively c1eaves the 
2'-5'-phosphodiester linkage at the branch site of either lariat or Y-shaped introns, thus 
converting them into linear molecules (Figure 1.5).[24] yDBR does not digest 3'-5' 
phosphodiester bonds differentiating it from snake venom phosphodiesterase, which 
c1eaves both 2'-5' and 3'-5' phosphodiester bonds. Debranching efficiency of yDBR is 
highly substrate-specific. Previous studies have shown that the branch point adenosine is 
more favored than other natural counterparts[25,26] and chemically modified branch points 
with different sugar conformations and phosphodiester configurations result in 
inactivation of debranching activity.[27] A vicinal 3'-5' phosphodiester bond (i.e. one 
nuc1eotide connecting to the 3' position) at the branchpoint is required since yDBR 
cannot not hydrolyze a 2'-5' connection in a linear fashion.[21] The nuc1eotide directly 
connected to the branchpoint is also important to the debranching activity and a 2'-purine 
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Figure 1.5: A lariat intron RNA undergoes debranching (the arrow shows the c1eavage site) 
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(A) is debranched more efficiently than either of the 2'-pyrimidines (C/T).[26,28) Synthetic 
Y-shaped RNAs have been shown to be valuable tools for understanding the molecular 
requirements of RNA splicing[29) and debranching[24,26,27) with the help of the 
development of branched oligonucleotide synthesis methodologies (see Section 1.5.1 
Y-shaped RNA solid-phase synthesis).[30-32) 
1.5 Solid Phase Oligonucleotide Synthesis 
Solid phase synthesis was first applied to polypeptide preparation by Merrifield[33) and 
Letsinger[34] and later adapted to oligonucleotides by Letsinger. [35) The advantages of 
solid phase synthesis include the fact that reactions can be forced to high yield end points 
by using a large excess of soluble monomers and coupling reagents; the covalent 
attachment of the growing chain to a solid support facilitates separation and purification; 
and the assembly of oligomers can be automated. The phosphite triester method has been 
the most popular chemical route for DNA synthesis. The method was initially developed 
by Letsinger and later refined by Beaucage and Caruthers. [36-39) Controlled pore glass 
(CPG) is widely applied as a solid support due to its uniform pore size and non-swelling 
feature during synthesis. It can be easily functionalized, first with a long chain 
alkylamine moiety (LCAA), followed by a succinyl linker[40) and the first 5'-protected 
nucleoside (Figure 1.6A). Recently a "univers al linker" has been developed and been 
found to be extremely convenient for synthesizing modified oligonucleotides (Figure 
1.6B). [41) Other polystyrene-based supports are available and allow for very high loading 
of nucleoside. 
Spacer (e.g. succinyl) 
Long·Chain Alkylamlne (LCAA) 
Figure 1.6: (A) Solid support for oligonucleotide synthesis and (B) a "unilinker" (ChemGene) 
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The rnonorners used for the autornated solid phase synthesis use orthogonal protecting 
groups for heterocyclic bases and the 5'-OH (and 2'-OH in RNA) (Figure 1.7). The 
protecting groups for bases are introduced by acylation of the exocyclic arnino groups of 
adenine and cytosine with benzoyl (Bz) groups and guanine with the iso-butyryl (i-Bu) 
group. The 5'-OH is usually protected by a trityl group, either 4'-rnonornethoxytrityl 
(MMT) or 4',4'-dirnethoxytrityl (DMT),[42,43] which can be easily rernoved under rnild 
acid condition during each synthesis cycle. Furthermore, the coupling efficiency can be 
quantitated by rneasuring the coloured trityl cations via spectrophotornetry in the visible 
region during the detritylation step (Figure 1.8). The rnost cornrnon protecting group for 
2'-OH in RNA is the tert-butyl dirnethylsilyl (TBDMS) groups originally ernployed in 
nucleosides by Ogilvie and coworkersJ44,45] TBDMS is stable to the rnild acid and base 
conditions ernployed in solid-phase cycles and can be rernoved in the presence of fluoride 
ions. [46] The phosphorarnidite rnoiety is protected by a ~-cyanoethyl protecting group, 
which is stable in synthesis cycles and only rernoved during the oligonucleotide 
deprotection step. 
S'-O-Trityl Protecting group 
MMT: R1=OCH3• R2=H 
DMT: R1• R2=OCH3 
Figure 1.7: Building block (phosphorarnidite) in DNA solid-phase synthesis 
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The automated solid-phase DNA synthesis strategy VIa the phosphite triester 
approach is shown in Figure 1.8. Briefly, the DNA synthesis cycle starts with the 
cleavage of the 5'-protecting group by acid treatment to afford the free 5'-hydroxyl group, 
followed by the coupling with next monomeric 3'-phosphoramidite in the presence of an 
activator such as tetrazole. Since the coupling reaction may not be quantitative, any 
unreacted 5'-OH is "capped" by acetylation. Oxidation of the trivalent phosphite triester 
to a more stable pentavalent phosphate triester is achieved using aqueous iodine. [38,39] 
Repeating the synthesis cycle N-times results in oligonucleotide products with N+ 1 
nucleotides (Figure 1.8). The DNA oligonucleotides are then cleaved under basic 
condition (aqueous ammonia) and purified by HPLC or polyacryamide gel 
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electrophoresis (PAGE). An extra step is required for RNA deprotection to remove the 
silyl protecting group on 2'-OH with a fluoride reagent such as tert-butylammonium 
fluoride (TBAF)[44,45] or triethylamine trihydrofluoride (TREAT-HF).[47] 
1.5.1 Y-shaped Branched RNA Synthesis 
Solid phase synthesis to make linear oligonucleotides can be easily applied to making 
Y-shaped branched RNAs (bRNAs) using well-established convergent methodology 
developed by Darnha and coworkers.[31,48] Briefly, the introduction of the branch point 
nucleoside is achieved by coupling of two adjacent CPG-bound oligonucleotide chains 
with a 2',3'-bis-phosphoramidite. The coupling time of a bis-phosphoramidite is extended 
to 30 min and it is introduced at a lower concentration (0.01-0.03 M) than typical amidite 
solutions during solid phase synthesis. [32] A low bis-phosphoramidite concentration 
reduces the formation of mostly "extended" linear isomeric failure sequences when the 
branch point is connected with only one oftwo support-bound oligonucleotide chains. 
NHBz 
th 
N N DMT~ 
,0 0, 
(i-Pr)2N-~ ~-N(i-Prlz 
NC~O O~CN 
rA, branch point Branch point coupling 
, 
Figure 1.9 Convergent branched oligonucleotide synthe sis developed by Darnha and 
coworkers [31] (R=H in DNA; R=OTBDMS in RNA) 
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High CPG loadings (> 30 ~mollg) are required to ensure two vicinal oligonucleotide 
chains are close enough to react with the branch point bis-phosphoramidite. The 
y -shaped constructs are purified by denaturing PAGE based on a very characteristic gel 
mobility (slower) as compared with linear failure sequencesy2] 
1.6 Techniques Applied for the Study of Nucleic Acids 
Nucleic acids are often studied by various techniques to understand their structure, 
dynamics, binding characteristics and biological properties. A few common techniques 
employed in this work are described below. 
1.6.1 Ultraviolet (UV) Spectroscopyl491 
UV spectroscopy is the most commonly used technique to study oligonucleotides since 
they exhibit strong UV absorption around 260 nm as a result of absorption by the 
chromophoric purine and pyrimidine bases. UV absorption can be employed to quantitate 
the amount of oligonucleotides by measure the optical density units (O.D.U.). The 
measurement is very sensitive since the molar extinction coefficients of oligonucleotides 
are at the magnitude of 104 M-1 cm-1 per nuc1eotide. UV absorption can also be employed 
to measure the relative affinity of an oligonuc1eotide to a complementary oligonucleotide 
target. UV absorption profile obtained with the increase of temperature is called thermal 
melting curve from which the melting temperature (Tm) of a nucleic acid duplex is 
defined by the midpoint of thermal melting curve, indicating 50% of nuc1eic acid is in a 
duplex state and 50% in a single stranded state (dissociated). The fact that UV absorption 
decrease with the decrease of temperature is known as hypochromicity which arises from 
the dipole-dipole interactions of the bases when they stack. [50] The Tm experiment can 
offer insight to the kinetics and thermodynamic parameters of that system. For example, 
hysteresis observed in the heating and cooling process often suggests a slow kinetic 
process of duplex formation. Unimolecular complex (e.g. hairpin structure) formation 
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does not depend on concentrations, while intermolecular complex (e.g. intermolecular 
duplex, guanine-quadruplex) should be concentration-dependent III Tm 
measurement. [49,51,52] 
1.6.2 Circular Dichroism (CD) Spectroscopy[S3,S4] 
CD spectroscopy has been used as a highly sensitive but qualitative technique by nuc1eic 
acid chemists to study the conformation of nuc1eic acids in solution. CD spectra record 
the differential absorption of left- and right-handed circularly polarized light as a function 
of wavelength as a result of the chirality of oligonuc1eotides, providing a CD "pattern" 
that is related to the overall structure of oligonuc1eotides. For example, two canonical A 
and B-form duplexes show distinct CD characteristics: A-form shows positive peak at ~ 
265 nm, negative peaks at ~ 230 and 210 nm and a cross line at 240 nm; while B-form 
shows a positive peak at 280 nm, a negative peak at ~ 240 nm and a cross line at 260 nm. 
CD spectra are a sensitive probe to the conformation of other unusual nuc1eic acid 
structures. For example, CD spectra have been used to distinguish between parallel and 
antiparallel guanine-quadruplexes (See more information in Section 1.7.1). 
1.6.3 Electrophoresis[SS,S6] 
Electrophoresis serves as an important purification and characterization technique for 
rtuc1eic acid structures. Oligonuc1eotides, due to their polyanionic nature, can move 
through a porous gel under the influence of an electric field based on their charge, size 
and molecular shape. Usually small oligonuc1eotides move faster relative to larger 
molecules, and branched molecules move slower than linear molecules. The cross-linked 
polymer used in gel electrophoresis in this work is polyacrylamide and the density of 
cross-linkers depends on the amount ofpolyacrylamide used in the polymerization. These 
gels can be run under denaturing (with urea added and elevated temperature) or native 
conditions (no urea and low temperature). Denaturing gels are typically employed for 
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purification purposes, whereas native gels are used to assess the formation of a nucleic 
acids complex such as nucleic acid and prote in complex structure. The oligonucleotides 
can be visualized by UV shadowing or staining the gel bands with a dye such as 
StainsAll®(Bio-Rad). 
1.7 Other Secondary Structures of Nucleic Acids 
Since the DNA "alphabet" is made up of only four basic building blocks, far less than 
that of the proteome, DNA must have the ability to adopt multiple structural polymorphs 
and is required to be intrinsically more flexible in order to me et its biological roles in 
cells.[57,58] As mentioned in Section 1.2, aside from the two canonical A- and B-forms, 
DNA can adopt many other secondary structures. For example, Z_DNA[59,60] is a 
left-handed helix, contrasted to the right-handed rotation of the A- and B-form. In 
Z-DNA, the orientation of the glycosidic bonds among the bases altemate between the 
syn and anti conformations (Figure lA). Z-DNA is preferentially formed by a sequence 
of altemating purines and pyrimidines. Compared with anti-parallel strands found in A-
and B-form, double helices can also be organized in a parallel orientation. [61-64] In 
addition to the typical double stranded structure, DNA can also form triplexes (or 
triads)[52,65], quadruplexes (or tetrads) with an i-motif66] or a guanine (G)-quartet 
structure[67-69] (Figure 1.10), even higher ordered structures su ch as pentads, hexads and 
heptads (see review in this topiC[70,71]). These structures involve non-canonical 
hydrogen-bonding among base pairs, [72] stronger base stacking, base-backbone 
interactions, backbone-backbone interactions, interactions of the complex with solvent 
and the complex with metal ions. A good example, shown in Figure 1.10, is that of a 
DNA sequence with human telomeric repeats (a telomere is a specific nucleoprotein 
structure at the end of eukaryotic chromosomes, which is essential for chromosome 
stability[73,74]). The pair of oligonucleotides consisting of a telomeric DNA with the 
sequence 5'-d(AGGG(TTAGGG)3)-3' and its complementary strand is able to form a 
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typical duplex by Watson-Crick 
base pairing (A:T, C:G) together; 
a unimolecular i-motif 
quadruplex by C:C+ base pairing 
(C+ refers to a protonated 
cytosine) involving the 
complementary strand alone, and 
aG-quadruplex by G:G base 
pamng involving the telomeric 
DNA strand alone. [75] The 
G-quadruplex structure will be 
focused on in the next section. 
1.7.1 G-quadruplex Structure 
G-quadruplex, by its name, is a 
four stranded nucleic acid 
structure containing a unique 
planar structural motif: G-quartet 
with four Hoogsteen G:G base 
pairs (Figure 1.11). The structure 
of G-quartets was first observed 
more than 40 years ago by 
Gellert et al. [67] when they found 
that guano sine 3'-monophosphate 
(3'-GMP) and 5'-monophosphate 
(5'-GMP) form 
hydrogen-bonded 
layers of 
tetramers. 
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Figure 1.10: Human telomeric DNA sequence 
5'-d(AGGG(TTAGGG)3-3' and its 
complementary strand can form different 
secondary structure: (A) G-quartet (left) and 
schematic structure of the intramolecular Na+ 
G-quadruplex (right). (B) C:C+ base pair (left) 
and schematic structure of the intramo1ecu1ar 
i-motif (right). (C) Watson-Crick A:T and G:C 
base pairs (left) and schematic structure of the 
Watson:Crick duplex (right). (adapted from Phan 
and Mergny 2004 [75] ) 
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They e1ucidated a planar structure where four guanines are arranged in a way that the 
N1-H and N2-H in one guanine forms hydrogen-bonds with the N7 and 06, respective1y, 
of another guanine (Figure 1.11). This structure is stabilized through the coordination of 
alkali-metal cations, particularly K+ and Na+, to the carbonyl oxygens (C=O) of the bases, 
otherwise the electrostatics of this cyc1ic arrangement would be unfavorable. [76] 
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Figure 1.11. Schematic presentation of the formation of G-quartet and G-quadruplex. 
Poorly defined aggregates are formed in the absence of cations. Cations can stabilize the 
formation of the planar G-quartets and helical G-quadruplex stacks (adapted from Davis, 
2004 [77]) 
Sen and Gilert[78] first demonstrated guanine-rich DNA oligonuc1eotides formed 
parallel 4-stranded complexes (i.e. G-quadruplex) with G-quartet structures. 
Subsequently, G-quartets have been shown to be the basic structural motif of 
G-quadrup1exes formed by a diverse number of guano sine-ri ch oligonuc1eotides in vitro. 
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These G-rich sequences are originated from biologically significant reglons of the 
genome, such as in telomeres (see below),[79,80] immunoglobulin switch regions,[78] gene 
promoter regions,[81,82] in sequences associated with human disease[83] and in sequences 
identified as potential therapeutics through screening techniques such as SELEX (see 
Section 1.8.3.1). Although these sequences have been demonstrated to form 
G-quadruplex structures in vitro, indirect evidence suggests that G-quadruplexes exist in 
vivo as weIl and are involved in important biological functions such as the stabilization of 
chromosome structure by telomeres.[73,74] The extreme 3'-end of telomeres consists of 
single-stranded G-rich DNA overhangs. [84,85] G-quadruplexes are thought to form in these 
regions and interact with telomerase, [86] an enzyme that adds a specific DNA repeat 
sequence, such as "d(TTAGGG)" for aIl vertebrates, to the ends of telomeres. Several 
small molecules have been shown to interact with G-quadruplexes and have been found 
to be credible selective inhibitors of telomerase, [87,88] suggesting G-quadruplexes are 
involved in telomerase binding and function. Further evidence for the existence of 
G-quadruplexes in vivo is found in the fact that the formation of G-quadruplexes can be 
promoted by certain proteins.[89-93] Lastly, the existence of G-quadruplexes in vivo is 
strongly supported by the discovery of helicases capable of unwinding G-quadruplex 
DNA. [94,95] 
Nuc1eic acid sequences containing G-quadruplex structures have drawn great 
attention not only for their biological functions in cells but also for their potential as 
therapeutic agents and as targets for anticancer therapeutics. [96] Nuc1eic acid 
quadruplexes have been demonstrated to inhibit human thrombin activity, [97,98] HIV 
infection,[98] HIV-l integrase activity,[99,IOO] and as candidates to inhibit telomerase 
activity in cancer cells. [lOI] Excellent reviews can be found to coyer different aspects of 
G-quadruplex activity in biology,[74,93,96] its biophysical properties,[I02,I03] structure[68,69] 
and uses in materials science. [77] 
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1.7.2 Polymorphism of G-quadruplexes 
G-quadruplexes display an extraordinary array of structural polymorphisms,l68,92,104] 
elucidated by a number of modem spectroscopy techniques including NMR spectroscopy, 
X-ray crystallography, thermal denaturation (see Section 1.6.1) and circular dichroism 
(see Section 1.6.2). Various G-quadruplex structures may be discussed through the 
following variations. 
1.7.2.1 Strand Stoichiometry 
A single sequence can form different types of structures by associating III various 
stoichiometries, for example four strands associating may form tetrameric 
G-quadruplexes (Figure 1.12A), while two strands may form dimeric G-quadruplexes 
(Figure 1. 12B,C,D,E,F), or a single strand may se1f-associate to form a unimolecuar 
G-quadruplex (Figure 1.12 G,H,I). Though complexes composed of three stranded 
structures can be imagined, none has been characterized to dateY04] 
1. 7 .2.2 Strand Alignments: Parallel and Antiparallel Configurations 
G-quadruplex strands can be assembled in both parallel or antiparallel alignments. As 
shown in Figure 1.12, d(TG4 T) (Figure 1.12A) forms linear intermolecular parallel 
structures; while dimeric edge-Ioop hairpins (Figure 1.12B, E, F) and unimolecular 
structures (Figure 1.12G) form in antiparallel orientations. Diagonal-Ioop hairpins 
(Figure 1.12C, D) and unimolecular G-quadruplexes (Figure 1.12H, 1) may contain a mix 
of parallel and antiparallel strands.[68] Previous studies have suggested that the parallel 
stranded structure is much more stableyo5] therefore short linear strands usually form 
parallel G-quadruplexes. [106] Loop connectivity, however, will change the strand 
alignments. edge-Ioops and diagonal-Ioop hairpins with the same sequences have 
different strand alignments, as shown in Figure 1.12. A recently reported unimolecular 
G-quadruplex d(AAAG3(T 2AG3)3AA)[I07] has an unusualloop structure leading to the 
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Figure 1.12 Schematic diagrams of a four-stranded linear quadruplex (A), sorne 
two-stranded dimeric hairpin quadruplexes and unimolecular quardruplexes, which are 
based on x-ray crystal structures of (A) [d(TG4T)]4[108] and (B) [d(G4T4G4)]}I09] and the 
NMR solution structures of (C) [d(G4T4G4)]zy lO,lll] (D) [d(G3T4G3)]z;[112-114] (E) 
[d(GCG2T3GCG2)h;[115] (F) [d(G3CT4G3C)h;[116,117] (G) d(G2T2G2TGTG2T2G2);[118,119] 
(H). d(TG4)4Y20] (1) d(AAAG3(T2AG3)3AA).[107] A solid line represents the sugar 
phosphate backbone. A solid circle indicates the 5' end of the strand and an arrow 
indicates the 3' end of the strand (adapted from Keniry, 2000 [104] except for (1)) 
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co-existence of paralle1 and antiparalle1 configurations, which again shows the amazing 
po1ymorphic versati1ity of G-quadrup1exes. 
1.7.2.3 Glycosidic Conformations (68) 
The studies of Mohanty and Bansa1[121] have suggested that G-quadrup1exes prefer 
specific sugar conformations. The guanosines that compose a G-quartet can adopt either 
entire1y syn glycosidic conformations (syn-Gs), entire1y anti conformations (anti-Gs), or 
a mix of both (the definition of syn and anti glycosidic conformation is shown in Figure 
1.4). It has been established that the strand a1ignments in G-quadrup1exes have a strong 
correlation to guanosine glycosidic conformations.[68] For examp1e, mo1ecu1ar mode1ing 
has indicated that a paralle1-stranded structure with exc1usive1y anti-Gs is more stable 
than a structure with altemating syn and anti-Gs and all syn-Gs; whi1e antiparalle1 
fo1d-back structures (e.g. hairpin dimeric G-quadrup1ex in Figure 1.12A-F) prefer the 
altemating syn-anti conformations. The theoretica1 calcu1ations support numerous 
G-quadrup1ex structures observed in experiments. [103,104] 
1.7.2.3 Ion-binding Geometry[103) 
Various cations (generally monovalent) interact with the G-quartet structures with 
differing binding affinities. The genera1 trend of monovalent cation-induced stabi1ization 
is found to be K+ > Rb + > Na + > Cs + > Li+. The fact that K+ is better than Na + in 
stabi1ization of quartets is like1y due to the difference in dehydration energy (K+ < Na l 
between the two rather than a better size match at the binding site of K+ over Na +. [103] A 
change in the type of cation bound to the G-quartet can have an effect on the cation to 
ligand stoichiometry. Furthermore, potassium-induced G-quartet structures can differ 
from their sodium-induced counterparts in terms of both stability and conformation. For 
examp1e, a te10meric DNA sequence d(G4T4G4) (Figure 1.12 B & C) can form two 
different kinds of dimeric quadruplex, with a diagonal 100p observed when Na+ is the 
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cation used (Figure 1.12 BillO,122] and an edge-Ioop when K+ is used (Figure 1.12 C)y09] 
1. 7.3 Three Examples of G-quadruplexes 
Three G-quadruplexes of relevance to this work are a thrombin-binding aptamer (Figure 
1. 12G), a te10meric DNA sequence (Figure 1. 12C), and an HIV infection inhibitor 
containing phosphorothioates linkages (Figure 1.12A). 
The thrombin-binding aptamer, generated via in vitro selection, is a 15 nuc1eotide 
long oligomer d(G2T2G2TGTG2T2G2i97] that has been intensively studied for its ability to 
bind and inactivate thrombin, a key enzyme in the blood c10tting cascade. NMR 
spectroscopy has revealed that it adopts a unique folded structure with two stacked 
G-quartets connected through edge-loops (one comprised ofTGT and two of TT) with an 
antiparallel alignment of adjacent strands (Figure 1. 12G). [118,119,123,124] A seemingly 
contradictory crystal structure of this aptamer-thrombin complex [125,126] was later 
shown to be in agreement with the previous NMR structure. [126,127] Potassium ions (K+) 
stabilize the structure of G-quadruplex by coordination to the G residues as previously 
discussed. [123] The G-quartet displays an altemating syn and anti conformation of 
guanosines (syn- and anti-Gs) within the same plane and 5'-syn-G/3'-anti-G confirmation 
along each strand of the quadruplex (i.e. 5'-syn-anti-3' connectivity where syn-Gs inc1ude 
G1, G5, GlO & G14 and anti-Gs inc1ude G2, G6, Gll & G15 in example G in Figure 
1.12) while all the thymidines are in the anti conformation.[J23] 
NMR and X-ray crystallographic analysis of a telomeric DNA sequence 
d(G4T4G4) has shown that it can form two kinds of symmetrical dimeric quadruplexes 
with four G-quartets via a diagonalloop in the presence ofNa+(Figure 1. 12C)[IIO,122] and 
an edge-loop formed in the presence of K+ (Figure 1. 12B). [109] The dimeric diagonal 
hairpin complex (Figure 1.12C) consists of 5'-syn-GI3'-anti-G along each G-strand, 
syn-syn-anti-anti conformations in a G-quartet and all deoxynuc1eotides in the south 
conformation. [122,128] 
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The final example is a therapeutically interesting G-quadruplex consisting of a 
phosphorothioate linked PS-d(T 2G4 T 2), which was first combinatoriallY selected for its 
inhibition ability of HIV envelope-mediated cell fusion during in vitro experiments (HIV 
infection). [98,129] PS-d(T 2G4 T 2) forms a parallel-stranded tetramer stabilized by four 
G-quartets with all anti-Gs, the same structure as that of PO-d(TG4 T) shown in Figure 
I.I2A. [78,98] 
1.8 Overview of Oligonucleotide-based Therapeutics and Diagnostics 
Chemically modified oligonuc1eotides have drawn great interest in the scientific 
community and in public eye for their important roles in gene silencing and regulations, 
and their tremendous potential for use in the development of innovative therapeutics and 
diagnostics. The different mechanisms of action and the various biological pathways that 
synthetic oligonuc1eotides are involved in as well as their applications will be briefly 
reviewed in this section. 
1.8.1. Antisense Oligodeoxynucleotides[130,l3l1 
Antisense molecules generally consist of a single strand of DNA, referred to as an 
antisense oligodeoxynuc1eotide (AS-ODN). The first demonstration of an AS-ODS to act 
as a gene silencing agent was reported by Zamecnick and Stephenson.[l32] Theoretically, 
chemically modified AS-ODNs can be introduced into cells and bind with very high 
specificity to targeted intracellular messenger RNA strands (rnRNA) through 
Watson-Crick base pairing (Figure 1.13). The binding of the AS-ODN to the rnRNA will 
arrest the translation machinery of the cell by physically blocking its progression along 
the rnRNA and then its presence may activate an RNA nuc1ease, RNase H,I133] an enzyme 
that recognizes DNAIRNA duplexes and selectively c1eaves the RNA strand, releasing 
the antisense strand (AS-ODN) untouched.[l3l,134] Though simple physical arrest of the 
translation machinery is effective in inhibiting gene expression, a therapy based on this 
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technique would reqU1re higher doses than one where RNase-H mediated rnRNA 
cleavage occurs. Eliciting RNase-H activity is thus desirable as it is much more efficient 
since it allows the AS-ODN to act catalytically, with a single antisense strand repeatedly 
involved in the rnRNA cleavage processes, allowing for a much smaller dose of 
therapeutic to be used. The length of AS-ODNs is typically 15-20 nucleotides in length in 
order to ensure optimal identification and binding of a unique targeted sequence, 
avoiding unintended silencing of other genesJ135,136] The ability of an AS-ODN to form a 
stable hybrid with rnRNA depends on its binding affinity and sequence-specificity, 
evaluated by determining the melting temperature (Tm), that is the temperature at which 
one half of a population of duplexes dissociate into single strands. The recognition of 
AS-ODN/RNA duplexes by RNase-H is, unfortunately, restricted to a small number of 
chemically modified, conformationally DNA-like nucleotidesY37] 
Figure 1.13: Different biological functions of synthetic oligonucleotides 
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1.8.2 Small Interfering RNA (siRNA)I1381 
Andrew Fire and Craig Mello were awarded the 2006 Nobel Prize for Physiology or 
Medicine for their discovery of RNA interference (RN Ai) in 1998. RNAi has been 
proven to be a powerful gene silencing mechanism triggered by long double-stranded 
RNA (dsRNA, 299nt long)Y39] RNAi most likely evolved as a natural defense 
mechanism against viral or bacterial infection. It was first observed in worms[139] and 
plants[140] and was then found in mammalian cellsY41] Silencing is achieved by the action 
of small interfering RNAs (siRNAs), 21 to 25 nuc1eotides long,P41-143] which is either 
generated in cells from longer dsRNA, through ATP-dependent c1eavage by an 
endogenous ribonuc1ease, a dsRNA specific RNase III enzyme called Dicer,[144] or 
introduced into cells as exogenous synthetic siRNAs.[141] These siRNAs are 
5'-monophosphorylated and have free hydroxyl groups at the 3'-termini. In addition, 
there are overhangs at the 3'-ends of each strand, consisting of two nuc1eotides each. 
siRNAs containing these overhangs are found to be much more effective in gene 
silencing than duplexes with blunt endsY43] Regardless of the source, the siRNAs are 
then taken up by an inactive ribonuc1eoprotein complex, in which A TP-dependent 
unwinding of the siRNAs by a helicase allows the antisense strand (guide strandp45] to 
bind to the targeted mRNA and yield an active RNA-induced silencing complex (RISC). 
The RNA target is then selectively c1eaved by a sequence-dependent endonuc1ease 
present in RISC (Figure 1.13)y46] This endonuc1ease contains the Argonaute proteins, 
whose crystal structure indicates that the Argonaute PIWI domain, responsible for the 
"Slicer" activity, is very similar to known RNase H structuresy47] RNAi has an antisense 
type of mode of action since it ultimately employs a single stranded RNA to bind to the 
target rnRNA through Watson-Crick base pairing, recruiting a ribonuc1ease to degrade 
the target (Fig. 1.13). Synthetic siRNAs have been shown to be more effective in gene 
silencing than AS-ODNs [141,148-150] and have great potential for use in the development of 
siRNA based therapeutics. [151,152] 
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1.8.3. Aptamers[153-157[ 
Oligonuc1eotide aptamers, usually derived from a Systematic Evolution of Ligands by 
EXponential enrichment (SELEX) process (see Section 1.8.3.1),[158-160] have drawn great 
attention for their potential as therapeutics and diagnostics. The word "aptamer" is 
derived from the Latin word "aptus" meaning "to fit" and the Greek "meros" meaning 
"part or region"). [159] Aptamers can form unique three dimensional structures that can 
selectively bind to almost any kind of molecular target inc1uding proteins,[161] nuc1eic 
acids[162] and small moleculesY63] Double-stranded DNA that can bind to transcription 
factors (i.e. proteins) and inhibit the transcription process, so as to regulate gene 
expression, is often termed a "decoy" oligodeoxynucleotide (ODN). [164,165] Aptamers are 
regarded as a type of oligonuc1eotide "antibody" due to their specificity and high binding 
affinity, usually measured at the nanomolar scale.[153] Furthermore, aptamers offer 
advantages over antibodies, such as ease of screening, uncomplicated and co st-effective 
large-scale manufacturing, and free of cell-culture-derived contaminants, by contrast, 
antibodies require complicated manufacturing processes using cell-based (eukaryotic or 
prokaryotic) expression systems. Binding affinity may be further enhanced to the 
picomolar scale by using SELEX with photo-cross-linkable aptamers, which allow the 
covalent attachment of aptamers to their bound proteins, while maintaining high 
selectivity. These aptamers have been shown great potential for the diagnostic 
applications Y 55] Functional groups such as fluorescence dyes or chemically reactive 
groups can be readily attached to the nuc1eotides during aptamer synthesis. These 
functional groups allow aptamers to serve as probes of enzymes, beads or radiotracers in 
diagnostic assays. [153,166,167] Shown in Figure 1.13 is an example of a DNA aptamer that 
can bind to the extracellular prote in thrombin, a key enzyme involved in the blood 
c10tting process. [97] Although they are only recent additions to the large number of nuc1eic 
acid-derived molecules being investigated as potential therapeutics, aptamers have gained 
recognition with the recent FDA approval of Macugen®, an RNA aptamer for the 
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treatment of neovascular age-re1ated macular degeneration (AMD) (Figure 1.15)y68] 
Aptamers may also prove useful for the treatment of other important human maladies, 
such as infectious diseases, cancer, and cardiovascular disease.[155] 
1.8.3.1 SELEX: A Powerful in vitro Selection Tooi 
SELEX[158-160] is often introduced by the preparation of a very large "library" of random 
sequences, usually containing 1014 unique DNA or RNA oligonucleotides that fold into 
unique three dimensional structures depending on their particular base sequence. The 
library is then incubated with a target molecule, such as a prote in, and a "selection" step 
is performed. Those oligonucleotides in the library that bind the target are separated and 
retained while those that do not are discarded. In DNA based SELEX, the retained DNAs 
are then amplified by a polymerization chain reaction (PCR), directly followed by a 
second round of selection (Figure 1.14). RNA based SELEX requires that the selected 
RNAs be converted to complementary DNA (cDNA), prior to PCR and then the 
amplified cDNAs be transcribed by T7 RNA polymerase to yield the enriched RNA 
library, finally followed by a second selection step. Typically, these selection and 
Step 2. 
Selection 
Step 1: DNA or RNA 
pool (-1014 randomnized 
sequences, -100 pmol) 
Step 4. SELEX Amplification 
Step 3: Smaller library 
with selected properties 
Figure 1.14: SELEX processes 
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on a larger scale, usually via solid-phase synthesis, and its prote in binding properties are 
confirmed through in vitro assaysy69] 
1.9. Chemical Modifications in Oligonucleotide Therapeutics and Diagnostics 
Although the mechanisms involved in the applications of synthetic oligonuc1eotides (i.e., 
antisense, siRNA and aptamers) are different, applications of oligonuc1eotide-based 
therapeutics and diagnostics face similar key hurdles e.g., delivery, cellular uptake and 
biostability.[I70] The primary concem is that natural, unmodified DNA and RNA strands 
are subject to rapid degradation, primarily through the action of 3' exonuc1eases, with a 
lesser amount endonuc1ease activity as weIl. For example, an unmodified antisense 
oligonuc1eotide exhibited a half-life III serum of less than one minute,[17l] and an 
unmodified thrombin-binding aptamer showed an in vivo half-life of 108 seconds 
onlyyn] Other concems such as selectivity (i.e. high binding affinity to the target and 
low non-specifie binding toward non-targets) must also be considered. ldeally, 
chemically modified nuc1eosides should allow their oligonuc1eotides to activate the 
mechanisms that lead to the selective destruction of mRNA in antisense and siRNA 
applications, or to main tain the desired three dimensional structures that allow for 
binding in aptamers applications. Two successful examples of oligonuc1eotide based 
therapeutics are shown in Figure 1.15. Vitravene™ is the first and only antisense drug 
approved for market. It was developed for the treatment of human cytomegalovirus 
(CMV) induced retinitis,[173] and was approved by the V.S. Food and Drug 
Administration (FDA) in 1998. It is a phosphorothioate based DNA (PS-DNA), in which 
a sul fur atom replaces a non-bridging oxygen in the natural phosphodiester backbone 
(Figure 1.15). The second example, named Macugen®, is a vascular endothelial growth 
factor (VEGF) RNA aptamer approved by the FDA in 2004 for the treatment of 
neovascular age-related macular degeneration (AMD)y74] Macugen consists of modified 
2'-fluoro pyrimidines and 2'-O-methyl purines, along with the 5'-terminus conjugated to a 
polyethylene glycol moiety as an anchor and a 3'-terminus protected by with an inverted 
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thymidine (Figure 1.15).[174] The chemical modifications improve the in vivo half-life, 
bioavailability and pharmacokinetic parameters of this aptamer. [175,176] 
1.9.1 Chemical Modifications for siRNA and Antisense 
Chemical modifications can be made to the heterocyclic base, the sugar and the 
phosphodiester backbone. For antisense applications, the structural requirements of 
RNase H activation[l37] pertaining to chemical modifications,[131,177,178] especially 
2'-carbohydrate modifications,[179] have been widely discussed in the literature. The 
experiences gained from applying chemical modifications to antisense may also benefit 
their use in siRNA based applications, with careful consideration to the differences in 
mechanisms of action in cells (Figure 1.13). Detailed discussions about chemically 
modified siRNA and their functions for RNAi can be found in several reviews.[178,180,181] 
VitraveneiM (ISIS) 
For the treatment of cytomegalovirus 
(CMV) retinitis in people with AlOS, 
FDA approved in 1998 
Phosphorothioate 
(PS-ONA) 
v 
- -
MACUGEN" IT TAKES ALL TYPES:--
" Macugen®(EyeTech) 
For the treatment of age-related macular 
degeneration (AMD), FAD approved in 2004 
AA 
G U 
U-G 
G-C : 2'-OCH3-RNA A-U 
C U A U Blue: 2'*F-RNA 
U A Black: unmodified 
A 
A U A C PEG: polyethylene 
G-C glycol 
G-C 
C-C 
/ \ 
40-kDa PEG-S' 3'-3'-dT-S' 
Figure 1.15: Two successful oligonucleotides based therapeutics (right figure is adapted 
from Ng et al., 2006[174]) 
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For both siRNA and antisense approaches, high thermal denaturation values with mRNA 
targets are generally required and are often used as the first evaluation criteria for 
interesting candidates for these applications. [177] 2'-Carbohydrate modifications are 
extremely important in modulating sugar conformations, impacting mRNA binding.[179] 
Generally RNA-like analogues with C3'-endo sugar conformation (Figure 1.17) 
are favored for strong mRNA bindingY 82] Substituents at the 2'-0 position, such as 
2'-0-methyl (2'-0-Me) or 2'-0-methoxyethyl (2'-0-MûE) (Figure 1.16a & b) or 
substitution of the hydroxyl group with a fluorine atom at the 2' position, such as 
2'-deoxy-2'-fluoro-ribonucleic acids (2'F-RNA) (Figure 1.16d) favor a C3'-endo sugar 
conformation (Figure 1.17). This conformation allows the 2'-electronegative atom to 
adopt a pesudoaxial position, minimizing energy through a gauche interaction with the 
û4'-ring oxygen (X-C2'-Cl'-û4', X is an electronegative atom).[183] 2'-0-Me, 
2'-0-MûE, and 2'F-RNA raise the Tm value by 1.7, 2, and 3 oC/modification in 
RNA/RNA duplexes, respectively.[179] An entirely C3'-endo conformation obtained for 
locked nucleic acids (LNA) through a methylene bridge between the 2'-oxygen and the 
4'-carbon shows an even higher Tm increase ( > 3 °C/modification)Y84] Preorganization 
of A-like (RNA) analogues is believed to reduce the entropy loss during duplex assembly 
of a complex, thus requiring A-like building blocks so in order to stabilize the 
complex. [182] Preorganization was first described by Cram in the analysis and design of 
small organic host-gue st complexesY85] ûligonucleotide duplex formation is an 
enthalpy-favored process due to the energy lost by the formation of hydrogen bonds and 
base stacking, while it is an entropy unfavoured process since an ordered structure 
(duplex) forms from a less ordered structure (single strands). If a monomeric unit 
preorganizes itself into a conformation required by a higher ordered structure, the entropy 
loss during duplex formation is reduced since the monomer is already in the required 
conformation and doesn't lose as many orders of freedom. 2'-Alkyl modifications[177] 
such as 2'-a-C-hydroxymethyl (2'-a-hm) (Figure 1.16f) are expected to adopt a C2'-endo 
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(DNA like) conformation (Figure 1.17), since the gauche effect of 2' group with the sugar 
ring oxygen is removed and steric concems become dominant. According to the 
preorganization the ory, chemical modifications leading to C2'-endo conformations 
generally result in lower affinity for mRNA. The 2'-a-C-hydroxymethyl modification, for 
instance, causes a 3°C decrease in a DNA:RNA duplex where the DNA strand is 
modified. [177] 
2'-Deoxy-2'-fluoro-D-arabinonuc1eic acids (2'F-ANA, Figure 1.16e) is an isomer 
of 2'F-RNA (Figure 1.16d). 2'F-ANA is expected to adopt C2'-endo (DNA like) 
conformation (Figure 1.17) due to the same reason that the most electronegative "up" 
fluorine prefers in a pseudo axial to the gauche interaction with the 04'-ring oxygen 
(F-C2'-C1'-04'). Previous studies have shown that the 2'F-ANA actually favors a 
south/east (C2'-endo/04'-endo) conformation Y 86] Interesting1y, the incorporation of 
2'F-ANA units, 1eads to ~ + 1°C/modification in binding affinity with RNA compared 
with DNA (i.e. 2'F-ANAlRNA>DNA/RNA)'p87] though stabi1ization caused by 2'F-ANA 
is much less than what is observed with 2'F-RNA. Pre-organization of 2'F-ANA sugar, 
or/and increase base stacking on 2'F-ANA sugar could le ad to the observed stability 
differenceY87] 2'F-RNA, and more recently 2'F-ANA, have been shown to be important 
chemical modifications for antisense and siRNA applications Y 80] 
1.9.1.1 Phosphodiester Backbone Modification: 2',5'-Linked RNA 
Natural phosphodiester (PO) backbone is often modified for antisense and siRNA 
applications. Much success has been made for phosphorothioate (PS) linkage in which a 
sulfur atom replaces a non-bridging oxygen in the PO backbone (Figure 1.15) as in the 
first antisense drug Vitravene™. The PS-DNA modification results in enhanced stability 
to enzymatic degradation and maintained abi1ity to activate RNase H. However, the 
PS-DNA duplex formed with the target RNA has a lower Tm (i.e. lower affinity) than the 
phosphodiester compound (PO-DNA), and phosphorothiates exhibit non-specifie binding 
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with cellular proteins, inducing undesirable effects (toxicity)Y88,189] Another interesting 
RNA analogue is the regioisomeric 2',5'-linked RNA (Figure 1.18). Actually 2',5'-RNA is 
found in sorne biological processes in cells such as lariat RNA splicing intermediates 
(Figure 1.5).[15]2',5'-RNA are not only interesting from a structural point ofview, but also 
have potential use in the down-regulation of gene expression.[190,191] For instance, 
previous studies show that DNA/2',5'-RNA chimeras and 2',5'-DNA show less 
nonspecific binding to plasma and cellular proteins minimizing toxicity in antisense 
applications Y 92] 2',5'-RNA is more nuclease resistant than unmodified DNA.[l92] In 
addition, 2',5'-RNAs are able to associate with complementary single-stranded RNA [190] 
as weIl as duplex DNA [193] and, as such, can potentially be used to down-regulate gene 
expression via the antisense and antigene approaches.[191,192,194,195] It is also 
well-documented that annealing two normal RNA strands is more favorable than 
annealing a 2',5'-RNA strand with a normal RNA strand. [190,196-198] Furthermore, mutually 
complementary 2',5'-RNA strands have the ability to associate, but exhibit much lower 
Tm than those of the corresponding RNA:RNA or RNA:2',5'-RNA duplexes. A 
comparison of the Tm values of various duplexes of mixed base composition revealed the 
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Figure 1.18: RNA, 2',5'RNA and their favored sugar conformations (adapted from 
Prernraj et al. 2001 [199]) 
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following order of duplex thermal stability: RNA:RNA > DNA:DNA::::: DNA:RNA > 
RNA:2',5'-RNA> 2',5'-RNA: 2',5'-RNA > DNA: 2',5'-RNA (undetected)Y96] Molecular 
modeling and circular dichroism (CD) studies of these duplexes revealed that RNA: 
2',5'-RNA hybrids adopt a continuous A-type helix structure similar to that of native 
RNA,[196,199] but have smaller interstrand phosphate-phosphate distances (by ca. 1 A). 
This may account, at least in part, for the lower thermal stability of RNA:2',5'-RNA 
relative to RNA:RNA and RNA:DNA helices. [196] Another interesting structural feature of 
2',5'-RNA is that it favors a "compact" structure which is defined by the intramolecular 
phosphate-phosphate distance (Figure 1.18). A compact 2',5'-RNA adopts C2'-endo sugar 
pucker, while extended 2',5'-RNA adopts C3'-endo. In RNA, a favored compact structure 
adopts the C3'-endo pucker due to the shift ofphosphodiester linkage (Figure 1. 18)YoO] 
1.9.2 Chemical Modifications for Aptamers 
The target binding activity of aptamers is strongly dependent on the folding or 3D 
structure of the oligonucleotide strand, so high thermal stability and nuclease resistance is 
very desirable. Important lessons leamed from the chemical modification of AS-ODNs 
and siRNA have informed aptamer modifications and several methods have been devised 
to improve the stability of aptamers towards endo/exonucleases. Chemical modifications 
of aptamers are made after in vitro selection, called post-SELEX modifications, as was 
previously mentioned with siRNA and antisense modificationsY01] Macugen® is an 
example of post-SELEX modification, composed of 2'-O-Me purines, and other 3',5' 
terminal modifications (Figure 1.15).[174] Precaution must be taken to keep the correct 
3-D structure of the modified oligomer so as to maintain the binding affinity and 
selectivity to a target. It has been shown that aptamers are often sensitive to chemical 
modifications. For example, several studies have been directed at modifying the 
thrombin-binding aptamer d(G2T2G2TGTG2T2G2) (Figure 1. 12G),l97] but very few, ifany, 
have led to an improvement over the original molecule. Heckel and Mayer reported that 
the introduction of thymidine residues modified with a nitrophenylpropyl moiety (T-NPP) 
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generaHy abolished interaction of the aptamer with thrombin. [202]. Di Giusto and King 
reported the synthesis of circular aptamers targeting thrombin with improved nuclease 
resistance and anticoagulant potency compared to a classical thrombin DNA aptamer. [203] 
However, circularization of the aptamers produced a mixture of constructs and required a 
ligase enzyme, making the method very difficult to scale-up. Other attempts to circularize 
the thrombin-binding DNA aptamer via chemical methods abolished the anti-thrombin 
activity [204]. Recently, Seela and coworkers reported the insertion of the hairpin-forming 
sequence GCGAAG into the central loop of the thrombin-binding aptamer, creating a 
G-quadruplex fused to a mini-hairpin structure. The Tm data suggested that the 
mini-hairpin induced a structural change in the aptamer section but binding to thrombin 
. . d [205] 
was not mvestlgate . Saccà et al. used spectroscopy to study a number of 
modifications, including the effects of backbone charge, atom size, base substitution and 
modification at the sugar 2'-position. AH the sugar (ribose, 2'-O-methylribose) and 
phosphate (methylphosphonate, phosphorothioate) modifications led to a reduction in the 
thermal stability of the thrombin binding aptamer. 2'-O-methylribose modification also 
disrupt the G-quadruplex conformation. [206) Another study suggests that incorporation of 
2'-O-methylribose results in structural changes or loss of activity in RNA aptamers 
binding to human transcription factor NF_KB.[20I) 
Another way to modify aptamers is called mirror-design (or "Spiegelmer"),[207) in 
which standard SELEX methods are used to select a normal RNA aptamer (D-RNA) 
against the enantiomer of the target protein which is composed of D-amino acids. The 
resulting RNA aptamer (D-RNA) sequence is then converted to its enantiomeric form, 
L-RNA, resulting in an aptamer with high binding affinity to the native protein molecule 
(L-amino acids) and high resistance against cleavage by nucleases. Unfortunately this 
strategy is limited to cases where an enantiomer of the target molecule is available. 
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1.9.2.1 Direct evolution with modified nucleoside 5'-triphospahtes (NTPs) 
An alternative approach for modifying aptamers is the directed evolution in SELEX 
procedure with modified deoxyribonucleoside S'-triphosphates (dNTPs) or ribonucleoside 
S'-triphosphates (rNTPs).[208] This method ensures the generation of modified aptamers 
with desirable binding properties and biostability. Two extra steps are added to the 
standard SELEX cycle (Figure 1.14), one to generate a library of modified 
oligonucleotides through the biosynthesis of the initial unmodified oligonucleotides 
(DNA or RNA) pool by polymerase; the other to convert a smaller library of se1ected 
modified oligonucleotides into cDNA through modified temp1ate-mediated po1ymerase 
biosynthesis (e.g. reverse transcription converts modified RNA into cDNA in 
RNA-SELEX, Figure 1.14). A successful SELEX procedure using modified NTPs has 
two main requirements; the first is a polymerase which can incorporate the modified 
NTPs, and the second is a po1ymerase which can direct DNA synthesis through modified 
templates. The biosynthesis of modified dNTPs and polymerase-directed DNA synthesis 
on a modified temp1ate have been investigated in preparation for SELEX aptamers and 
other purposes (example 10-13 in Table 1.1). 
In Table 1.2, a summary of catalytic (RNA or DNA enzymes) or selective binding 
aptamers that have been successfully generated by SELEX with modified NTPs is 
presented. Many of these NTPs modified at CS in pyrimidines or C8 in purines can 
generate RNA or DNA enzymes with new catalytic functions. Very few modified 
nucleoside S'-triphosphates are compatible with the SELEX process since few modified 
rNTPs are substrates of RNA polymerases and few modified oligonucleotides are faithful 
temp1ates for reverse transcriptases. It is interesting to note that most RNA aptamers 
evolved via SELEX for therapeutics utilize 2'-fluoro or 2'-amino modified rNTPs (Table 
2). Other successful SELEX processes with modified rNTPs include ribonucleoside 
5'-( a-P-borano )-triphosphates (BH3-RNA), [209] ribonucleoside 5'-( a-thio )triphosphates 
(S_RNA)[210] and 4'-thio-ribonucleoside S'-triphosphates (4'S_RNA)[211] as shown in 
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Table 1.1: Biosynthesis ofmodified nucleoside 5'-triphosphate and polymerase directed DNA synthesis on a modified template 
No. Modified triphosphates 
Modified NTPs and DNA polymerases 
1* 
2* 
3 
4 
5 
6 
7 
8 
9* 
10 
11 
Cyclohexenyl adenine 5 
-triphosphates (CeATP) 
a-L-Threofuranosyl nucleoside 
5'-triphosphates (TNA-5'-TP) 
TNA templates 
TNA-5'-TPs 
2'-5'-linked DNA template 
2'-OMe 
Ali four 2'F-rNTPs 
2'OMe-rUTP and 2'OMe-rCTP 
2'-Deoxyribonucleoside 
5'-( a-methyl)triphosphates (P-Me 
dNTPs) 
Ali four 2'F-rNTPs 
2'F-rCTP 
Polymerases and biosynthesis 
Substrate of Vent (exo-), Taq DNA polymerase and HIV-I RT; Taq and HIV-I 
RT were able to incorporate seven consecutive CeNA; ail three enzyme can 
mediate DNA biosynthesis (6 nt) on a CeNA template 
Therminator™was able to synthesize 50 nt through a DNA template 
DNA polymerase-mediated DNA synthesis on a chimeric DNNTNA template 
(9 TNA); trace of full-Iength product was observed by Est, T7 DNA polymerase 
(exo-), its mutated commercial version Sequensase, MMLV-RT and its mutated 
commercial version SuperScript II 
TNA synthesis by DNA polymerase; Deep Vent (exo-), the most effective 
enzyme tested, was able to extend three TNA after 24hours 
2'-5'-liked DNA serves a template for polymerase-directed DNA synthesis. Only 
Kf(exo-) and HIV-l RT could extend 4 nt to give full-length products 
Evolution of a DNA polymerase (Taq) variant for 2'-OMe rNTP incorporations 
Ali four 2'F -rNTPs are substrate of human DNA pol y; 2'F -rUTP, 2'F -rCTP and 
2'F-rGTP are substrate ofpol a 
Human DNApol a and y could not incorporate 2'OMe-NTPs 
Biosynthesis of modified DNA by E. coli DNA polymerase 1 
Year 
2005 
2005 
2003 
2003 
2003 
2003 
2000 
2000 
1997 
Substrates ofPfu (exo-), Vent (exo-), Deep Vent (exo-), UlTma DNApol 1997 
Mouse cell pol rand Xenopus laevis pol a, wheat germ DNA pol A and C, and 1985 
AMV reverse transcriptase could incorporate 2'F-dCTP but the elongation was 
difficult (chain termination) 
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Kempeneers et al. 
[212] 
Horhota et al. [213] 
Chaput et al. [214] 
Chaput and Szostak 
[215] 
Sinha et al. [216] 
Fa et al. [217] 
Richardson et al. [218] 
Richardson et al. [218] 
Dineva [219] 
Ono et al. [220] 
Aoyama et al. [221] 
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Table 1.1 (continued) 
No. Modified triphosphates Polymerases and biosynthesis Year Reference 
Modified NTPs and DNA polymerases 
12 
13 
2'F -araTTP, 5-Me-2'F -araCTP and Chain tenninator of HSV-l and HSV-2 DNA pol 1981 
5-1-2'F-araCTP 
2'F-rUTP,2'F-rCTP 2'F-rCTP is a substrate of pol II but not III; E. coli pol II and III; 2'F-dUTP is 1978 
not a substrate for both enzymes 
Ruth and Cheng [222] 
Helfman et al. [223] 
Modified NTPs and RNA polymerases 
15* 
16 
17* 
18 
19 
20 
* 
Adenosine 5'-(a-P-Seleno) 
triphosphate (ATPaSe) 
2'-OMe 
2'-dexoy-2'-a-C-branched-homo-
udine-5'-triphosphate 
2'-OMe, 2'-Nr rNTPs 
2'-deoxy-2'-thio-CTP (2'S-rCTP) 
2'F pyrimidines (2'F-rUTP, 
2'F -rCTP); 2'NH2 pyrimidines 
(2'NHz-rUTP, 2'NHz-rCTP); 
000 
T7 RNA polymerase only incorporates one diasteromer of ATPaSe (ATPaSe l, 
Sp) 
Evolution of a T7 RNA polymerase variant for 2'-OMe rNTP incorporations 
Substrate of T7 RNA polymerase in the presence of Mn2+ (extension of 20-21 nt 
in RNA strand) 
Y639F!H784A T7 RNA polymerase (double mutations) can incorporate 
2'-OMe,2'-Nr rNTPs 
A mutant T7 polymerase (Y639F) can incorporate 2'S-rCTP and replace all CTP 
in HDV (hepatitis delta virus) ribozymes 
They are substrate of T7 RNA pol which was able to synthesis 2500 nt modified 
RNAs 
2006 Carrasco et al. [224] 
2004 Chelliserrykattil and 
Ellington [225] 
2004 Pavey et al. [226] 
2002 Padilla and Sousa 
[227] 
1998 Raines and Gottleib 
[228] 
1992 Aurup et al. [229] 
Il Il 11_ o-~-~-~ t F\,ase 
0-0-0- V o 0 0 Base IIIIII~ o 0 0 Base IIIIII~ 
o 0 0 A _IIIIII~ o 0 0 u IIlIlI
rt O-P-P-P-O_O 1 1 1 0- 0_ 0- O-P-P-P-O 0 1 1 1 0- 0_ CH3 O-P-P-P-O 0 1 1 1 0- 0_ Se_ O-P-P-P-O 0 1 1 1 0- 0_ 0-HO"" 2 OH 8 OH OH 15 OH OH 17 OH OH 
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Table 1.2. Successful SELEX reported in the literature 
No. Modified triphosphates Polrmerases used Class Target/function** Year Reference 
Base modifications 
1* 2'-deoxyuridine triphosphates KOD Dash DNA polymerase, DNA Protein-like DNA molecules 2006 Kuwahara et al. [230] 
bearing amino acids at the C5 aptamer 
position 
2* 8-[2-( 4-Imidazolyl)ethylamino ]deo Sequenase 2.0 (genetically Deoxy- RNase (internai rC with 2001 Perrin et al. [231] 
xyadenosine and engineered variant ofT7 DNA ribozyme no Mg2+) 
5-(3-aminoallyl)-deoxyuracil polymerase) 
3 N-6-Aminohexyl adenosine T7 RNA pol Ribozyme Ligation to its 5' end (250 2000 Teramoto et al [232] 
fold more activie) 
4* C5-Imidizole-uracil analog Superscript II Reverse Deoxy- Sequence directed RNase 2000 Santoro et al. [233] 
(unnamed) Transcriptase ribozyme 
5* 5 -(3' -aminopropyny l)-deoxyuracil Vent DNA polymerase Deoxy ATP 1999 Battersby et al.[234] 
aptamer 
6 5-Imidizole-uracil T7 RNA polymerase Ribozyme Amide synthase 1997 Wiegand et al. [235] 
7* 5-Pyridylmethylcarboxamid-uracil Not mentioned Ribozyme Diels-Alderase (800 fold 1997 Tarasow et al. [236] 
more active) 
8* 5-(l-Pentynyl)-deoxyuracil Vent DNA polymerase Deoxy Thrombin 1994 Latham et al. [237] 
More info about thrombin aptamer 
binding interaction!! 
Backbone modifications 
9* Guanosine and Uridine 5' AmpliScribe™ Transcription RNA ATP 2002 Lato et al. [209] 
(a-P-borano )-triphosphates Kits aptamer 
(BHrG(U)TP) 
10* a-S-rNTP, a-S-dNTP T7 RNA pol in transcription with Detai\ed optimization of the aptamer 2000 Andreola et al. 
(phosphorothioate linked RNA, or S-rNTPs; HIV-RT in reverse selection process with S-rNTPs and 
DNA) incorporation transcription with S-dNTPs S-dNTPs; direct PCR amplification with 
S-dNTPs to have PS-DNA libraries 
11 a-S NTPs (phosphorothioate T7 RNA polymerase RNA bFGF 1998 Jhaveri et al. 
linked RNA, S-RNA) aptamer 
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12 a-S dNTPs (phosphorothioate 
linked DNA, or S-DNA) 
Sugar modification 
13* 4'-Thio-ribonucleoside 
5'-triphosphates (4'-S-UTP and 
4'-S-CTP) 
14 2'NH2-dCTP 
15 2'NHz-dUTP,2'NH2-dCTP 
16 2'F-dUTP, 2'F-dCTP 
17 
18 
19 
20 
21 
2/-Fluoro pyrimidines 
2'NHz-dUTP,2'NH2-dCTP 
2/-Fluoro pyrimidines 
2'NHz-dUTP, 2'NH2-dCTP 
2'NH2-dUTP, 2'NH2-dCTP 
2'NHz-dUTP, 2'NH2-dCTP 
2'NHz-dUTP, 2'NH2-dCTP 
Taq polymerase Deoxy 
aptamer 
NF-IL6 transcription factor 1998 
T7 RNA polymerase RNA 
aptamer 
Thrombin 2005 
T7 RNA polymerase 
T7 RNA polymerase 
T7 RNA polymerase 
T7 RNA polymerase 
T7 RNA polymerase 
Ribozyme 
Ribozyme 
Aptamer 
Aptamer 
Aptamer 
metalation reaction of 
porphyrin 
Trans cleavage of RNA 
VEGF(165), leading to the 
discovery of Macugen 
hKGF 
IFN-y 
T7 RNA polymerase Aptamer VPFNEGF 
T7 RNA polymerase Aptamer bFGF 
T7 RNA polYtnerase J\ptamer HUtnanneutr()phil elastase 
2001 
2000 
1998 
1997 
1997 
1995 
1995 
1994 
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King et al. [238] 
Kato et al. [211] 
Kawazoe et al. [239] 
Beaudry et al. [240] 
Ruckman et al. 
Pagratis et al. [241] 
Kubik et al. [242] 
Green et al. [243] 
J ellinek et al. [244] 
Lin et al. [245] 
* 
o 
o 0 0 HN~R1 O-~_II Il .l. 1 
1 ~-~-o 0 N 
0- 10-. 0-. îd 
OH 
NH2 N~ NH ~ N f) 
N- À~N N N j H 
o 
HN~ 
o.l._.J ~H3 
N 
2 ~ 
o 0 
HN~I ~ N~N 
O
.l._J H - l ~ 
N NH 
~ Y
EB
NH3 
HN 0 # 
o.l. 1 N 
2 4 ~ 5 
Y ~ ~ o 0 0 ~ _ ? U/G ? A _ ~ ~ ~ U/C yNU HN P H3B-P-0~ 5_-P-0~ O-P-P-P-O~ HN 1 1 1 1 Il II 1 1 1 1 H N?-... 0 0 -0 0-0-. O~N '" 0 N 
~ ~ r-r0 OH 10.JVV'0 OH 13 OH OH ~ 7 ~ 8 9 
** Abbreviations: bFGF, basic fibroblast growth factor; hKGF, human keratinocyte growth factor; IFN-y, interferon y; NF-IL6, nuclear factor for human 
interleukin 6; VEGF, vascular endothelial growth factor; VPF, vascular permeability factor 
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Table 1.2, 2'-OMe ribonucleosides are an important post-SELEX modification. 
Unfortunately 2'-OMe rNTPs are not substrates of T7 RNA polymerase, although recent 
reports have shown that genetically engineered RNA or DNA polymerases actually can 
incorporate 2'-OMe rNTPs (example 14, 16 in Table 1.1) but the procedure is usually 
tedious. There are even fewer examples for DNA SELEX as most studies are still at the 
initial stage of searching for a DNA polymerase that efficiently accepts modified dNTPs 
as substrates (example 1-5 in Table 1.1). For example, a-L-Threofuranosyl nucleoside 
S'-triphosphates (TNA-5'-TP) are not easily accepted by many common DNA 
pOlymerases[246] and efficient oligonucleotide (bio )synthesis requires very specialized 
mutant DNA polymerases. [247] TNA synthesis on a DNA template required at least 1 day 
incubation with Deep Vent (exo-) for an insertion of three contiguous TNA residues[215] 
and DNA synthesis on a TNA template by common polymerases such as Bst Pol land 
MMLV reverse transcriptase required at least 1 hour to obtain full-Iength extension 
products. [214] 
The general poor enzymatic recognition of modified NTPs underscores the 
difficulties involved in using DNA/RNA polymerases to synthesize unnatural 
oligonucleotides. Accordingly, there is a need for modified NTPs that are faithful 
substrates for DNA and RNA polymerases. Ideally, the resulting modified 
oligonucleotide would also serve as template for cDNA synthesis, so that the selection 
and amplification steps of the SELEX protocols could be applied. 
2.0 Thesis Objectives 
During the past decades, the use of oligonucleotides as therapeutics and diagnostics has 
drawn great attention. Chemical modifications are generally required to offer flexibility 
in the design and utility of these molecules, and to improve their "drug-like" properties 
such as efficacy, selectivity and delivery. These requirements have been cleady seen in 
the development of antisense, siRNA and aptamer therapeutics. My thesis focused on two 
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important chemical modifications, namely, 1-(2-deoxy-2-C-a-hydroxymethyl-
~-D-ribofuranosyl)thymine (or 2'-a-hm-dT, abbreviated as "H") and 2'-deoxy-2'-fluoro-D-
arabinonucleic acid (FANA), and their applications. 
Chapter II provides the total synthesis of H and the first investigation of 
oligoribonucleotides containing this chemical modification. The shorter inter-strand 
phosphate-phosphate distance of 2',5'-RNA duplexes inspired us to consider this 2' 
methylene modification. We hypothesized that the extended 2',5'-RNA resulting from 
incorporation of H could increase the P-P distance so as to decrease the charge repulsion 
interactions and stabilize duplex formation. Both the 2'-CH20-phosphoramidite and 
3'-O-phosphoramidite derivatives of H were synthesized and incorporated into both 
2',5'-RNA and RNA chains. Hybridization was evaluated by Tm and CD experiments. The 
thermal stability and conformation of a 2',5'-linked RNA hairpin modified with H units 
was also investigated. 
Chapter III presents one of the potential applications of oligonucleotides 
incorporating the H modification, namely a novel branched RNA structure for the 
inhibition of yeast debranching enzyme (yDBR). The preparation, debranching activity 
and inhibition of several Y-shaped RNAs were evaluated. 
Chapter IV deals with the first study of G-quadruplexes modified with 
2'-deoxy-2'-fluoro-D-arabinonucleotides (2'F-ANA). The effect of 2'F-ANA in the 
G-quadruplex was investigated In the thrombin-binding DNA aptamer 
d(G2T2G2TGTG2T2G2), an anti-HIV phosphorothioate aptamer PS-d(T2G4T2), and a DNA 
telomeric sequence d(G4T4G4) via Tm and CD experiments. 2'F-ANA-modified 
thrombin-binding aptamers were further evaluated in terms of their nuclease resistance in 
10% fetal bovine serum (FBS) and the binding affinity to thrombin. 
Chapter V reports the first study on the biosynthesis of 2'F-ANA with 
2'-deoxy-2'-fluoro-D-arabinonucleoside 5'-triphosphates (2'F -araNTPs) catalyzed by 
DNA polymerases. Primer extension reactions were conducted to evaluate nine different 
43 
Chapter 1 
DNA polymerases for their ability to incorporate 2'F-araNTPs, as weIl the ability ofthese 
polymerases to accept F ANA-DNA chimeras as template strands for the synthesis of a 
complementary DNA or a FANA-DNA chimeric strand. The fidelity of incorporation of 
2'F-araNTPs by Deep Vent (exo-) (DV), 9°Nm™ (9N) and Phusion™ High Fidelity (Ph) 
DNA polymerases was also evaluated. 
Chapter VI reports a foIlow-up study of Chapter V, showing the first comparison 
studies on the efficiency of incorporation of 2'F-araNTPs and 
2'-deoxy-2'-fluoro-D-ribonucleoside 5'-triphosphates (2'F-rNTPs) by four DNA 
polymerases, namely, DV, 9N, HIV -1 reverse transcriptase and Moloney Murine 
Leukemia Virus (MMLV) reverse transcriptase. 
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Dr. Damha's group has a long-standing interest in 2',5'-linked oligonuc1eotides 
which serves as not only a interesting structure to understand why nature chooses 3',5'-
linked RNAIDNA interested of 2',5'-linked counterparts, but also a novel chemical 
modification with potential use in gene silencing (antisense and siRNAs). An interesting 
finding about 2',5'-linked RNA duplex is its smaller interstrand phosphate-phosphate 
distances (by ca. 1 Â). This may account, at least in part, for the lower thermal stability 
of RNA: 2',5 '-RNA relative to RNA:RNA and RNA:DNA helices. The CUITent chemical 
modification aims to prepare extended 2',5'-RNA by adding extra CH2 group on 2' 
position of sugar ring. This work demonstrates the first studies of 2',5'-RNA modification 
and its effect of incorporation on the stabilization of duplex. 
Reprint from Peng, c.G. and Damha, M,J. (2005) Synthesis and hybridization studies 
of oligonucleotides containing 1-(2-deoxy-2-a-C-hydroxymethyl-~-D-ribofuranosyl)­
thymine (2'-a-hm-dT). Nucleic Acids Research, 33(22), 7019-7028. With permission 
from Oxford University Press 
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Chapter II. Synthesis and Hybridization Studies of Oligonucleotides Containing 1-
(2-Deoxy -2-a-C -hydroxymethyl-~-D-ribofuranosyl)thymine (2' -a-hm -dT) 
Abstract 
We report the first investigation of oligoribonucleotides containing a few 1-(2-deoxy-2-
a-C-hydroxymethyl-~-D-ribofuranosyl)thymine units (or 2'-hm-dT, abbreviated in this 
work as "H"). Both the 2'-CH20-phosphoramidite and 3'-O-phosphoramidite derivatives 
of H were synthesized and incorporated into both 2',5'-RNA and RNA chains. The 
hybridization properties of the modified oligonucleotides have been studied via thennal 
denaturation and circular dichroism studies. While 3',5'-linked H was previously shown 
to significantly destabilize DNA:RNA hybrids and DNA:DNA duplexes (modification in 
the DNA strand; I1Tm - -3 Oc / insert), we find that 2',5'-linked H have a smaller effect on 
2',5'-RNA:RNA and RNA:RNA duplexes (I1Tm = -0.3 oc and -1.2 oC, respectively). The 
incorporation of 3',5'-linked H into 2',5'-RNA:RNA and RNA:RNA duplexes was found to 
be more destabilizing (-0.7 oC and -3.6 oC, respectively). Significantly, however, the 2',5'-
linked H units confer marked stability to RNA hairpins when they are incorporated into a 
2',5'-linked tetraloop structure (I1Tm = + 1.5 °C/insert). These results are rationalized in 
terms of the compact and extended conformations of nucleotides. 
Introduction 
Our group has had a long-standing research interest in the physicochemical and 
biochemical properties of 2' ,5'-linked ribonucleic acids (2' ,S'-RNA, Figure 2.1). [1,2] These 
regioisomers of standard (i.e. 3',5'-linked) RNA are not only interesting from a structural 
point of view, but also have potential use in the down-regulation of gene expressionY,4] 
For instance, 2',5'-RNAs are able to associate with complementary single-stranded 
RNA[3] as weIl as duplex DNA[5] and, as such, can potentially be used to down-regulate 
gene expression via the antisense and antigene approaches (Figure 2.1).[4,6-8] It is also 
well-documented that annealing two normal RNA strands is more favorable than 
annealing a 2',5'-RNA strand with a normal RNA strand. [1,3,8,9] Furthermore, mutually 
complementary 2',5'-RNA strands have the ability to associate, but exhibit a transition 
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temperature (Tm) that is considerably lower than those of the corresponding RNA:RNA 
or RNA:2',5'-RNA duplexes. A comparison of the Tm values of various duplexes of 
mixed base composition revealed the following order of duplex thermal stability: 
RNA:RNA > DNA:DNA z DNA:RNA > RNA:2',5'-RNA > 2',5'-RNA: 2',5'-RNA > 
DNA: 2',5'-RNA (undetected).[l] 
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Figure 2.1: Structure of RNA, 2',5'RNA, and strands comprising 2',5'-linked H and 3',5'-
linked H units. 
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Scheme 2.1: Structures of 2'-(X.-hm-dT ("H") and its phosphoramidite derivatives 8 and 
11. 
Molecular modeling and circular dichroism (CD) studies of these duplexes revealed 
that RNA: 2',5'-RNA hybrids adopt a continuous A-type helix structure similar to that of 
native RNA, [1] but have smaller interstrand phosphate-phosphate distances (by ca. 1 Â). 
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This may account, at least in part, for the lower thermal stability of RNA:2',5'-RNA 
relative to RNA:RNA and RNA:DNA helicesY] 
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0 .... 
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CP'o~oJase HO ~, O .... p 
Extended 2',5'-RNA 
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2',5'-linked H 
Figure 2.2: The C2'- and C3'-endo sugar puckers are favored in 2',5'-linked RNA and 
3',5'-linked RNA, respectively.[IO,II] The intra-residue P-P distance determines the 
"compact" or "extended" backbone structure. [11] Lengthening by an extra carbon C2' (H) 
removes the gauche effect between the ring oxygen and 02', which is expected to 
reinforce the C2'-endo or compact conformation for 2',5'-linked H units. 
As part of our ongoing study of these systems, we now present an investigation of 
2',5'-RNA chains containing one or more 1-(2-deoxy-2-a-C-hydroxymethyl-~-D­
ribofuranosyl)thymine (2'-a-hm-dT; abbreviated in this work as "H", Figure 2.1 and 
Scheme 2.1). We anticipated that lengthening the sugar-phosphate backbone by one 
methylene unit would not only diminish putative P-P repulsions in 2',5'-RNA:RNA 
duplexes, but would also provide a "compact" nucleotide conformation favoring tighter 
RNA binding (Figure 2.2).[10,11] This interesting modification was first studied by Schmit 
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and co-workers[12] and reviewed more recently by Freier and Altmann.[13] Schmit et 
al. [12] reported that 3',5'-linked H units (3',5'-H) significantly destabilize DNA:RNA 
hybrids and DNA:DNA duplexes (modification in the DNA strand; /)'Tm = -2.9 OC). 
Destabilization due to the 2'-a-hydroxymethyl and other 2'-a alkyl groups was explained 
by the tendency of these substituents to shift the conformation al equilibrium of the sugar 
toward the C2'-endo pucker and away from the C3'-endo pucker found in RNA, 2'-0-
alkyl RNA and 2'F-RNA duplexes.[12,13] To the best of our knowledge, neither 2',5'-
linked H units (2',5'-H) nor incorporation into RNA have ever been examined. The 
present study revealed that 2',5'-H units have a modest destabilizing effect on 2',5'-
RNA:RNA (/)'Tm = -0.3 oC) and RNA:RNA duplexes (/)'Tm = -1.2 OC), whereas 3',5'-H 
units are significantly more destabilizing (-0.7 oC and -3.6 oC, respectively), consistent 
with the results of Schmit et al..[12] In contrast, we find that 2',5'-H units confer 
significant stability to RNA hairpins, particularly when the y are placed in the loop 
structure (/).T ID = + 1.5 OC). 
Materials and Methods 
General reagents 
AlI reactions were carried out in oven-dried glassware un der a N2 atmosphere. 
Dichloromethane (CH2Cb) and acetonitrile (CH3CN) were dried by refluxing and 
distilling over calcium hydride (CaH2) under a N2 atmosphere. Tetrahydrofuran (THF) 
was dried by refluxing over sodium and benzophenone un der a N2 atmosphere and 
collected before use. Anhydrous methanol (MeOH), pyridine (py), N-ethyl-N,N-
diisopropylamine (DIPEA), N,N-dimethylformamide (DMF) and 2,6-lutidine were 
obtained from Aldrich. The following chemicals were used as received from Aldrich: p-
anisy1chlorodiphenyl (MMTr-CI), benzoyl chloride (Bz-CI), tert-butyldimethylsilyl 
triflate (TBDMSOTf), tert-butyldimethylsilyl chloride (TBDMSCI), 4,5-
dicyanoimidazole (DCI), 4-dimethylaminopyridine (DMAP), 1,1,1,3,3,3-
hexamethyldisilazane (HMDS), 10 wt% palladium on carbon powder (10% PdlC), 
triethylamine tris(hydrofluoride) (TREAT HF), D-ribose, silver nitrate (AgN03), 1.0 M 
tin (IV) tetrachloride solution in dichloromethane (SnCI4), thymine. ~-cyanoethyl-N,N-
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diisopropy1chlorophosphoramidite and other solid-phase synthesis reagents and regular 
nucleoside monomers were purchased from ChemGenes Corp. (Ashland, MA). 
Methyl 2-a-benzoyloxymethyl-2-deoxy-3,5-di-O-(2,4-dichlorobenzyl)-a-D-ribo-
furanoside (2). Comp (1) was obtained following slight modifications of the procedure 
described by Martin [14l. Under a N2 atmosphere, 1.5 mL (1.78 g, 12.7 mmol) BzCI was 
added to a solution of 1 (4.83 g, 9.73 mmol) in 75 mL dry pyridine. The resulting 
solution was kept stirring at Lt. for 4 h. The reaction progress was monitored by TLC. 
When the reaction was complete, the reaction mixture was concentrated under reduced 
pressure, and th en washed with saturated NaHC03 and brine. The aqueous phase was 
extracted with CH2Ch three times. The combined organic layers were evaporated to 
dryness to afford 2 in quantitative yield (5.84 g). Rf (Si02) = 0.86 (2: 1 EtOAc/hexane); 
0.70 (1:2 EtOAc/hexane); IH NMR (400 MHz, CDCh): 87.98-7.09 (m, IIH, ArH), 5.11 
(d, 311_2 = 5.2 Hz, IH, Hl), 4.73-4.55 (m, 6H, benzyl CH2 and CH2-C2), 4.40-4.43 (m, IH, 
H4), 4.08 (dd, 3 h-2 , 3 h-4 = 5.2, 2.4 Hz, IH, H3), 3.54-3.64 (AB dd, 215,5' = 22.4 Hz, 
3 h5+5' = 4.4, 5.2 Hz, 2H, H5 & H5'), 3.45 (s, 3H, OCH3), 2.74-2.67 (m, IH, H2). ESI-MS 
for C28H26Cl406 [MNa+] ca1cd. 621.05, found 621.1. 
1-[2-a-Benzoyloxymethyl-2-deoxy-3,5-di-O-(2,4-dichlorobenzyl)-D-ribo-
furanosyl]thymine (3). Under a N2 atmosphere, a mixture of dry thymine (1.35 g, 10.7 
mmol), ammonium sulfate (0.136 g, 1.029 mmol), and HMDS (2.87 mL, 13.8 mmol) in 
anhydrous CH3CN (41 mL) was refluxed at 100 Oc for 4 h until the reaction mixture was 
cleaL The reaction mixture was cooled to Lt. and added to a solution of 2 (2.47 g, 4.12 
mmol) in dry CH3CN (19.5 mL) followed by 1.0 M SnCl4 in CH2Ch (4.12 mL, 4.12 
mmol). The resulting solution was warmed to 50 oC and left stirring for an additional 12 
h. After the reaction was complete, the reaction mixture was cooled to Lt., washed with 
saturated NaHC03 (50 mL) and filtered. The filtrate was extracted three times with the 
same volume of CH2Ch and the organic layer was washed with brine, dried over Na2S04 
and evaporated to yield a white foam. Purification by silica gel column chromatography 
with EtOAc/hexane (2:1 v/v) afforded the title compound in 72% yield (2.06 g, ~:a = 5:1). 
Rf (Si02) = 0.6 (2:1 EtOAc/hexane); 'H NMR of p-isomer (400 MHz, CDCh): 87.97-
7.19 (m, 12H, ArH and H-6), 6.35 (d, 3Jr,2' = 8.8 Hz, IH, Hl'), 4.74, 4.47 (2dd, 21cH2_C2' = 
12 Hz, 31CH2_C2" H2,=7.6, 7.2 Hz, 2H, CH2-C2'), 4.69-4.56 (m, 4H, benzyl CH2), 4.38 (br, 
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m, IH, H4'), 4.31-4.28 (m, IH, H3'), 3.90, 3.70 (2 dd, 215',5" = 10.8 Hz, 314',5'+5" = 3.2, 2.4 
Hz, 2H, H5' & H5"), 2.99-2.92 (m, IH, H2'), 1.64 (d, 41CH3-C5,H6 = 1.2 Hz, 3H, CH3-C5). 
ESI-MS for C32H2sCl4N207 [MNa+] calcd. 717.39, found 717.0. 
1-(2-a-C -Benzoyloxymethyl-2-deoxy -~-D-ribofuranosyl)thymine (4). To a 
solution of 3 (1.065 g, 1.53 mmol) in dry MeOH (50 mL) was added 10% PdlC (0.39 g, 
0.37 mmol). The resulting mixture was kept shaking under 40-50 psi H2 at Lt. for 6 h. 
The mixture was filtered and evaporated to dryness, and the residue was purified by silica 
gel column chromatography (eluent 40: 1 to 15: 1 CH2Ch/MeOH) to separate the 
a ançi ~ isomers. The desired fi isomer was obtained in 71 % yield (0.41 g). Rf (Si02) = 
0.51 (6:1 CH2ChlMeOH); 0.31 (10:1 CH2Ch/MeOH); IH NMR (400 MHz, DMSO-d6): t5 
11.22 (s, IH, N-H), 7.78-7.41 (m, 5H, Bz), 7.70 (s, IH, H6), 6.14 (d, 311 ',2' = 8.8 Hz, IH, 
Hl'), 5.52 (d, 31oH,H3' = 4.8 Hz, IH, HO-C3'), 5.10 (t, 31oH,H5'+H5" = 5.2 Hz, IH, HO-C5'), 
4.57,4.26 (2dd, 21cH2_C2 = 11.6 Hz, 31CH2_C2, H2' = 5.6,8.8 Hz, 2H, CH2-C2'), 3.88 (br, IH, 
H4'), 3.54-3.64 (AB, dd, 215',5" = 17.7, 314',5'+5" = 5.2, 4.8 Hz, 2H, H5' & H5"), 2.72-2.29 
(m, IH, H2'), 1.74 (s, 3H, CH3-C5). Four NOESY cross peaks identified the ~ isomer: 
Hl'-H4', H2'-H6', 2'-CH2-H4', H5'-H6. ESI-MS for CIsH20N207 [MNa+] calcd. 399.13, 
found 399.1. Isolated a isomer, IH NMR (500 MHz, acetone-d6): t51O.11 (s, IH, N-H), 
8.02-7.46 (m, 5H, Bz), 7.90 (s, IH, H-6), 6.55 (d, 3lr ,2' = 7.5 Hz, IH, Hl'), 5.13 (d, 31oH, 
H3' = 3.5 Hz, IH, HO-C3'), 4.66 (m, IH, H3'), 4.52-4.30 (m, 2H, CH2-C2'), 4.48 (m, IH, 
H4'), 4.19 (br, IH, HO-C5'), 3.66 (br, 2H, H5' and H5"), 3.33 (m, IH, H2'), 1.82 (s, 3H, 
CH3-C5). ESI-MS for a CIsH20N207 [MNa+] calcd. 399.13, found 399.1. 
1-[2-a-C -Benzoyloxymethyl-2-deoxy -5-0-( 4-methoxytrityl)-~-D-ribofuranosyl]-
thymine (5). Compound 4 (0.555 g, 1.47 mmol) and AgN03 (0.375 g, 2.21 mmol) were 
dissolved in dry pyridine (10 mL). The flask was purged with N2 and a solution of 
MMTrCI (0.683 g, 2.21 mmol) in dry pyridine (5 mL) was added. After stirring for 6h at 
Lt., the reaction was worked up by evaporating most of the pyridine and taking up the 
residue in CH2Ch (20 mL). The solution was washed with saturated NaHC03 (20 mL), 
dried, filtered, and finally evaporated to yield the crude product. Purification by silica gel 
column chromatography with 0.5% NEt3 in CH2ChIMeOH (49: 1 to 15: 1 v/v) afforded 
the title compound as a white solid (687 mg; 72% yield). Rf (Si02) = 0.66 (10: 1 
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CH2ChlMeOH); I H NMR (400 MHz, pyridine-d5): 812.12 (s, 1H, N-H), 6.95-5.75 (m, 
19H, ArH), 6.73 (d, 4JCH3_C5, H6= 1.2 Hz, 1H, H6), 5.94 (d, 3J I',2'= 12 Hz, 1H, Hl'), 4.12-
3.83 (m, 3H, CH2-C2' and H3'), 3.43 (br, m, 1H, H4'), 2.48 (s, 3H, OCH3), 2.45 (m, 2H, 
H5' & H5"), 2.30 (m, 1H, H2'), 0.50 (s, 3H, CH3-C5). IH NMR (400MHz, DMSO-d6): 8 
11.26 (s, 1H, N-H), 7.81-6.88 (m, 19H, ArH), 7.44 (s, 1H, H6), 6.20 (d, 3 JI',2' = 8.8 Hz, 
1H, Hl'), 5.62 (d, 3 ho,OH = 5.2 Hz, 1H, OH), 4.70, 4.31 (2dd, 2JCH2_C2' = 11.2 Hz, 3 JCH2-C2', 
H2' = 5.2, 8.4 Hz, 2H, CH2-C2'), 4.43 (m, IH, H3'), 4.0 (br m, 1H, H4'), 3.73 (s, 3H, 
OCH3), 3.27, 3.16 (2dd, 2J5 ',5" = 10.4 Hz, 3h ,5'+5"= 6.4,3.2 Hz, 2H, H5' & H5"), 3.01-2.94 
(m, 1H, H2'), 1.30 (s, 3H, CH3-C5). ESI-MS for C3sH36N20S [MNa+] ca1cd. 671.25, 
found 671.2. 
1-[2-a-C -Benzoyloxymethyl-3-0-tert -butyldimethylsilyl-2-deoxy -5-0-(4-
methoxytrityl)-p-n-ribofuranosyl]thymine (6). To a solution of 5 (205 mg, 0.316 mmol) 
in dry CH2Ch was added 2,6-lutidine (0.15 mL, 1.26 mmol) under a N2 atmosphere. tert-
Butyldimethysilyl triflate (TBDMOTf; 0.218 mL, 0.948 mmol) was then added dropwise 
with stirring at r.t. to yield a c1ear yellow solution. After stirring at 40°C for 12 h, 
saturated NaHC03 (12 mL) was added. The aqueous phase was separated and washed 
several times with CH2Ch. The combined CH2Ch layers were dried over Na2S04 and 
evaporated to dryness. Purification by silica gel column chromatography with 0.5% NEt3 
in CH2Ch:MeOH (100:1 to 20:1 v:v) afforded 6 in 72% yield (0.173 g). When the 
silylation reaction was conducted at r.t. for 4 h, the yield of the title compound increased 
to 83%. Rf (Si02) = 0.64 (15: 1 CH2Ch/MeOH); IH NMR (500 MHz, DMSO-d6): 811.33 
(s, 1H, N-H), 7.83-6.88 (19H, ArH), 7.50 (s, IH, H6), 6.12 (d, 3J1 ',2' = 8.5 Hz, 1H, Hl'), 
4.57,4.30 (2m, 2H, CH2-C2'), 4.55 (m, IH, H3'), 3.97 (m, 1H, H4'), 3.71 (s, 3H, OCH3), 
3.24 (m, 2H, H5' & H5"), 3.00 (m, IH, H2'), 1.42 (s, 3H, CH3-C5), 0.80 (s, 9H, t-Bu-Si), 
0.02, -0.06 (2s, 6H, (CH3h-Si). IH NMR (400 MHz, acetone-d6): 89.94 (s, 1H, N-H), 
7.96-6.91 (17H, ArH), 7.61 (s, IH, H6), 6.35 (d, 3JI ',2' = 8.8, IH, Hl'), 4.78-4.42 (m, 3H, 
H3' and CH2-C2'), 4.15 (br, m, IH, H4'), 3.79 (s, 3H, OCH3), 3.44 (m, 2H, H5' & H5"), 
3.18 (m, 1H, H2'), 1.44 (s, 3H, CH3-C5), 0.92 (s, 9H, t-Bu-Si), 0.14, -0.08 (2s, 6H, 
(CH3h-Si). ESI-MS for C44H50N20sSi [MNa+] ca1cd. 785.33, found 758.3. 
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1-[3-0-tert-Butyldimethylsilyl-2-deoxy -2-a-C -hydroxymethyl-5-0-( 4-methoxy-
trityl)-~-D-ribofuranosyl]thymine (7). A saturated solution of NaOMe in Me OH (4 mL) 
was added to 6 (0.337 g, 0.442 mmol) at r.t. After stirring for 2-3 h, the reaction mixture 
was washed with saturated NaHC03 (10 mL). The aqueous phase was separated and 
washed several times with CH2Clz. The combined CH2Clz layers were dried over Na2S04, 
filtered and evaporated to dryness. Purification by silica gel column chromatography with 
0.5% NEt3 in CH2ClzIMeOH (100: 1 to 15: 1 v/v) afforded 7 in quantitative yield (290 mg). 
Rf (Si02) = 0.43 (15: 1 CH2ClzlMeOH); IH NMR (400 MHz, DMSO-d6): <:5 11.30 (s, 1H, 
N-H), 7.47 (s, 1H, H6), 7.40-6.89 (m, I4H, ArH), 5.93 (d, 3 h,2' = 7.6 Hz, 1H, Hl'), 4.57 
(d, 3 JoH, H3' = 4.8 Hz, 1H, OH); 4.45 (br m, IH, H3'), 3.90 (br, IH, H4'), 3.73 (s, 3H, 
OCH3), 3.68, 3.45 (2m, 2H, CH2-C2'), 3.19 (m, 2H, H5' and H5"), 2.53 (m, 1H, H2'), 
1.51 (s, 3H, CH3-C5), 0.82 (s, 9H, t-Bu-Si), 0.05, -0.04 (2s, 6H, (CH3h-Si). ESI-MS for 
C37H46N207Si [MNa+] calcd. 681.31, found 681.2. 
1-[2-a-C -( (~-Cyanoethyl-N,N -diisopropylphosphoramidic )-hydroxymethyl)-2-
deoxy-5-0-(4-methoxytrityl)-~-D-ribofuranosyl]thymine (8). N-ethyl-N,N-diisopropyl-
amine (0.276 mL, 0.205 g, 1.58 mmol) was added to a solution of 7 (0.29 g, 0.44 mmol) 
in dry THF (3 mL) under a N2 atmosphere. The reaction was initiated by addition of ~­
cyanoethyl-N,N-diisopropylchlorophosphoramidite via syringe (0.125 g, 0.118 mL, 0.528 
mmoI). After 2 h, the reaction mixture was passed through a 2-cm layer of silica gel (pre-
neutralized with 1 % NEt3), and the desired compound eluted by washing with ice cold 
hexane followed by CH2Ch. Evaporation of the solution afforded the title compound as a 
nice white foam (353 mg, 97% yield). Rf (Si02) = 0.63 (2: 1 EtOAc/hexane); 31p NMR 
(200 MHz, CDCh): <:5 148.90, 148.24. ESI-MS for C46H63N40gPSi [MNa+] calcd. 881.42, 
found 881.2. 
1-[2-Deoxy -2-a-C -hydroxymethyl-5-0-( 4-methoxytrityl)-~-D-ribofuranosyl]­
thymine (9). A saturated solution of NaOMe in Me OH (2 mL) was added to 5 (0.208 g, 
0.321 mmol) and the resulting mixture stirred at r.t. for 2 h. The reaction mixture was 
then washed with brine (5 mL) followed by CH2Clz (20 mL). The combined CH2Clz 
layers were dried over Na2S04, filtered and evaporated to dryness. Purification by silica 
gel flash column chromatography with 0.5% NEt3 in CH2C}z/MeOH (15: 1 v/v) afforded 9 
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in quantitative yield (175 mg). Rf (Si02) = 0.26 (15:1 CH2CblMeOH); lH NMR (400 
MHz, acetone-d6): 57.6 (d, 41cH3-C5,H6 = 1.2 Hz, IH, H6), 7.52-6.91 (m, 14H, ArH), 6.21 
(d, 31r,2' = 8.4 Hz, IH, Hl'), 4.65 (br, m, IH, H3'), 4.10-4.12 (m, IH, H4'), 3.98, 3.79 
(2dd, 21CH2_c2' = 11.2 Hz, 31cH2_C2', H2' = 10.0, 6.8 Hz, 2H, CH2-C2'), 3.42-3.35 (AB, dd, 
215',5" = 9.6 Hz, 314',5'+5" = 4.0,3.2 Hz, 2H, H5' & H5"), 2.64-2.71 (m, IH, H2'), 1.49 (s, 3H, 
CH3-C5). lH NMR (500 MHz, DMSO-d6): 511.30 (s, IH, N-H); 7.47 (s, IH, H6); 7.39-
6.89 (m, 14H, ArH); 5.97 (d, 311 ',2' = 8.5 Hz, IH, Hl '), 5.30 (d, 310H, H3' = 5.5 Hz, IH, 3'-
OH); 4.54 (bs, IH, C2'-C-OH); 4.30 (bs, IH, H3'); 3.91 (m, IH, H4'); 3.73 (s, 3H, OCH3); 
3.74-3.43 (2m, 2H, CH2-C2'); 3.20, 3.12 (2dd, 215',5" = 10.5 Hz, 314',5'+5" = 4.5, 3.0 Hz, 2H, 
H5' & H5"), 2.45 (m, IH, H2'), 1.40 (s, 3H, CH3-C5); ESI-MS for C3lH32N207 [MNa+] 
ca1cd. 567.22, found 567.2. 
1-[2-a-C-tert-Butyldimethylsilyloxymethyl-2-deoxy-5-0-(4-methoxytrityl)-P-n-
ribofuranosyl]thymine (10). To a solution of 9 (0.186 g, 0.342 mmol) in dry pyridine (3 
mL) under a N2 atmosphere was added AgN03 (0.067 g, 0.393 mmol) followed by 
TBDMSCI (59 mg, 0.393 mmol). After stirring for 12 h at r.L, the reaction was 
concentrated and the residue taken up in CH2Cb. The solution was washed with saturated 
NaHC03 (10 mL), dried, filtered, and finally evaporated to yield the crude product. 
Purification by silica gel column chromatography with 0.5% NEt3 in CH2CbIMeOH 
(100: 1 to 15:1 v/v) afforded the title compound in 66% yield (148 mg). Rf (Si02) = 0.64 
(15: 1 CH2CblMeOH); lH NMR (300 MHz, DMSO-d6): 511.25 (s, IH, N-H); 7.47 (s, IH, 
H6); 7.39-6.87 (m, 14H, ArH); 6.08 (d, 31r,2' = 8.7 Hz, IH, Hl '); 5.32 (d, 310H, H-3' = 4.8 
Hz, IH, OH); 4.31(br m, IH, H3'); 3.98-3.64 (m, 2H, CHr C2'); 3.73 (s, 3H, OCH3); 3.23, 
3.13 (2dd, 314',5'+5" = 4.2, 3 Hz, 2H, H5' and H5"); 2.57 (m, IH, H2'); 1.37 (s, 3H, CH3-
C5); 0.79 (s, 9H, t-Bu-Si); 0.01- -0.04 (t, 6H, (CH3hSi); ESI-MS for C37~6N207Si 
[MNa+] calcd. 681.31, found 681.2. 
1-[2-a-C-tert-Butyldimethylsilyloxymethyl-3-0-(p-cyanoethyl-N,N-diisopropyl-
phosphoramidic )-2-deoxy -5-0-( 4-methoxytrityl)-p-n-ribofuranosyl]thymine (11). p-
cyanoethyl-N,N-diisopropylchlorophosphoramidite (32 ilL, 0.034 g, 0.145 mmol) was 
slowly added to a solution of 10 (0.148 g, 0.121 mmol) and N-ethyl-N,N-
diisopropylamine (76 Ill, 0.056 g, 0.436 mmol) in dry THF (1.2 mL) under a N2 
75 
Chapter II 
atmosphere. After stirring for 2.5 h, the crude mixture was passed through a 2-cm layer of 
silica gel (pre-neutralized with 1 % NEt3), and the desired compound eluted by washing 
with ice cold hexane followed by CH2Ch Evaporation of the solution afforded the title 
compound as a nice white foam (101 mg, 52% yield). Rf (Si02) = 0.46 (2:1 
EtOAc/hexane); 31p NMR (200 MHz, CDCh): J 151.7, 150.3; ESI-MS for 
C46H63N40SPSi [MN a +] ca1cd. 881.42, found 881.2. 
Solid Phase Synthesis of Oligonucleotides. 
Oligonucleotide syntheses were carried out on a 1 J.tmol scale usmg an Applied 
Biosystems DNAIRNA 381A synthesizer as previously described [1,3,151. Solutions of 
phosphoramidites 8 and 11 in acetonitrile (0.09 M) were allowed to react with the solid 
support for an extended coupling time of 30 min using DCI in acetonitrile (0.5M) as 
catalyst. These conditions afforded over 99% coupling efficiency. Deprotection was 
conducted by addition of (a) conc. aq. ammonia/ethanoI (3: 1 v/v, 1 mL, 48 h, r.t.) 
followed by evaporation; (b) TEA·3HF (100-200 J.tL, 48 h, r.t.) followed by evaporation. 
TypicaIly, 40-80 OD units (A260) of the oligonucleotides were obtained at this point. 
OIigonucleotides were purified by anion-exchange HPLC (Protein Pak DEAE-5PW 
column-Waters; 7.5 mm x 7.5 cm), desalted by size-exclusion chromatography on 
Sephadex G-25 matrix, and characterized by MALDI-TOF mass spectrometry (Ivatos 
Kompact-III instrument; Kratos Analytical Inc., New York). Purity of the isolated 
oligonucleotides was >95%. 
UV Thermal Denaturation Studies. 
UV thermal denaturation data was obtained on a Varian CARY 1 spectrophotometer 
equipped with a Peltier temperature controller (Varian; Mulgrave, Australia). Oligomers 
and complementary targets were mixed in equimolar ratios in 140 mM K+, 1 mM Mg2+, 
and 5 mM Na2HP04 buffer, pH 7.2, which is representative of intracellular conditions [161. 
The total strand concentration was 2.6 J.tM. Samples were heated to 90 Oc for 5 min, 
cooled slowly to r.t., and refrigerated (4 OC) overnight before measurements. Prior to the 
thermal run, samples were degassed by placing them in an ultrasound bath for 1 min. 
Denaturation curves were acquired at 260 nm at a rate of heating of 0.5° C/min. The data 
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were analyzed with the software provided by Varian Canada and converted to Microsoft 
Excel. Tm values were calculated as the maximum of the first-derivative plots of 
absorbance versus temperature and have an uncertainty of ±l Oc. Hyperchromicity values 
(i.e. changes in relative absorbance) were calculated using the formula: H = (AcAD/Ah, 
where H is the hyperchromicity, At is the absorbance at any given temperature (t), Ai is 
the initial absorbance reading, and Ah is the absorbance at the highest temperature. 
Circular Dichroism (CD) Spectra. 
CD spectra (200-350 nm) were collected on a Jasco J-71O spectropolarimeter at a rate of 
100nrnlmin using fused quartz cells (Hellma, 165-QS). Measurements were carried out in 
140 mM K+, 1 mM Mg2+, and 5 mM Na2HP04 buffer, pH 7.2 [16] at a duplex 
concentration of 2.6 M-M. The temperature was controlled by an external circulating bath 
(VWR Scientific) at constant temperature (5 OC). The data were processed on a PC 
computer using J-700 Windows software supplied by the manufacturer (JAS CO, Inc.). To 
facilitate comparisons, the CD spectra were background subtracted, smoothed and 
corrected for concentration so that molar ellipticities could be obtained. 
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Scheme 2.2: Synthesis of 8. (i) BzCI, py., r.t., 4 h, 100%; (ii) bis(trimethylsilyl) thymine, 
SnCI4, CH3CN, 50°C, overnight, 72% (isomer mixture, ~/a 5: 1); (iii) 10% Pd/C, H2 (40-
50 psi), MeOH, r.t., 6 h, 71 % ~ pure isomer; (iv) MMTr-CI (l.5eq.), AgN03, py, r.t., 
overnight, 72%; (v) TBDMSOTf, 2,6-lutidine, THF, r.t., 4 h, 83%; (vi) NaOMe, MeOH, 
r.t., 2-3 h, 100%; (vii) iPr2NEt, (iPr2N)(OCH2CH2CN)PCI, THF, r.t., 2 h, 97%. 
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Scheme 2.3 Synthesis of 11. (i) NaOMe, MeOH, Lt., 2 h, 100%; (ii) TBDMSCl, AgN03, 
py, Lt., overnight, 66%; (iii) iPr2NEt, (iPr2N)(OCH2CH2CN)PCl, THF, Lt., 2.5 h, 52%. 
Results and Discussion 
Monomer Synthesis 
Schemes 2.2 and 2.3 show the synthesis of 2'-a-hm-dT (abbreviated in this work as "H") 
and its conversion to the 2'-CH20- (8) and 3'-O-phosphoramidites (11), using a synthetic 
strategy analogous to that previously described by Schmit [17] and Li and Piccirilli [18]. We 
protected the C2'-CH2-OH moiety of O-glycoside 1[14] as the benzoyl ester rather than as 
Schmit's acetyl ester, since we found that the latter was not stable un der the conditions of 
the subsequent hydrogenolysis reaction (Scheme 2.2). Coupling of 2 with 
bis(trimethylsilyl)thymine in the presence of SnCl4 catalyst gave anomeric nuc1eosides 3 
in good yield with a ~/a stereoselectivity of 5: 1. It is interesting to note that the ~/a 
stereoselectivity was found to be higher for the C2-CH2-OAc derivative (10: 1), in 
agreement with Schmit's findings.[12,17] Separation of the anomers by column 
chromatography was achieved after removal of the 2,4-dichlorobenzyl protecting groups, 
to provide the desired ~ anomer in 71 % yield from 3. The anomeric configuration of 4 
was unequivocally established using NOESY NMR, which displayed strong Hl'-H4', 
H2'-H6', 2'-CH2-H4', and H5'-H6 cross peaks. Reprotection of hydroxyl groups with 
MMTrCl followed by TBDMSOTf gave 6 in good yields. [19] Attempts to carry out the 
silylation reaction with TBDMSCI (DMF/imidazole or AgN03/py) proved to be 
problematicYO] Lastly, we converted 6 to the 2'-CH20-phosphoramidite derivative 8 via 
consecutive debenzoylation and phosphitylation reactions (Scheme 2.2). To access the 3'-
O-phosphoramidite derivative, nucleoside 5 was treated with NaOMe to give diol9 
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Table 2.1: Thermal denaturation data (Tm) of duplexes 
Tm3 (!1T m)b 
No. Designation Oligonucleotide 
DNA RNA 2',S'-RNA 
2',S'-RNA containing 2',S'-H (H) and 3',S'-H (H) C 
1 2,SRNA S'-rGUC UGU UGU GUG ACU CUG GUA AC-2' br d 61.6 41.3 
II 2',S'-H S'-rGUC UGU HGU GUG ACU CUG GUA AC-2' br 60.7 (-0.9) 40.5 (-0.8) 
III 2'-S'-Hx2 S'-rGUC UGH HGU GUG ACU CUG GUA AC-2' br 60.6 (-O.S) 40.0 (-0.7) 
IV 2',S'-Hx3 S'-rGUC UGH HGH GUG ACU CUG GUA AC-2' br 60.S (-0.3) 39.1 (-0.6) 
V 2',S'-rA S'-rGUC UGU AGU GUG ACU CUG GUA AC-2' br S6.8 (-4.8) 37.3 (-3.5) 
VI 2',S'-rAx2 S'-rGUC UGA AGU GUG ACU CUG GUA AC-2' br S4.3 (-3.7) 34.0 (-3.7) 
VII 2',S'-rA x3 S'-rGUC UGA AGA GUG ACU CUG GUA AC-2' br 48.0 (-4.S) 28.0 (-4.3) 
VIII 3',S'-H S'-rGUC UGU HGU GUG ACU CUG GUA AC-2' br S8.0 (-3.6) 37.4 (-3.9) 
RNA containing 2',S'-H (H) and 3',S'-H (H) 
IX RNA S'-rGUC UGU UGU GUG ACU CUG GUA AC-3' 6S.0 78.4 S7.1 
X 2',S'-H S'-rGUC UGU HGU GUG ACU CUG GUA AC-3' 62.0 (-3.0) 77.2 (-1.2) S2.8 (-4.3) 
XI 3',S'-H S'-rGUC UGU HGU GUG ACU CUG GUA AC-3' 63.0 (-2.0) 77.7 (-0.7) S4.1 (-3.0) 
XII 2',S'-rU S'-rGUC UGU UGU GUG ACU CUG GUA AC-3' 62.0 (-3.0) 78.0 (-0.4) 54.1 (-3.0) 
XIII 3',5'-rA S'-rGUC UGU AGU GUG ACU CUG GUA AC-3' 61.1 (-3.9) 74.1 (-4.3) 51.1 (-6.0) 
DNA control 
XIV DNA S'-dGTC TGT TGT GTG ACT CTG GTA AC-3' 68.0 69.0 br 
a Tm in oC, deviation ±1 oC; Complementary DNA sequence S'-dGUU ACC AGA GUC ACA CAA CAG AC-3'; complementary RNA 
sequence: S'-rGUU ACC AGA GUC ACA CAA CAG AC-3'; complementary 2',S'-RNA sequence: S'-GUU ACC AGA GUC ACA 
CAA CAG AC-2'; Buffer: 140 mM K+, 1 mM Mg2+, and S mM Na2HP04, pH = 7.2; b!1Tm, the Tm change per one modified nucleotide 
or mismatch relative to entries 1 or IX; C 2',S'-H is shown as H; 3',S'-H as H; 2',S'-rA as A, 3',S'-rA as &.; 2',S'-rU as U in the 
sequence. d Broad transition. 
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quantitatively. Consecutive silylation with TBDMSCI (AgN03/py) and phosphitylation 
reactions then afforded the desired compound 11 in moderate yield (52%) (Scheme 2.3). 
Oligonucleotide Synthesis. 
To investigate the effect of 2',5'- and 3',5'-linked H units on the stability of duplexes, 
monomers 8 and 11 were incorporated into various oligonucleotide sequences by 
convention al phosphoramidite chemistry (Table 2.1).[1,15,20] 4,5-Dicyanoimidazole (DCI) was 
used to activate the phosphoramidites[15] and provided average coupling efficiencies of 99% 
as monitored by the release of the monomethoxytrityl (MMT) cation (see Materials and 
Methods). Deprotection conditions of oligonucleotides were similar to those employed in 
RNA synthesis.[20] Oligonucleotides were purified by anion-exchange HPLC and their identity 
verified by MALDI-TOF mass spectrometry (Supplementary Data). The HPLC 
chromatograms showed that 2',5'-RNA oligomers elute more rapidly relative to 3',5'-RNA 
oligomers of the same base composition (Supplementary Data). 
Hybridization Studies (Tm and CD analysis). 
The binding affinity of various mixed backbone oligonucleotides with one to three H units to 
complementary ssDNA, ssRNA and 2',5'-ssRNA targets was evaluated in a buffer designed to 
simulate intracellular conditions (Table 2.1). The oligomers, 23 nt in length, were a U5 region 
of HIV-l genomic RNA. Oligomers containing 2',5'-H substitutions (II-IV, X), 3',5'-H 
substitutions (VIII, XI) or mismatched bases (V-VII, XIII) were prepared in order to 
ascertain Watson-Crick pairing of the H residues. As a comparison, the hybridization 
properties of unmodified 2',5'-RNA (1), RNA (IX) and DNA (XIV) sequences were also 
measured, along with a 3',5'-linked oligomer containing a single 2',5'-linked uridine residue 
(XII). Thermal dissociation data (Tm, 15.T m) for the complexes formed are presented in Table 
2.1 and representative melting and circular dichroism (CD) curves are shown in Figure 2.3. 
The key observations can be summarized as follows: 
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Figure 2.3: Buffer: 140 mM K+, 1 mM Mg2+, and 5 mM Na2HP04, pH 7.2. Oligonucleotides 
were hybridized to complementary RNA (A and C) Thermal melting curves and CD profile, 
respectively, of 2',5'-RNA with 2',5'-H, 3',5'-H and mismatch 2',5'-rA; (B and D). Thermal 
melting curves and CD profile, respectively, of RNA with 2',5'-H, 3',5'-H, 2',5'-rU and 
mismatch 3',5'-rA. 
(a) 2',S'-H Substitutions in the 2',S'-RNA strand: Both 2',5'-RNA:RNA and 2',5'-
RNA: 2',5'-RNA duplexes can accommodate a single 2',5'-H residue with a small loss of 
stability (I1T fi - -0.8-0.9 OC). This destabilization is significantly smaller than that created by 
a mismatch at the same position (I1Tm - -4 oC ), suggesting that 2',5'-H residues in the se 
duplexes retain classical base-pairing interactions. When the number of 2',5'-H units is 
increased to three (e.g., hybrid IV:RNA) the depression in Tm is only -0.3 oC/modification, 
suggesting a stabilizing effect by the nearly contiguous 2',5'-H residues (Figure 2_3A). A 
nearly superimposable CD signature of the singly and triply substituted hybrids (II:RNA and 
IV:RNA) with control duplex I:RNA was observed, strongly suggesting that the 2',5'-H 
inserts do not perturb the global morphology of the duplexes (Figure 2.3C)- The affinity 
towards RNA targets is likely to be dependent upon the ratio and intrastrand placement of 
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normal (2',5'-rN) and 2',5'-H units, and based on the above results, a smaller thermal 
destabilization is to be expected upon increasing the number of consecutive H residues. In 
fact, based on the observed trend from one to three inserts, a fully-modified strand constructed 
from 2',5'-H units might possibly have a binding affinity to RNA targets comparable to that of 
2',5'-RNA. 
The mode st destabilization induced by 2',5'-H units is remarkable in view of the one 
bond chain extension introduced at each of these residues compared with 2',5'-RNA (Figure 
2.1 and Scheme 2.1). In addition to the energy (electrostatic) considerations described above, 
these phenomena may be explained by the anticipated conformation of the 2',5'-H units 
(Figure 2.2). Yathindra et al. have shown that the sugars of 2',5'-linked RNA favor a C2'-endo 
conformation, which renders the backbone to be "compact" and of almost equivalent length to 
that found in the native RNA (i.e., C3'_endo).[IO,II] With the C3'-endo sugar, the 3'-hydroxyl 
group would sterically interfere with the 2'-O-phosphate linkages. The same "compact" 
conformation is expected for 2',5'-H residues, since a strong 04'-C4'-C3'-03' gauche effect 
(and lack of an opposing 04'-Cl'-C2'-02' gauche effect) would reinforce the C2'-endo pucker 
(Figure 2.2). Rence, oligonucleotides that are pre-organized in a "compact" (or RNA-like) 
conformation are expected to bind to "compact" RNA strands, and bind weakly, if at aH, to 
"extended" oligonucleotide targets (e.g. ssDNA). Such conformational compatibility or 
spatial "matching" likely accounts for the ability of oligonucleotides 1 through VIII to 
maintain a stable association with complementary RNA, but not with ssDNA (Table 2.1).[1] 
(b) 2',5'-H Substitutions in the RNA strand & 3',5'-H substitutions in the 2',5'-
RNA strand: The destabilizing effect of 2',5'-H units appears to be greater when incorporated 
into RNA strands (I1T ID > -1°C/modification), regardless of whether the target is 
complementary RNA or 2',5'-RNA (Sequence X, Table 2.1). Similarly, the presence of 3',5'-H 
within 2',5'-RNA leads to reduced duplex stability, with an equal destabilization observed 
when targeting both RNA and 2',5'-RNA (Sequence VIII, Table 2.1). Consistent with this 
notion, the singly-substituted hybrids VIII:RNA and X:RNA showed a blue shift in the CD 
band at 270 nm, whereas hybrids II:RNA and XI:RNA displayed nearly the same CD profile 
as the corresponding unmodified controls (Figure 2.3-C and D). As pointed out previously, 
[l,Il] these observations may reflect the major disruption in the normal helical structure 
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induced by the abrupt displacement of the backbone from the periphery towards the interior of 
the helix (2'-CH20P to 3'-OP) and vice versa (3'-OP to 2'-CH20P). 
(c) 3',5'-H Substitutions in the RNA strand: Regarding the effects of 3',5'-H units 
within an RNA strand on hybridization affinity for complementary RNA, a significantly less 
pronounced decrease in duplex stability was observed in RNA:RNA duplexes (I1Tm - -0.7 OC) 
than for Schmit's DNA:RNA hybrids (3',5'-H in the antisense DNA strand; I1Tm - -3 oC).[12] 
It may be speculated that this is caused, at least in part, by the narrower minor groove width 
of DNA:RNA hybrids (compared to RNA:RNA) leading to more unfavourable interactions 
involving the large 2'-CH2-OH group. A much larger decrease in binding affinity was 
observed for the RNA strand containing a mismatch, confirming the contribution of the 
thymine base of 3',5'-H to binding (XIII:RNA vs XI:RNA; Table 2.1). 
Stabilization of Hairpin Structures by 2',5'-H Units. 
We next tumed our attention towards RNA "hairpins" and studied the effect of incorporating 
single or multiple 2',5'-H units into the loop of these structures (Figure 2.4-A and Table 2.2). 
We have previously shown that hairpin Pl retains an A-form conformation, displays ample 
resistance against nucleases, and inhibits the RNase H activity of HIV reverse transcriptase. 
[15,21,22] The ribonucleotide residues in the loop are connected by 2',5'-phosphodiester linkages 
and collectively fold into a distinct rigid structure that is unlike the native 3',5'-tetraloop 
structureY5] In view of the anticipated compact conformation of 2',5'-H residues (Figure 2.2), 
it was of interest to discover how these units would influence the stability of the hairpin. This 
Table 2.2: Thermal denaturation data of RNA hairpins with modified 2',5'-linked loops 
ID Designation a Hairpin Loop 
Pl RRR 5'-GGAC(UUCG)GUCC-3' 64.7 
P2 RR(H21R 5'-GGAC(HUCG)GUCC-3' 63.7 (-1.0) 
P3 RR(H61R 5'-GGAC(UHCG)GUCC-3' 66.2 (+1.5) 
P4 RR(H5,61R 5'-GGAC(HHCG)GUCC-3' 65.1 (+0.2) 
aUnderlined residues are connected via 2',5'-phosphodiester linkages; b Tm was measured 
at the wavelength of 260 nm in 0.01 M Na2HP04, 0.1 mM Na2EDTA, pH 7.0; 
oligonucleotide concentration -4.5 IlM. Values represent the average of at least five 
independent measurements. Error in Tm is within ±1 Oc. cl1Tm, the Tm change per one 
2',5'-H (represented as H in the sequence). 
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Figure 2.4. (A). Hairpin structure and residue numbering: the tetra loop UUCG is connected 
via 2',5'-phosphodiester linkages, and the modification occurs at the lli and/or U6 positions; 
(B). Thermal melting curves of RNA hairpins with 2',5'-H modified loops; (C). Tm 
concentration independence over 30-fold range; (D). CD spectra. 
was particularly intriguing given that a recent study by Denisov et al. showed that the 2',5'-
rUCCG loop residues of hairpin Pl adopt a U5(extended)-U6(compact)-C7(compact)-
G8( extended) conformation. [22] Therefore, we anticipated that substitution at position 6 would 
be better tolerated than one at position 5, particularly if the compact conformation of the 2',5'-
H unit was preserved at both loop positions. Indeed, we found that a 2',5'-H unit at position 6 
(P3) increases hairpin stability, with an increase in Tm of + 1.5 oc relative to the parent hairpin 
Pl (Table 2.2). This stabilization is nearly offset by the incorporation of a second 2',5'-H unit 
at position 5 (P4, I1T m +0.2 OC), which may again be rationalized on the basis of a very 
strong preference of the 2',5'-H unit for a compact (C2'-endo) conformation. In view of this, it 
is not surprising that a single 2',5'-H substitution at position 5 (P2), where an extended 
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nuc1eotide conformation is preferred, is destabilizing (l1T m -1.0 OC). Regarding the CD 
profiles, the solution conformations of aIl hairpins are similar to that of the control Pl, with 
only slight variations in the intensity of the bands. The hairpins containing 2',5'-H units at 
position 5 (P2 and P4) were found to present a reduction in the positive CD band at 260 nm 
(Figure 2.4-D) relative to Pl and P3, consistent with the expected conformational change at 
this position, i.e., extended 2',5'-rU ~ compact 2'S-H. 
Conclusions 
In summary, we have studied the behavior of oligoribonuc1eotides (2',5'-RNA and RNA) 
containing H units toward complementary RNA, 2',5'-RNA and DNA. The data obtained 
demonstrated a destabilization effect upon substituting a rU with H, regardless of whether H 
was 2',5' or 3',5'-linked. This destabilization was minimized when the 2',5'-H and 3',5'-H were 
incorporated into 2',5'-RNA and RNA strands, respectively (l1T m < -1.0 OC). It is expected 
that longer oligomers containing this modification, particularly if they contain 2',5'-linkages, 
will show adequate thermal stability, significant nuc1ease stability [23) and binding to mRNA 
targets. 
In spite of the drop in thermal stability observed when 2',5'-H units are incorporated 
into RNA duplexes, a significant increment in stability was observed when they were 
incorporated into hairpin loops (l1T m + 1.5 OC). These results and those described above lend 
strong support to the notion of 'compact'/'extended' 2',5'/3',5'-backbone structure and its 
effect on hybrid stability [Il). The ability of hairpins containing stabilizing 2',5'-H units to 
inhibit RN RT in vitro will be the subject of a separate publication. 
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Scheme S2.2a: preparation of 1 in Scheme 2.2: (i) MeOH, H2S04, 4°C, overnight, 95%; 
(ii) 2,4-dichlorobenzyl chloride, NaH, DMF, 40°C, overnight, 73%; (iii) a. SnC14, 4°C, 
overnight; b. H20, 84%; (iv) Dess-Martin periodinane, CH2Clz, r.t., overnight, 100%; or 
pyridinium dichromate, acetic acid, CH2Clz, r.t., over night, 68%; or Cr03, py., AC20, 
CH2Clz, r.t., 4 h, 42%; (v) methyltriphenylphosphonium bromide (Ph3PCH3Br), sodium 
tert-pentoxide (t-C5H70Na), ether, benzene, 4°C, overnight, 95%; (vi) a. 9-bora-
bicyclo[3.3.1]nonane (9-BBN), THF, 40°C, overnight; b. NaB03, H20lEtOH, 50°C, 4 h, 
82%; 
Methyl 2,3,5-tri-O-(2,4-dichlorobenzyl)-a,~-D-ribofuranoside (lb). A solution 
of D-ribose la (25 g, 167 mmol) in 500 mL dry methanol was cooled to O°C and treated 
with 2.5 mL concentrated H2S04 under a N2 atmosphere. The reaction mixture was 
stirred at 4°C overnight (12-16 h) and then neutralized by passing through a bed of 
Amberlite IRA-400 (Aldrich) in the free base form. The filtrate was concentrated under 
vacuum to a colourless syrup (5 g, 30.5 mmol), then redissolved in 30 mL anhydrous 
DMF. A solution of NaH (4.4 g, 183 mmol) in 50 mL anhydrous DMF was cooled to 
O°C under a N2 atmosphere and then added. The reaction mixture was gradually warmed 
up and kept at 60°C for one hour until no more gas was produced. The reaction mixture 
was cooled down to O°C again and 2,4-dichlorobenzyl chloride (12.7 mL, 91.41 mmol) 
was added slowly. The reaction solution was gradually warmed up and stirred at 40°C 
overnight (16 h). The reaction progress was monitored by TLC. The reaction mixture was 
poured into ice and washed with three portions of CH2Ch. The combined organic phases 
were dried over Na2S04 and concentrated until a precipitate formed, which was filtered 
and washed by cold hexanes several times, then dried under vacuum to afford lb (14.27 g, 
73% yield). The mother liquid after the filtration was evaporated to an oily liquid and still 
contained sorne product lb (not isolated). Rf (Si02) = 0.5-0.54 (3:5 Ether/Hexane); 0.83 
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(5:2 EtherlHexane); I H NMR (200 MHz, CDCb): 87.12-7.45 (m, 9H, ArH), 4.98 (s, IH, 
Hl), 4.59-4.7 (m, 6H, benzyl CH2), 4.32-4.40 (m, 1H, H4), 4.16 (dd, 3 h,3 = 4.6 Hz, 3 J3,4 
= 7.0 Hz, 1H, H3), 3.97 (d, 3 h,3 = 4.6 Hz, IH, H2), 3.60-3.78 (AB dd, 2J55' = 16.8 Hz, 
3 J4,5;4,5' = 3.9, 5.3 Hz, 2H, H5), 3.36 (s, 3H, OCH3). ESI-MS for C27H24CI605[MNa+] 
ca1cd. 660.98, found 662.9. 
Methyl 3,5-di-O-(2,4-diehlorobenzyl)-a.-D-ribofuranoside (le). Under a N2 
atmosphere, a solution of lb (14.27 g, 22.2 mmol) in 140 mL CH2Ch was cooled to O°C 
and a 1 M solution of SnCl4 in dry CH2Ch (34 mL, 34 mmol) was added. The reaction 
mixture was stirred at 4°C overnight until TLC analysis showed the reaction was 
completed. The reaction mixture was poured into 140 mL saturated aqueous NaHC03 
and gently mixed to minimize emulsion formation. The aqueous layer was washed with 3 
x 150 mL CHCh. The combined organic phases were dried over Na2S04 and evaporated 
to an oil. Purification by silica gel column chromatography with ether/hexanes (1: 1 v/v) 
afforded the title compound le as an oil (9 g, 84% yield). Rf (Si02) = 0.54-0.58 (5:2 
ether/hexanes); IH NMR (200 MHz, CDCb): 87.18-7.42 (m, 6H, ArH), 4.91 (d, 3 Jl,2 = 
4.6 Hz, 1H, Hl), 4.70, 4.56 (2AB, 2J = 16.6,6.6 Hz, 4H, benzyl CH2), 4.19-4.26 (m, IH, 
H4), 4.14 (dd, 3 h3 = 7 Hz, 3JI ,2 = 4.6 Hz, 1H, H2), 3.84 (dd, 3 h,4 = 3.2 Hz, 1H, H3), 3.59 
(d, 3 J4,5 = 4.4 Hz, 2H, H5), 3.48 (s, 3H, OCH3), 2.90 (d, J = Il.4, 1H, OH). ESI-MS for 
C2oH2oCl405 [MNa+] ca1cd. 505.18, found 505.0. 
Methyl 3,5-di-O-(2,4-diehlorobenzyl)-2-oxo-a.-D-ribofuranoside (Id). A 
solution of le (9 g, 18.7 mmol) in 27 mL dry CH2Ch was added to an ice cold suspension 
of Dess-Martin periodinane (9.5 g, 22.4 mmol) in 27 mL dry CH2Ch. The resulting 
mixture was kept stirring at r.1. under a N2 atmosphere overnight (8-12 h). The reaction 
progress was monitored by TLC after 4 h. (If necessary, a further 0.2 equiv. (1.58 g, 3.73 
mmol) of Dess-Martin periodinane can be added to the reaction mixture to push the 
reaction to completion.) The reaction mixture was passed through a 2-cm silica gel layer 
in a sintered glass filter. After washing with ether, the combined filtrates were washed by 
saturated aqueous NaHC03 153 mL, brine 153 mL, dried by Na2S04, and evaporated to 
dryness. The residue was dissolved in ice-cold ether and filtered to remove insoluble 
impurities. Evaporation of the ether solution afforded an oil Id (8.96g, quantitative yield) 
which was used for the next reaction without further purification. 
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Under a Nz atmosphere, aeetic acid (1.27 mL, 2.22 mmol) was added to an iee-
cold suspension of pyridinium dichromate (7.22 g, 19.2 mmol) in 20 mL dry CHzClz. The 
mixture was stirred at O°C for 10 min and a solution of le (6.15 g, 12.8 mmol) in 40 mL 
dry CHzClz was added. The reaction mixture turned dark brown, and was stirred at r.t. 
over night. The reaction progress was monitored by TLC until completion. The reaction 
mixture was evaporated to dryness, then ether was added and the mixture was filtered 
through a 2cm silica gel layer in a sintered glass fil ter to remove most of the chromium 
salts. After washing with ether, the filtrates were evaporated to an oil Id (4.14 g, 68% 
yield) which was used for the next reaction without further purification. 
Under a Nz atmosphere, aeetic anhydride (10.6 mL, 110 mmol) and dry pyridine 
(17 mL, 210 mmol) were added to an ice-cooled suspension ofCr03 (10.19 g, 101 mmol) 
in 90 mL dry CHzClz and the reaction mixture was stirred at r.t. for 0.5 h. A solution of 
le (11.86 g, 24.6 mmol) in 30 mL dry CHzClz was added and the mixture was stirred at 
r.t. for 4 h to get a dark brown solution which was poured into 750 mL EtOAc with 
vigorous stirring. The resulting mixture was filtered through a 2-cm layer of silica gel in a 
sintered glass filter, followed by washing with 300 mL EtOAc. The combined filtrates 
were evaporated « 30°C) to dryness. The residue was coevaporated with toluene (75 mL) 
followed by 30 mL CHzClz to yield 5 g (42%) Id as a syrup, which was used 
immediately for the next reaction without further purification. Rf (SiOz) = 0.4 (5:2 
ether/hexanes); I H NMR (300 MHz, CDCb): J 7.40-7.20 (m, 6H, ArH), 4.87 (d, 1H, 
4J1,3 = 0.9 Hz, Hl), 4.56-5.05 (m, 4H, benzyl CHz), 4.37 (ddd, 3J3 ,4 = 9 Hz, 3J4,5;4,5' = 3.3, 
2.1 Hz, 1H, H4), 4.22 (d, 3h,4 = 9 Hz, 4h,1 = 1.2 Hz, IH, H3),3.94, 3.80 (2dd, zJ5,5' = 11.4, 
3 J4,5; 4,5' = 3.3, 2.1 Hz, 2H, H5), 3.50 (s, 3H, OCH3). 
Methyl 3,5-di-O-(2,4-dichlorobenzyl)-2-methylene-a.-D-ribofuranoside (le). 
Under a Nz atmosphere, a solution of sodium t-pentoxide (3.698 g, 33.6 mmol) in 33 mL 
dry benzene was added to an lee cold suspenSIOn solution of 
methyltriphenylphosphonium bromide (13.335 g, 37.3 mmol) in 853 mL dry ether at O°C 
with strong stirring. The resulting mixture was warmed up to r.t. and stirred for 4-6 h. 
The reaction mixture turned to bright yellow cloudy solution. The reaction mixture then 
was cooled down to -78°C and a solution of Id (8.96 g, 18.7 mmol) in 22 mL dry ether 
was carefully added. The reaction was then warmed to 4°C and stirred at that 
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temperature ovemight (10-14 h). The reaction progress was monitored by TLe. After the 
reaction was completed, the reaction mixture was washed with saturated NH4Cl (1440 
mL) and the aqueous phase was extracted by ether three times. The combined organic 
phases were dried over Na2S04 and evaporated to dryness. Purification by silica gel 
column chromatography with EtOAclHexane (1:4 v/v) afforded le (8.45 g, 94.7%). Rf 
(Si02) = 0.8 (5:2 ether/hexane); 0.55 (1:4 EtOAc/Hexane). IH NMR (400 MHz, CDCh): 
f5 7.18-7.42 (m, 6H, ArH), 5.46-5.48 (m, 2H, CH2-C2), 5.26 (t, IH, Hl), 4.56-4.71 (m, 
3 4H, benzyl CH2), 4.33-4.37 (m, IH, H4), 4.30-4.34 (m, IH, H3), 3.70 (d, 14.s = 4 Hz, 2H, 
H5), 3.44 (s, 3H, OCH3). ESI-MS for C21H20Cl404 [MNa+] calcd. 499.01, found 498.9. 
Methyl 2-deoxy-3,S-di-O-(2,4-dichlorobenzyl)-2-a-hydroxylmethyl-a-D-ribo-
furanoside (1) Under a N2 atmosphere, le (20.521 g, 42.91 mmol) was added 9-BBN 
(0.5 M in THF, 250 mL, 125 mmol). The resulting solution was stirred at r.1., then at 
40°C ovemight (10 h), cooled to r.1., and transferred to a round bottom flask containing a 
solution of sodium perborate tetrahydrate (39.61 g, 257 mmol) in 257 mL H20 and 257 
mL ethanol. The resulting solution was kept vigorous stirring at 50°C for 4 h and a lot of 
gas was produced. The reaction mixture was cooled to O°C, neutralized by acetic acid to 
pH 8 and concentrated to a small volume which was diluted with 65 ml water and 
extracted with 436 ml CH2Cb three times. The combine organic phases were washed by 
brine, dried over Na2S04 and evaporated to dryness. Purification by silica gel column 
chromatography with EtOAc/hexane (1:4 v/v) afforded pure 1 (16.414 g, 82% yield). Rf 
(Si02) = 0.54-0.59 (1:4 EtOAc/Hexane). IH NMR (400 MHz, CDCh): 07.19-7.40 (m, 
6H, ArH), 5.04 (d, 311,2 = 5.2 Hz, IH, Hl), 4.52-4.60 (m, 4H, benzyl CH2), 4.31-4.35 (m, 
IH, H4), 4.06 (dd, 3 h.2 = 7.8 Hz, 3 h,4 = 3.4 Hz, IH, H3), 3.94 (t, 2H, CH2-C2), 3.55-3.64 
(AB dd, 21s,5' = 20.6 Hz, 3hs;4,S' = 4.8,4.4 Hz, 2H, H5), 3.424 (s, 3H, OCH3), 2.51-2.58 
(m, IH, H2), 1.834 (t, 3JOH.CH2 = 5.6, IH, OH). ESI-MS for C2I H22C140s [MNa+] ca1cd. 
517.02, found 517.1. 
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Figure S2.13: Thennal melting curves of 23-bp U5 region duplexes. Buffer: 140 mM K+, 1 
mM Mg2+, and 5 mM Na2HP04, pH 7.2. Oligonucleotides were hybridized to DNA (A) 2'5'-
RNA with 2',5'-H and 3',5'-H (B) 2'5'-RNA with mismatch 2',5'-rA. (C) RNA with 2',5'-H, 
3',5'-H, 2',5'-rU and mismatch 3',5'-rA (See Table 2.1, Tm column 1) 
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Figure 2.15: Thennal melting curves of 23-bp U5 region duplexes. Buffer: 140 mM K+, 1 
mM Mg2+, and 5 mM Na2HP04, pH 7.2. Oligonuc1eotides were hybridized to complementary 
2',5'-RNA. (A) 2'5'-RNA with 2',5'-H and 3',5'-H (B) 2'5'-RNA with mismatch 2',5'-rA. (C) 
RNA with 2',5'-H, 3',5'-H, 2',5'-rU and mismatch 3',5'-rA (See Table 2.1, Tm column 3) 
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Table 82.1: M t t 
"' 
1 . 
"' 
Calculated Observed Observed 
1 NO. Designation Oligonucleotide squence (5'->2'/3' direction) E Mass Mass (L/(mol.cm» (g/mol) (g/mol) Molecular Ion 
1 2,5RNA 5'-rOUC UOU UOU OUO ACU CUO OUA AC-2' 223500 7318 7319 (M-2H+Na)-
II 2',5'-H 5'-rOUC UOU HOU GUO ACU CUO OUA AC-2' 223500 7346 7351 (M-4H+2Na+Li)-
III 2'-5'-Hx2 5'-rOUC UOH HOU OUO ACU CUO OUA AC-2' 223500 7374 7377 (M-3H-2Li)-
IV 2',5'-Hx3 5'-rOUC UOH HOH GUO ACU CUO OUA AC-2' 223500 7402 7397 (M-H)-
V 2',5'-rA 5'-rOUC UOU AOU GUO ACU CUO OUA AC-2' 228000 7341 7345 (M-3H+3Li)-
VI 2',5'-rAx2 5'-rOUC UOA AOU OUO ACU CUO OUA AC-2' 229300 7364 7364 (M-4H+3Na)-
VII 2',5'-rA x3 5'-rOUC UOA AOA OUO ACU CUO OUA AC-2' 232800 7387 7387 (M-2H+Li)-
VIII 3',5'-H 5'-rOUC UOU HOU OUO ACU CUO OUA AC-2' 223500 7346 7348 (M-2H+Na)-
IX RNA 5'-rOUC UOU UOU OUO ACU CUO OUA AC-3' 223500 7318 7319 (M-2H+Na)-
X 2',5'-H 5'-rOUC UOU HOU OUO ACU CUO OUA AC-3' 223500 7346 7343 (M-4H+Na+2Li)-
XI 3',5'-H 5'-rOUC UOU HOU OUO ACU CUO OUA AC-3' 223500 7346 7349 (M-3H+2Li)-
XII 2',5'-rU 5'-rOUC UOU UOU GUO ACU CUO OUA AC-3' 223500 7318 7323 (M-4H+3Na)-
XIII 3',5'-rA 5'-rOUC UOU AOU OUO ACU CUO OUA AC-3' 228000 7341 7342 (M-5H+3Na+Li)-
XIV DNA 5'-dOTC TOT TOT OTO ACT CTO OTA AC-3' 214100 7076 7076 (M-4H+Na+Li)-
Pl RRR 5 '-GGAC(UUCG)GUCC-3 , a 111600 3787 3783 [M-H]-
P2 RR(H21R 5'-GGAC(HUCG)GUCC-3' 111600 3815 3814.2 [M-H]-
P3 RR(H61R 5'-GGAC(UHCG)GUCC-3' 111600 3815 3813.3 [M-H]-
P4 RR(Hs61R 5'-GGAC(HHCG)GUCC-3' 111600 3843 3842.5 [M-H]-
a Underlined letters are 2',5'-RNA loop (e.g. UU=U2'pSUZ'p); 2',5'-H is shown as H; 3',5'-H as H; 2',5'-rA as A, 3',5'-rA as A; 2',5'-rU as U in the sequence. 
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Chapter III 
The prevlOus Chapter described the synthesis of oligonuc1eotide chains 
containing 1-(2-deoxy-2-a-C-hydroxymethyl-~-D-ribofuranosyl)thymine units (or 
2'-a-hm-dT). In a follow-up project, we incorporated 2'-a-hm-dT and other modified 
nuc1eosides (arabino and seconuc1eosides) at the branch point of Y-shaped 
oligoribonuc1eotides with the intention of probing the substrate specificity of the yeast 
lariat RNA debranching enzyme (yDBR). These studies led to the identification of a 
potent inhibitor of yDBR, making this compound a potential good choice for future 
enzyme co-crystallization and X-ray analysis of the yDBR active site structure. 
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Chapter III. Yeast Debranching Enzyme (yDBR) Inhibition by Novel Branched 
RNAs 
Abstract 
A series of branched or "Y-shaped" RNAs related to a viral pre-mRNA splicing 
intermediate with a uridine branch point (rU) were synthesized to examine yeast 
debranching activity and inhibition. Each of these synthetic molecules were 
modified at the branch point by incorporating both natural (i.e. ribose) and 
non-natural nucleosides (i.e. arabinose, acyclic nucleoside, and 1-[2-deoxy-2-C-a-
hydroxymethyl-~-D-ribofuranosyl]thyrnine (2'-a-hm-dT; denoted as "H" in this study). 
31p NMR of 2',3'-bis-phosphoramidites revealed an unusual splitting pattern between 
adjacent phosphorus nuclei in sorne but not aH bis-phosphoramidites suggesting the 
presence of a through-space phosphorus-phosphorus (P-P) coupling interaction. 
Debranching assays show that branched ribonucleic acids (bRNAs) with ribose 
branch points (rA and rU) are substrates of the debranching enzyme (yDBR) whereas 
other modified branch points (sU, H) were not recognized. Debranching inhibition 
study found H branch point linked with cytidine have great inhibition potency (ICso = 
70 nM) while that with guanine connected did not show any inhibition. 
Introduction 
Branched ribonucleic acids (bRNAs) containing vicinal 2',5'- and 3',5'-phosphodiester 
linkages (Figure 3.1) were first detected in nuclear polyadenylated RNA from HeLa 
cells by Wallace and Edmonds,r'l and were subsequently shown by others to be 
mRNA splicing intermediatesYl Two unique branched RNA configurations have been 
detected: circles with a tail containing a branch point (i.e., a "lariat" configuration) in 
monomolecular cis-splicing reactions, [2l or branches between two linear RNAs (i.e., a 
"Y"-like structure) in the case ofbimolecular trans-splicing reactionspl Both in yeast 
and in mammalian cells, the branch point nucleotide is an adenosine (rA),[4,5l which 
can have stronger base stacking ability within the branch structure than other 
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ribonucleosides as branch points. This could 
be a possible reason why all lariat RNA 
introns conserve rAJ6] 
Branched RNAs are hydrolyzed by a 
specific enzyme which was first identified in 
HeLa cell extracts and named the RNA lariat 
debranching enzyme. [7] It is involved in the Branched RNA 
Figure 3.1. Structure ofbranched 
RNA 
intron turnover pathway found in mammalian 
cells[7] and in yeast. [8,9] The yeast lariat 
debraching enzyme (yDBR) is a unique manganese-dependent phosphodiesterase 
which selectively cleaves the 2',5'-phosphodiester linkage at the branch site of either 
lariat or Y-shaped introns, thus converting them into linear molecules.[IO] As yDBR 
does not digest 3',5'-phosphodiester bonds, its activity differs from snake venom 
phosphodiesterase, which indiscriminately cleaves both 2',5'- and 3',5'-phosphodiester 
bonds. The debranching efficiency ofyDBR is also highly substrate-specific in that an 
adenosine residue at the branch point position is more rapidly hydrolyzed by yDBR 
than other natural counterparts, [II, 12] and chemically modified branch points with 
different sugar conformations and phosphodiester configuration inactivate 
debranching activity altogetherY3] At least one 3',5'- appended nucleotide residue at 
the branch point is known to be required (i.e. one nucleotide connected at the 3' 
position) since yDBR cannot hydrolyze a 2',5'- connection when located within a 
linear nucleic acid substrate. [7] The nucleotide directly connecting to the branch point 
is also important to the debranching activity and a purine (A) is debranched more 
efficiently than either of the pyrimidines (C/T)J12,14] With these studies available, 
however, the real picture of yDBR binding with bRNAs and debranching mechanism 
is not known. Searching debranching inhibitors of yDBR could be useful for enzyme 
co-crystallization and X-ray analysis ofyDBR active site structure. 
Our group has had a long-standing interest in using synthetic Y-shaped bRNAs 
as intron mimics to study the molecular requirements of RNA splicing[15] and 
debranching,[10,12,13] largely aided by the development of branched oligonucleotide 
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synthesis methodologyY6-181 Previous studies indicate that the murine norovirus,[191 
MNV-1, seems to possess bRNA structure in its genome with an uridine branch point 
(rU) which could be involved in the viral replication and translation process (Karst, 
Wobus, and Virgin, unpublished data). As an extension of our attempt to use synthetic 
bRNAs to inhibit norovirus replication (Karst, Wobus, Darnha, Peng, Sabatino, and 
Virgin, unpublished data), we prepared a series ofbRNA mimics of the proposed viral 
branched structure and applied them in yDBR. We report herein the first synthesis of 
novel bRNAs containing the 1-[2-deoxy-2-a-C-hydroxymethyl 
-p-D-ribofuranosyl]thymine (denoted "H") which has been recently reported for its 
incorporation into 2',5'-linked RNA,[201 2',5'-100ped RNA hairpins and siRNA (Peng 
and Darnha, unpublished results). The debranching efficiency and inhibitory 
properties ofthese molecules on yDBR activity were investigated, and compared with 
other bRNAs containing natural and unnatural branch points. 
Material and Methods 
General Preparation of Branch point Synthons by Phosphitylation 
Bis-phosphitylation of nucleosides was conducted by a modified published 
procedureY61 N-ethyl-N,N-diisopropylamine (10 eq.) was added to a solution of 
5'-MMT protected nucleoside (1 eq.) containing free 2'- and 3'-OH groups (rU-OH, 
aU-OH, sU-OH, H-OH, Scheme 3.1) in dry THF (3 mL) under a N2 atmosphere. The 
reaction was initiated by adding 3 eq. p-cyanoethyl-N,N-diisopropylchlorophosphor-
amidite dropwise via syringe. A white precipitate (diisopropylethylammonium 
hydrochloride) usually appeared within five minutes indicating a progressing reaction. 
The reaction was monitored by TLC until complete conversion. After 0.5-2 h, the 
reaction mixture was washed with 50 mL ethyl acetate (pre-washed with 5% 
NaHC03), then with saturated NaCI and dried over sodium sulfate. The crude product 
was concentrated to dryness and purified via silica gel colurnn chromatography with 
1% NEt3 in CH2ChIMeOH (100:1 to 20:1 v/v) to afford the corresponding 
bis-phosphoramidites (rU, aU, sU and H) in 50-87% yield. 
1-[2,3-0-bis-(f3-cyanoethyl-N,N-diisopropylphosphoramidite)-5-0-(4-meth 
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oxytrityl)-J3-D-ribofuranosyl]uracil (rU). 87% isolated yield; Rf (Si02) = 0.55 - 0.39 
(1:1 Ether/CH2Ch); 31 p NMR (200 MHz, ppm, CDCh): 0152.41, 152.35, 151.77, 
151.70; 151.46, 151.43; 151.39, 151.35, 151.24, 151.20, 151.13, 151.0, 150.89 (13 
peaks). ESI-MS (in acetone) for C47H62N609P2 [MNa+] ca1cd. 939.98, found 939.3. 
MMTO\oj MMTO U iPr2NEt, THF ~0-J 
(iPr2N)(OCH2CH2CN)PCI ~ f 
OH OH 
sU-OH 
MMTO~o-1 
)--fR1 
OH R2 
rU-OH: R1=H, R2=OH 
aU-OH: R1=OH, R2=H 
H-OH: R1=OH, R2=CH20H 
R10 OR1 
sU 
SU:R1=OP(O(CH2hCN)NiPr2 
MMTO~o-1 
)--fR1 
OR3 R2 
rU: R1=H, R2 R3=OP(O(CH2)2CN)NiPr2 
aU:R2=H, R1:R3=OP(O(CH2hCN)NiPr2 
H: R1=P(O(CH2hCN)NiPr2 
R2=CH20P(O(CH2hCN)NiPr2 
Scheme 3.1. Phosphitylation reactions 
1-[2,3-0-bis-(J3-cyanoeth yl-N,N-diisopropylph osp ho rami dite )-5-0-( 4-meth 
oxytrityl)-J3-D-arabinofuranosyl]uracil (aU). 75% isolated yield; Rf (Si02) = 0.68 -
0.48 (1:1 Ether/CH2Ch); 31p NMR (200 MHz, CDCh): 0152.32, 152.27, 152.05, 
151.98, 151.92, 151.85, 151.28, 151.22, 151.18, 151.15, 151.51, 150.44, 150.16. 
ESI-MS (in acetone) for C47H62N609P2 [MNa+] ca1cd. 939.98, found 939.3. 
1-[2,3-0-bis-(J3-cyanoethyl-N,N-diisopropylph osphoramidite )-5-0-( 4-meth 
oxytrityl)-2,3-seco)-J3-D-ribofuranosyl]uracil (sU). sU-OH (Scheme 1) was obtained 
by a published procedureY1l 50% isolated yield; Rf (Si02) = 0.71 - 0.63 (4:1:1 
Ether/CH2Cb/hexane); 31 p NMR (200 MHz, CDCh): 0 150.39, 150.34, 150.19, 
149.86, 149.84, 149.58, 149.53, 149.11. ESI-MS for C49H66N409P2 [MNa+] ca1cd. 
940.02, found 941.3. 
1-[2-a-C-(J3-Cyanoethyl-N,N-diisopropylphosphoramidic)-hydroxymethyl 
-3-0-(J3-Cyanoethyl-N,N-diisopropylphosphoramidite)-2-deoxy-5-0-(4-methoxyt 
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rit yl)-p-n-ribofuranosyl] thymine (H). H-OH (Scheme 3.1) was obtained by a 
published procedure. [20] 77% isolated yield; Rf (Si02) = 0.63 -0.57 (50:45:5 
EtOAclhexane/NEt3); 31 p NMR (200 MHz, CDCh): 0 151.88, 150.47, 150.34, 148.80, 
148.67, 148.06, 147.97. ESI MS (in acetone) for C49H66N609P2 [MNa+] calcd. 968.03, 
found 967.4. 
N6-benzoyl-9-[2,3-0-bis-(p-cyanoethyl-N,N-diisopropylphosphoramidite)-
5-0-(4-methoxytrityl)-p-n-ribofuranosyl]adenine (rA) was prepared according to a 
published procedureY8] 75% isolated yield; Rf (Si02) = 0.71 - 0.57 (1:1 
Ether/CH2Ch); 31P NMR;[18] ESI MS (in acetone) for CS6H69N909P2 [M+] calcd. 
1074.15, found 1074.1. 
Branched RNA Synthesis 
Branched oligonucleotides were synthesized on 500 A controlled pore glass solid 
support using an AB! 381A DNA synthesizer (1 /-lmol scale) according to our 
well-established convergent solid phase synthetic methodologyY8,22] Briefly, an 
inverted thymidine (3'-DMT-dT) was first attached to the solid support (90 I!mol/g), 
which is shown to increase nuclease resistance. The introduction of the branch point 
nucleoside was achieved by coupling of two adjacent CPG-bound nucleotide chains 
with different 2',3'-bis-phosphoramidites. The coupling conditions and times of 
branch point addition during solid phase synthe sis were identical to those for bRNA 
synthesis[18] and employed a 0.03 M 2',3'-bis-phosphoramidite concentration, 30 min 
coupling time and 0.5 MDCI in acetonitrile as coupling activator. The Y-shaped 
constructs were purified by either 24% denaturing PAGE or anion-exchange HPLC 
(Protein Pak DEAE-5PW column-Waters; 7.5 mm x 7.5 cm) with proper linear RNA 
controls. The bRNA products were also analyzed by negative-mode MALDI-TOF MS 
(Kratos Kompaet-III instrument; Kratos Analytieal Ine., New York) (Table 3.2),r23,24] 
S'-End Labeling of bRNAs 
5'-End 32p labeling ofbRNAs was based on a published proeedureYS] Briefly, bRNAs 
were radiolabeled at the 5'-hydroxyl terminus with a radioactive 32p probe and the 
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enzyme T4 polynucleotide kinase (T4 PNK; MBI Fermentas Life Sciences, 
Burlington, ON). Incorporation of the 32p label was accomplished in reaction mixtures 
consisting of branched nucleic acid substrate (100 pmol), 2 ilL 10x reaction buffer 
(500 mM Tris-HCl, pH 7.6 at 25°C, 100 mM MgCb, 50 mM DTT, 1 mM spermidine 
and 1 mM EDTA), 1 ilL T4 PNK enzyme solution (10 U/1IlL in a solution of 20 mM 
Tris-HCl, pH 7.5, 25 mM KCI, 0.1 mM EDTA, 2 mM DTT and 50% glycerol), 6 ilL 
[y_32p]_ATP solution (6000 Ci/mmol, 10 mCi/ml; Amersham Biosciences, Inc.) and 
sterile water to a final volume of 20 ilL. The reaction mixture was incubated for about 
30-45 min at 37°C, quenched by heating (95°C, 5 min) and purified by 16% 
denaturing polyacrylamide gel (20%, 7 M urea). The pure labeled product was kept at 
-20°C for future use. 
Debranching Activity Assay 
The debranching assay was conducted at room temperature (~ 22°C) with 3-10 pmol of 
radiolabeled bRNAs, 1-6 ilL of yDBR enzyme (28 mg/mL) in Tris-HCl buffer (500 
mM, pH 7.4) containing 10% glycerol, 500 mM NaCI, 5 mM DTT, 1 mM EDTA); 2 
ilL optimized 10x debranching buffer (500 mM Tris-HCl, pH 7.0,20 mM DTT, 5 mM 
MnCb); and autoclaved water to a final volume of 20 ilL. Different time points (5, 10, 
20, 30,60 min) were obtained by taking 4 ilL aliquots from the reaction mixture and 
quenching the aliquot by the same volume of a stopping dye solution (98% deionized 
formamide, 10 mM EDTA, 1 mg/mL bromophenol blue and 1 mg/mL xylene cyanol). 
The product pattern from each time point was analyzed by 16% denaturing 
polyacrylamide gel electrophoresis (PAGE) and subsequent autoradiography analysis. 
Debranching Inhibition Assay 
The debranching inhibition by bRNAs was perfonned at room tempe rature (~22°C) in 
the presence of co Id bRNA inhibitors (0.01-20 IlM), 0.5 ilL 10x debranching buffer 
(500 mM Tris-HCI, pH 7.0, 20 mM DTT, 5 mM MnCb), the radiolabeled rAG 
substrate (Table 3.2, entry 4; 0.9 pmol) and sterile water. The reaction was initiated by 
the addition of 0.6 ilL yDBR enzyme to a final volume of 5 ilL. The reaction was 
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maintained for 30 min and quenched by a 5 ilL stopping dye solution (98% deionized 
formamide, 10 mM EDT A, 1 mg/ml bromophenol blue and 1 mg/ml xylene cyanol). 
The product pattern from each inhibitor concentration was analyzed by 16% denaturing 
PAGE and subsequent autoradiography analysis. 
Results and Discussion 
Synthesis of Branch Points 
Bis-phosphitylation of nuc1eosides[16] with excessive phosphitylation reagent usually 
worked very well to afford moderate to high yields (Scheme 3.1). After 
phosphitylation, two new chiral centers were generated to give four diastereomers. 
Consistent with a previous study'p3] the 31 p NMR spectra ofboth ribouridine (rU) and 
arabinouridine (aU) show 14 splitting peaks, indicating a through-space P-P coupling. 
This coupling should give 16 splittings but we could not observe all the peaks due to 
overlapping signaIs (Table 3.1 and Figure S3.1). It was previously shown that the 
xyloadenosine (xA) bis-phosphoramidite did not show this coupling interaction (7 
peaks observed) for a trans-diaxial arrangement of the 2',3'-phosphite groups in a 
C3'-endo conformation which places them sufficiently far from each other and 
abolishes any through space effectJ13] Previous modeling shows that aA branch point 
adopts C3'-endo or 04'-endo usual conformation which could allow c10ser P-P 
distance for coupling since both phosphorus atoms are not in the trans-diaxial 
arrangement. [I3] Our result of aU bisamidite is consistent with aA (Table 3.1 and 
Figure 3.2). The H bisamidite has an extra methylene group at the 2'-sugar position 
relative to the rU counterpart and thus accommodates larger P-P distance which tend 
to be larger to reduce the P-P steric interaction. In 31 p NMR we only observed 8 peaks 
corresponding to the fact that through-space P-P coupling was not observed in H 
(Table 3.1 and Figure S3.4). The acyclic nucleotide (sU) bisamidite also allows more 
space for these two phosphorus atoms and for this reason a through-space P-P 
coupling was not observed (Table 3.1 and Figure S3.3). 
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Debranching Activity Assay 
The solid-phase synthesis of bRNAs with a convergent method[18,22] offers different 
yields among which bRNA with aU branch point shows the worst coupling efficiency 
Table 3.1: Proton-decoupled 3Ip_NMR splitting patterns 
No. Componnd3 # of # of Major 
peaksb conpled conformer 
nnlcei 
1 Bis-ribo-A (rAp3] 
B=A,RI,~=H 16 8 
R2' R3 = OP(O(CH2)2CN)NiPr2 C2'-endo[13] 
2 Bis-ribo-U (rU) 
B=U,RI,~=H >14c 8 
R2, R3 = OP(O(CH2)2CN)NiPr2 
3 Bis-arabino-A (aA)(l3] 
B=A,R2,~=H 16 8 04'-endo(l3] 
RI, R3 = OP(O(CH2)zCN)NiPrz C3'-endo 
4 Bis-arabino-U (aU) 
B=U,R2,~=H >14c 8 
RI, R3 = OP(O(CH2)2CN)NiPr2 
5 Bis-xylo-A (xAP3] 
B = A, RI, R3= H 7 0 C3'-endo[13] 
R2, ~ = OP(O(CHZ)2CN)NiPrz 
6 Bis-seco-A (sA) [13] 6 0 NIA 
B =A; RI = OP(O(CH2)zCN)NiPrz 
7 Bis-seco-U (sU) 
8 0 NIA 
B = U; RI = OP(O(CHz)zCN)NiPr2 
8 Bis-hydroxymethyl-T (H) 
B=T,RI =H, 8 0 NIA R2 = CHzOP(O(CHz)zCN)NiPrz, 
R3 = OP(O(CHz)zCN)NiPrz, 
a 
MMTO~ MMTO,\-o B ~ RI j 
R3 R2 R, R, 
1-5,8 6-7 
b 31 P-NMR on 200 MHz with external reference H3P04 . 
c Overlapping peaks (see Figure 3.2 and Figure S3.1, Supplementary Data) 
132 
i 
l 
Chapter III 
J 
i 
Figure 3.2: 31p NMR of 1-[2-a-C-(~-Cyanoethyl-N,N- diisopropylphosphor-
amidic )-hydroxymethy 1)3 -O-(~-Cyanoethy 1-N, N-diisopropy Iphosphoramidite )-2-deox 
y-5-0-(4-methoxytrityl)-~-D-ribofuranosyl]thymine (H). 31 p NMR (200 MHz, CDCh): 
J 151.88, 150.47, 150.34, 148.80, 148.67, 148.06, 147.97 (8 peaks) 
B A rAG He HG sUG aUG rUG B rUU* rUU 
Figure 3.3: Denaturing PAGE analysis ofbRNAproducts (crude) (rUU*: purified) 
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Table 3.2: Branched RNA and Iinear controis synthesized in this study 
No. Code Branched RNAs and bRNA purity (%) M.W. M.W. 
controls' and retention (calcd.) (MALDI) 
time (min) in 
HPLC 
GUGAt 
1 rUG GAUCrU< 30 (33.84) 4774 4772 
GUGAt 
GUGAt 
2 aUG GAUCaU< 6 (34.37) 4774 4773 
GUGAt 
u(GUGAt 
3 sUG GAUCs 35(34.10) 4776 4776 
GUGAt 
GUGAt 
4 rAG GAUCrA< 25 (34.19) 4797 4796 
GU GAt 
<CGGGt 
5 HC GAUCH 17 (33.90) 4832 4832 
CGGGt 
<GUGAt 
6 HG GAUCH 16 (32.72) 4802 4800 
GUGAt 
UUUUt 
7 rUU Uuuuru< 52 (31.45) 4512.3 4513 
UUUUt 
8 A 5'-GUUCUGUGAt 60 (30.72) 3149 3151 
9 B 5'-GUUCUCGGGGUGAUt 18 (34.07) 4791 4889 
a 3' termini are capped with an inverted thymidine (3'-3'-dT) 
0.7 
0.6 <CGGGt 
-He GAUCH 
0.5 CGGGt 
0.4 
-HG <GUGAt 
-
GAUCH ï: 0.3 GUGAt / Branched ~ 0.2 products 
0.1 
0 }; 
-0.1 ~ 5 10 15 20 25 30 35 40 45 
Time(min) 
Figure 3.4: HPLC analysis of crude He and HG 
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and rU the best yield (Table 3.2). The characteristic slow moving bands shown in 
Figure 3.3 correspond to Y-shaped bRNA products, compared with linear RNA 
controls. HPLC also show bRNAs have a longer retention time (Figure 3.4 and Figure 
S3.5 in Supplementary Data). MALDI experiments confirmed that we obtained the 
branched oligonuc1eotides (Table 3.2). 
Debranching assays were first conducted to evaluate the ability of yDBR to 
debranch these bRNAs. As expected, the wild-type rAG shows the best debranching 
activity whereas rUG, while also serving as a substrate for yDBR, is debranched 
much less efficiently based on previous work.[141 After 10 min, rAG is completely 
debranched to generate the detectable linear product as indicated by a linear control, 
while ca. 50% rUG still remains intact after 60 min in the same debranching 
conditions (Figure 3.5). Doubling the amount ofyDBR in the reaction 
,;, GUGAt yDBR S'.32P-GAUCX, -:::::====> S'M32P-GAUCX, + GUGAt 
3' GUGAt-;a::-.. 3' GUGAt 
rUG rAG HG He sUG A 
Tlme , , ---, ----, ---=--J _-===::=:J 
(min) 0 51020 3060 0510203060010203060010203060 01020 3060 010 
CI) 100 
C) 
.s 90 
s:::: 80 CI) 
~ 70 
8._60 
C) ';;ft. 50 
s::::-~ 40 
g 30 
E 20 
.g 10 
c 0 
~rAG --rUG 
-___ ~.--~--- .. :.,;~~ ... r.=-.~-~-l 
o 10 20 30 40 50 60 
Time (min) 
Figure 3.5: Debranching activity of different branched RNAs 
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medium (2 )..lL), resulted in complete degradation ofrUG after 5 min (data not shown). 
Other non-natural branch points (sUG, He, HG) did not show any debranching 
activity indicating they are not a substrate of yDBR, consistent with a previous 
study.[13] The linear control was not a substrate ofyDBR either (Figure 3.5). 
Debranching inhibition assay 
We next evaluated whether branch point-modified bRNAs found to be inactive 
towards yDBR branch point hydrolysis could instead serve to inhibit the enzyme's 
debranching activity toward the wild-type rAG substrate. Increasing concentrations 
(0.01-20 )..lM) of sUG, He and HG were added in a debranching reaction with rAG 
and yDBR (Figure 3.6). Of the inhibitors tested, sUG, HG and the linear control did 
not show any concentration-dependent inhibition pattern. Only He exhibited 
excellent debranching inhibition with an ICso of 70 nM. Previous studies also indicate 
the debranching inhibition by ara-A branched RNA to have an ICso of 450 nMy3] We 
currently find He to exhibit much greater potency in debranching inhibition. 
Interestingly, we also find that while bRNA with H linked to cytidine at 2' (i.e., He, 
Table 3.2 and Figure 3.6) competitively inhibits debranching, H linked to guano sine 
at the 2' position (i.e. HG) does not, indicating the importance of the environment 
around the branch point for enzymatic bindingY4] Early NMR study of branched 
trinucleotides by Chattopadhyaya and coworkers indicates that the lariat RNA branch 
point adenosine prefers an unusual C2'-endo (south) conformation which reduces the 
charge repulsion of 2',5' and 3',5'-linked phosphate groups and is stabilized by base 
HC HG sUG A 
rAG J ----======::J -, --==::::::J Control 00.01 0.1 1 51020 0 0.01 0.1 110 0 0.01 0.1 1 10 1 1020 
• 
fJ.'" ... , .... ',.;;i),.;;" ., . ., 
·,.1111111 ••.. • 1IJl·. Il •• , 32~ J!ldil.:IL "'liL .. :.UI.~l.' 
>~t>:i,,~,~ , 
Control 
- ,,*,IVJ-';'lc,", 
Figure 3.6: Debranching inhibition of He, HG, sUG and linear RNA control CA). 
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stacking within the branched RNA. [6] The unusual sugar pucker could be a specifie 
conformation for enzymatic recognition. [6] This south conformation should be more 
favored in branch point H due to 2' alkyl group[20] and extended 2'-phosphate linkage 
allow larger P-P distance so as to reduce the P-P repulsion. It is hard to justify based 
on the present data why cytidine is more favored to inhibit yDBR debranching than 
guanosine, but again it suggests that yDBR recognition is very sensitive to not only 
the branch point but also the environment ofbranch point (i.e. bases connecting to the 
branch point). Therefore, He could be an interesting analogue for future attempts at 
co-crystallization of y D BR. 
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G-quadruplexes are interesting structures consisting of a square arrangement of 
four guanines (a G-quartet) stabilized by Hoogsteen hydrogen bonding and monovalent 
cations (e.g. K+) that bind in the center of the quartets. While they can be formed from 
both DNA and RNA, nothing is known about the capability of arabinose-based 
oligonucleotides to form quadruplex structures. The Darnha group has reported that 2'-
deoxy-2'-f1uoro-~-D-arabinonucleic acid (2'F-ANA) oligonucleotides enhance the 
thermal stability of various DNA structures such as duplexes, triplexes, and cytosine-rich 
quadruplexes. In light ofthis and other advantageous characteristics of2'F-ANA, such as 
synthetic accessibility through conventional solid-phase phosphoramidite chemistry, 
significant nuclease resistance, and promising antisense properties, we have undertaken 
the first study conceming the ability of 2'F-ANA to form G-quadruplex structures. The 
outcome ofthese and other studies reported here and in subsequent Chapters have opened 
new perspectives for the biological application of 2'F-ANA as aptamer oligonucleotides. 
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Chapter IV. G-quadruplex Induced Stabilization by 2'-Deoxy-2'-fluoro-~-D­
arabinonucleic Acids (2'F-ANA) 
Abstract 
The impact of 2'-deoxy-2'-fluoro-~-D-arabinonucleotide residues (2'F-araN) on different 
G-quadruplexes derived from a thrombin-binding DNA aptamer d(G2 T 2G2 TGTG2 T 2G2), 
an anti-HIV phosphorothioate aptamer PS-d(T2G4T2), and a DNA telomeric sequence 
d(G4T4G4) via UV thermal melting (Tm) and circular dichroism (CD) experiments has 
been investigated. Generally, replacement of deoxyguanosines that adopt the anti 
conformation (anti-guanines) with 2'F-araG can stabilize G-quartets and maintain the 
quadruplex conformation, while replacement of syn-guanines with 2'F-araG is not 
favored and results in a dramatic switch to an alternative quadruplex conformation. It was 
found that incorporation of 2'F-araG or T residues into a thrombin-binding DNA G-
quadruplex stabilizes the complex (!1Tm up to ~ + 3°C / 2'F-ANA modification); 2'F-araN 
units also increased the half-life in 10% fetal bovine serum (FBS) up to 48 fold. Two 
modified thrombin-binding aptamers (PG13 and PG14) show an approximate1y four fold 
increase in binding affinity to thrombin, as assessed via a nitrocellulose filter binding 
assay, both with increased thermal stability (ca. +loC /2'F-ANAmodification in Tm) and 
nuclease resistance (4-7 fold) as well. There fore , the 2'-deoxy-2'-fluoro-~-D­
arabinonucleoic acid (2'-FANA) modification is well suited to tune (and improve) the 
physicochemical and biological properties of naturally occurring DNA G-quadruplexes. 
Introduction 
Oligonucleotide aptamers derived from a Systematic Evolution of Ligands by 
EXponential enrichment (SELEX) processp-31 have drawn great attention for their 
potential as therapeutic and diagnostic agents?-71 The application of nucleic acid 
aptamers in vivo and their possible use in pharmacotherapy face the same key hurdles as 
siRNA and antisense based therapeutics, e.g., delivery, cellular uptake and biostability. To 
date, several methods have been devised to improve the stability of aptamers, most of 
which make use of SELEX, including a mirror-design of RNA aptamers (or 
"Spiegelmers,,);[81 post-SELEX modification by 2'-OMe to increase the stabilization of 
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RNA aptamers;[9] and direct evolution in SELEX using modified dNTPs or rNTPs (e.g. 
2'-F, 2'-NH2 pyrimidine 5'-triphosphate ).[10-14] Macugen®, an aptamer recently approved 
by the FDA for the treatment ofneovascular age-related macular degeneration, is a 2'F/2'-
OMe ribose-modified oligomer. [15] There still exists a great demand for new methods and 
more diverse range of chemistries to create aptamers with more favorable 
pharmacokinetic properties. 
A guanine quartet (G-quartet) structure with four Hoogsteen-paired, coplanar 
guanines (Figure 4.IA) was first observed more than 40 years ago[16] and later 
demonstrated to be a unique structural motif of guanine-rich oligonucleotides.f17] These 
guanine-rich segments are found in nature and also in sequences identified by screening 
techniques such as SELEX. Nucleic acid G-quadruplexes have also aroused interest as 
therapeutic agents to inhibit human thrombinp S,19] HIV infectionp9] HIV-I integrase 
activity, [20,21] and as targets to inhibit telomerase activity in anticancer drug design.[22] 
H R ~ ~ N 1 
R_N -=N---------~=Hr .. y) 
N>:=<rO---- îi' \ 
LN Cl li G1 Il ... \ 
H-N H H N-H \.. I-{ lf-"-O~ ~N 1 N~N-H----------N~N_R T1 
R 1 H 
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c D 
Figure 4.1: Structure of (A) G-quartet with cyclic array of four guanines linked by 
Hoogsteen H-bonds;[16] (B) thrombin-binding DNA d(G2T2G2TGTG2T2G2) with an edge-
loop (chair-like) unimolecular G-quadruplex in K+Y3,24] (C) a telomeric DNA d(G4T4G4) 
with diagonal-loop dimeric hairpin complex [dCG4T4G4)]z in Na+ [25,26] CD) a tetrameric 
G-quadruplex [d(PS-T2G4T2)]4 with four parallel strands.[17,19] 
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G-quartets display extraordinary structural polymorphism.[27-29] The 15-mer DNA 
sequence d(G2T2G2TGTG2T2G2P8] binds and inactivate thrombin, a key enzyme in the 
blood clotting cascade. NMR spectroscopy reveals that it adopts a uniquely folded 
structure with two stacked G-quartets connected through edge-Ioops (one TGT and two 
TT loops) involving antiparallel alignment of adjacent strands (see Figure 4.1B).[23,24,30,31] 
A seemly different crystal structure of this aptamer-thrombin complex[32,33] was later 
ana1yzed to be in agreement with the previous NMR structure. [33,34] Potassium ions 
stabilize the G-quadrup1ex by coordination to the G residues. [23] The G-quartet displays 
an altemating syn and anti conformation of guanine bases (syn- and anti-Gs) on the same 
plane and 5'-syn-G/3'-anti-G along each strand of the quadruplex (i.e. 5'-syn-anti-3' 
connectivity where syn-G includes G1, G5, G10 & G14 and anti-G includes G2, G6, GU 
& G15 in Figure 4.1B) and all the thymidines are in the anti orientation.[23] 
The telomeric sequence d(G4T4G4) adopts symmetrical dimeric quadruplexes 
comprising four G-quartets linked through a diagonalloop (Na +) (Figure 1 C)[25,26] or an 
edge-loop structure (K+).[35] The diagonalloop configuration (Figure 1C) consists of 5'-
syn-GI3'-anti-G along each G-strand, syn-syn-anti-anti conformations in a G-quartet and 
all sugar residues puckered in the south (C2'-endo) conformation. [26,36] 
Another interesting example is the phosphorothioate oligonucleotide PS-
d(T 2G4 T 2) identified as an inhibitor of HIV -1 infection in vitro by combinatorial 
screening of a library of DNA strands. This aptamer inhibits HIV envelope-mediated cell 
fusion in vitro and its structure consists of a parallel-stranded tetramer with all 
guanosines in the anti-conformation (Figure 1D).[17,19] 
Based on the above, the glycosidic conformations of guanines (i.e. syn- and anti-
Gs) have a strong correlation with strand alignments. Parallel-stranded quadruplexes 
(Figure 4.1D) support only anti-G residues, while antiparallel-stranded quadruplexes 
favor altemating syn-anti Gs engaged in unimolecular (Figure 4.1B) or intermolecular 
complexes (Figure 4.1 C). [27,37] 
G-quadrup1exes are sensitive to chemical modifications. Several studies aimed at 
modifying the thrombin-binding aptamer d( G2 T 2G2 TGTG2 T 2G2) have been reported, but 
very few, if any, have led to an improvement over the original molecule. For example, 
Heckel and Mayer reported that the introduction of thymines modified with a 
nitrophenylpropyl moiety (T-NPP) at certain positions generally abolished interaction of 
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the aptamer with thrombin. [38] Di Giusto and King reported the synthesis of circular 
aptamers targeted against thrombin that showed improved nuclease resistance and higher 
anticoagulant potency than those of the canonical thrombin DNA aptamer. [39] However, 
circularization of the aptamers produces a mixture of constructs and requires a ligase 
enzyme, making the method very difficult to scale-up. Other attempts to circularize the 
thrombin-binding DNA aptamer via chemical methods resulted in a complete loss of the 
anti-thrombin activity. [40] Recently, Seela and coworkers reported the insertion of a 
hairpin-forming sequence GCGAAG into the position of the centralloop (TGT) of the 
thrombin-binding aptamer. This construct formed aG-quadruplex fused to a mini-hairpin 
structure. According to the Tm data, the mini-hairpin induces a structural change in the 
aptamer section, leading to less stable G-quadruplex. Binding to thrombin was not 
investigated. [41] Saccà et al. studied the effect of backbone charge and atom size, base 
substitutions as weIl as the effect of modification at the sugar 2'-position as analyzed by 
spectroscopy. AIl sugar (ribose, 2'-O-methylribose) and phosphate (methylphosphonate, 
phosphorothioate) modifications led to a reduction in the thermal stability of the 
aptamer. [42] In fact, the 2'-O-methylribose modification led not only to a destabilization 
of the structure but to a complete transformation of the G-tetrad conformation, as shown 
by spectroscopy in potassium buffer.[42] 2'-O-methylribose was also shown to causes 
structural changes in RNA aptamers and often resulted in a loss of activity. [9] 
Accordingly, there is a need for new chemical modifications to improve the nuclease 
stability of this and other aptamers. IdeaIly, these modifications will not alter the subtle 
binding interactions of the selected native aptamers and the thermal stability of G-
quadruplexes. 
2'-Deoxy-2'-fluoro-B-D-arabinonucleic acids (2'F-ANA) confer DNA-like 
(South/East) conformations[43] to oligonucleotides while rendering them more nuclease 
resistant.[44] The incorporation of 2'F-araN units in oligonucleotides also raises the Tm of 
different systems, i.e., duplexes (~+ 1 °C/nt),[45] triplexes (~+O.8 °C/nti46] and C-rich 
quadruplexes (~+ 1°C/nt, pH<4.0). [47] In light of this and other advantageous 
characteristics of 2F-ANA, such as synthetic accessibility through conventional solid-
phase phosphoramidite chemistry, and promising antisense/siRNA properties, we have 
undertaken the first study conceming the ability of 2'F-ANA to form various G-
quadruplex structures as analyzed by Tm and CD experiments. 2'F-ANA modified 
152 
Chapter IV 
thrombin-binding aptamers were further evaluated by their nuclease resistance and 
binding affinity to thrombin. The outcome of these studies has opened new perspectives 
for the application of 2'F-ANA as aptamer oligonucleotides. 
Materials and Methods 
Chemical Synthesis of Oligonucleotides 
The sequence and composition of the oligomers prepared in this study are shown in Table 
4.1 and Table 4.2. Arabinose modified aptamer synthe ses were carried out at a 1 ~mol 
scale on an Applied Biosystems (ABI) 3400A synthesizer using standard fJ-
cyanoethylphosphoramidite chemistry according to published protocolsJ48] The final 
concentrations of the monomers were 0.10 M for 2'-deoxyribonucleoside 
phosphoramidites and 0.125 M for the 2'F-arabinose phosphoramidites. The coupling 
time was extended to 150 seconds for the 2'-deoxyribonucleoside phosphoramidites dC 
and dG, and 15 min for the 2'F-araG and T phosphoramidites. These conditions gave 
about 99% average stepwise coupling yields. Oligonucleotides were purified by anion-
exchange HPLC (Waters Protein Pak DEAE-5PW column; 7.5 mm x 7.5 cm), desalted by 
size-exclusion chromatography on Sephadex G-25 resin, and characterized by MALDI-
TOF mass spectrometry (luatos Kompact-III instrument; Kratos Analytical Inc., New 
York). Purity of the isolated oligonucleotides was >95% by HPLC. 
UV Thermal Dissociation Studies (Tm) 
UV thermal dissociation data was obtained on a Varian CARY 1 spectrophotometer 
equipped with a Peltier temperature controller. Thrombin-binding aptamers (PG 1-14) 
were dissolved in Tm buffer (10 mM Tris, pH 6.8, with and without 25 mM KCI) at a final 
concentration of 8 ~M. [49] Thrombin-binding aptamers were annealed in Tm buffer at 
80°C for 10 minutes, allowed to cool to room temperature and refrigerated (4°C) 
ovemight before measurements. dT 2G4 T 2 and related sequences (PG 17 -20) were 
dissolved in phosphate buffered saline (PBS buffer, pH 7.2) composed of 137 mM NaCl, 
2.7 mM KCI, 1.5 mM KH2P04, 8 mM Na2HP04 at a final concentration of 20 ~MYO] 
The telomeric DNA dG4T4G4 and related sequences (PG21-24) were dissolved in 10 mM 
sodium phosphate buffer (pH 7, 0.1 mM EDTA, and 200 mM NaCl) at a final 
concentration of 100 ~M.[51] All samples (PGI7-24) were annealed at 98°C for 5 minutes, 
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naturaUy coo1ed down to room temperature and refrigerated (4°C) overnight before 
measurements. The annea1ed samp1es were transferred to pre-chilled HeUma QS-1.000 
(Cat #114) quartz ceU, sea1ed with a Teflon-wrapped stopper and degassed by p1acing 
them in an ultrasonic bath for 1 min. Extinction coefficients were obtained from the 
foUowing internet site (http://www.idtdna.com/ana1yzer/applications/oligoana1yzer) 
based on the nearest-neighbor approach[52] and modified aptamers (phosphorothioates 
and 2'F-ANA) were assumed to have the same extinction coefficient as the natura1 DNA 
aptamer. Denaturation/coo1ing curves were acquired at either at 295 nm for 
d(G2T2G2TGTG2T2G2) and re1ated sequences (PGl-14), dG4T4G4 and re1ated sequences 
(PG21-24), or at 260 nm for dT2G4T2 and re1ated sequences (PG17-20), at a 
heating/cooling rate ofO.5°C/min between 10°C and 80°C (for PGl-14), 20°C and 90°C 
(for PG17-20) or 40°C and 98°C (for PG21-24). The data were ana1yzed with the 
software provided by Varian and converted to Microsoft Excel (Table 4.1 & 4.2). The 
decreases in UV absorbance (hypochromicity) with increasing temperature were 
normalized between 1 and 0 by the formula: N = (AcAl)/(Ah-Al), where At is the 
absorbance at any given temperature (t), Al is the minimum absorbance reading at high 
temperature, and Ah is the maximum absorbance reading at low temperature. Tm 
concentration dependence studies were also conducted in the same way at 295 nm using 
thrombin-binding aptamers (PG 1-14) with different concentrations ranging from 4 to 76 
/lM. Starna quartz ceUs (Starna CeUs, Inc., Cat. # 1-Q-1) with 1mm path length were 
used at high concentrations to reduce the amount of aptamers required and to avoid 
exceeding the Absorbance range of the instrument (Figure 4.4). 
Circular Dichroism (CD) Spectra 
CD spectra (200-320 nm) were coUected on a Jasco J-710 spectropolarimeter at a rate of 
100nm/min using fused quartz ceUs (HeUma, 165-QS). Measurements were carried out 
either in 10 mM Tris, pH 6.8 (with and without 25 mM KC1) at a concentration of 8 /lM 
for thrombin-binding aptamers (PGI_14);[49 j in PBS buffer (pH 7.2, 137 mM NaC1, 2.7 
mM KC1, 1.5 mM KH2P04, 8 mM Na2HP04) for dT2G4T2 and related sequences (PG17-
20) at a final concentration of 20 )lM, [50] or in sodium phosphate buffer (10 mM sodium 
phosphate buffer, pH 7, 0.1 mM EDTA, and 200 mM NaCl) for dG4T4G4 and related 
sequences (PG2l-24) at a final concentration of 100 )lM.[51] Temperature was controUed 
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by an internaI circulating bath (VWR Scientific) at constant temperature. The data was 
processed using J-700 Windows software supplied by the manufacturer (JASCO, Inc.). 
To facilitate comparisons, the CD spectra were background subtracted, smoothed and 
corrected for concentration so that molar eHipticities could be obtained (Figure 4.3 C&D 
and Figure S4.4 in Supplementary Data). Temperature-dependent CD spectra were also 
conducted for dT 2G4 T 2 and related sequences (PG 17 -20). A 10 min equilibration time 
was allowed at each temperature before CD scanning. The Tm profile was obtained by 
plotting the maximum molar ellipticities vs. temperature and normalizing (Figure 4.5 and 
Figure S4.5 in Supplementary Data). 
Nuclease Stability Assay 
Nuclease stability of anti-thrombin aptamers was conducted in 10% fetal bovine serum 
(FBS, Wisent Inc., Cat. #080150) diluted with multicell Dulbecco's Modified Eagle's 
Medium (DMEM, Wisent Inc., Cat. #319005-CL) at 37°C. A single strand DNA (ssDNA) 
23mer (P-8), which is unable to form G-quadruplexes, was used as a control. 
Approximately 8 Ilmol of stock solution of aptamers and ssDNA control (~1.2 O.D.U) 
was evaporated to dryness under reduced pressure and then incubated with 300 III 10% 
FBS at 37°C. At 0, 0.25, 0.5, 1,2,6, and 24 h, 50 III of samples were collected and stored 
at -20°C for at least 20min. The samples were evaporated to dryness and then 10111 of gel 
loading buffer and 10 III of autoclaved water was added. 10 III of the mixture was used 
for polyacrylamide gel electrophoresis (PAGE), which was carried out at room 
temperature using 20% polyacrylamide gel in 0.5 x TBE buffer (Tris-borate-EDTA). The 
degradation patterns on the gels were visualized using Stains-AH (Bio-Rad) according to 
the manufacturer's protocol (Figure 4.8 and Figure S4.6 in Supplementary Data). 
5'-End Labeling of Synthetic Oligonucleotides 
Aptamers (PGl-14) were radiolabeled at the 5'-hydroxyl terminus with a radioactive 32p 
probe using a T4 polynucleotide kinase (T4 PNK) according to the manufacture's 
specifications (MBI Fermentas Life Sciences, Burlington, ON). Incorporation of the 32p 
label was accompli shed in reaction mixtures consisting of DNA aptamers substrate (100 
pmol),2 III lOxreaction buffer (500 mM Tris-HCl, pH 7.6 at 25°C, 100 mM MgCh, 50 
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mM DTT, ImM spermidine and 1 mM EDTA), 1 /lI T4 PNK enzyme solution (10 UI1!-l1 
in a solution of 20 mM Tris-HCl, pH 7.5, 25 mM KCI, 0.1 mM EDTA, 2 mM DTT and 
50% glycerol), 6 /lI [y_32p]_ATP solution (6000 Ci/mmol, 10 mCi/ml; Amersham 
Biosciences, Inc.) and autoc1aved sterile water to a final volume of 20 /lI. The reaction 
mixture was incubated for 30-45 min at 37°C, followed by a second incubation for 5 min 
at 95°C to thermally denature and deactivate the kinase enzyme. The solution was 
purified according to a standard protocol[53] and the isolated yield of 32p_5'_DNA 
following gel extraction averaged 50%. The pure labeled samples were kept at -20°C for 
future use. 
Nitrocellulose Filter Binding Assay 
Labeled aptamers (1.25 pmol) were heated to 95°C for 5 minutes in the binding buffer 
(Tris-Ac, pH 7.4, 140 mM NaCI, 5 mM KCl, 1 mM CaCh, 1 mM MgCh)[18] and 
immediately placed on ice for 5 minutes before binding to increasing concentrations of 
thrombin protease (Amersham Biosciences, Inc.) ranging from 10-1000 nM in the 
binding buffer at 37°C in a final volume of 20 /lI for 30 minutes. Mixtures were filtered 
through a nitrocellulose filter (13 mm Millipore, HAWP, 0.45 /lm) pre-wetted with 
binding buffer in a Millipore filter binding apparatus, and immediately rinsed with 600 /lI 
ice cold washing buffer (Tris-Ac, pH 7.4,140 mM NaCI, 5 mM KCI, 1 mM CaCh, 1 mM 
MgCh, 1% sodium pyrophosphate (w/v)), then the filter was air dried and the bound 
aptamer quantified by scintillation counting. The binding percentage (%) was calculated 
by the subtraction of the background from the counts in the microtube. Ki was roughly 
estimated from the concentration (nM) where 50% of the maximum binding percentage 
was observed with a certain aptamer during the thrombin concentrations studied. The 
binding curves for various aptamers, inc1uding controIs, are shown in Figure 4.9, whereas 
binding data are given on Table 4.1. 
Results and Discussion 
A Fully 2'F-ANA Modified Thrombin-binding Aptamer 
The study began with the replacement of all the deoxynuc1eotides in the thrombin-
binding aptamer d(G2T2G2TGTG2T2G2) by 2'F-ANA units. Consistent with literature 
156 
Chapter IV 
results,[23,49] it was found through comparisons of the Tm profiles both with and without 
the presence of K+, that potassium ions stabilized the unimolecular G-quadruplex of the 
DNA aptamer (PG 1) (Figure 4.3A & B). As shown in the literature, similar 
hypochromicity (UV absorbance decrease with increased temperature) was observed at 
295 nm for aU DNA (PG 1),[49] which is an indication of G-quartet formation.[28,54] The Tm 
of the aU DNA aptamer obtained in this study was 47.4°C (Table 4.1 and Figure 4.3B), 
consistent with 46.4°C reported by Smimov and Shafe[49] and the CD spectra also support 
the UV melting experiment. Previous studies have shown two typical CD spectra: a CD 
spectrum with a positive CD band at ~ 265 nm and a negative band at ~ 240 nm (Type l 
CD spectrum) is related to parallei quadruplex with aIl anti-Gs, while one with a positive 
band at ~295 nm and a negative band at ~ 260 nm (Type II CD spectrum) corresponds to 
antiparaUel quadruplex with altemating syn-anti Gs. [28] The aU DNA aptamer shows very 
low amplitude bands without K+, whereas it demonstrates characteristic Type II CD when 
K+ is present, indicating a G-quadruplex structure with altemating syn-anti Gs (Figure 
4.3C & D).l27,28] The lack of concentration dependence in the Tm data (Figure 4.4) and the 
lack ofhysteresis in the heating/cooling processes (Figure 4.5) support a unimolecular G-
quadruplex structure (Figure 4.IB). Lack of hysteresis at a heating/cooling rate of 0.5 
oC/min indicates a fast kinetics for the formation of unimolecular quadruplexes. [54] 
The aU 2'F-ANA aptamer (PG2) also forms a defined G-quadruplex stabilized by 
K+ in the UV melting experiment (Figure 4.3A &B). The G-quadruplex of aU 2'F-ANA 
aptamer (PG2) is more thermaUy stable than the aU DNA aptamer (PG1) (tlTm = 0.4 °C/ 
2'F-ANA modification in Table 4.1). Further characterization experiments indicated that 
the G-quadruplex PG2 formed in K+ is different from that of that of PG 1. The effect of 
K+ on the CD spectra is consistent with the Tm experiment: very low absorbance in the 
absence of K+ and a strong positive absorbance peak at 260 nm in the presence of K+. 
Clearly this CD spectrum is type I, which corresponds to a paraUel quadruplex with aU 
anti_Gs.[27,28] It is a strong indication that the aU 2'F-ANA aptamer (PG2) could not 
maintain the unimolecular G-quadruplex topology (Figure 4.1 B). An intermolecular G-
quadruplex is thus formed to support a G-quartet structure with aU anti-Gs. A 
concentration-dependent Tm profile supports the existence of intermolecular G-
quadruplex formation (Figure 4.4). Hysteresis was observed in the heating and cooling 
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Table 4.1: Seguences, CD, Tm and bindin~ data of2'F-ANAmodified thrombin-bindin~ aEtamers 
Code Type Sequeucea Tm (A Tm)b CD Hysteresis K.J t V2 (h)f {oC} Typee iu T rnd (nM)" 
PGl AllDNA d(GGTTGGTGTGGTTGG) 
46.4[49] 
II 210 0.5 47.4 no 200[18] 
PG2 A1l2'F-ANA d(GGTTGGTGTGGTTGG) 54.1 (+0.4) 1 yes 500 >24 
PG3 2'F-ANA G-anti d(GGTTGGTGTGGTTGG) 53.3 (+1.5) II no >700 4.8 
PG4 2'F-ANA G-anti& loop d(GGTTGGTGTGGTTGG) 61.6 (+1.3) II no 500 9.4 
PG5 2'F-ANA G-syn d(GGTTGGTGTGGTTGG) 45.4 (-0.5) 1 yes >700 0.8 
PG6 2'F-ANA G-syn&loop d(GGTTGGTGTGGTTGG) 48.5 (+0.1) 1 yes >700 0.6 
PG7 2'F-ANA G-quartet d(GGTTGGTGTGGTTGG) 50.2 (+0.4) 1 yes 450 4.0 
PG8 2'F-ANA all-loop d(GGTTGGTGTGGTTGG) 56.3 (+1.3) II no 280 5.9 
PG9 2'F-ANA loop d(GGTTGGTGTGGTTGG) 57.1 (+1.6) II no 300 2.8 
PGlO 2'F-ANA loop d(GGTTGGTGTGGTTGG) 51.2 (+0.8) II no 250 2.7 
PGll 2'F-ANA loop d(GGTTGGTGTGGTTGG) 56.6 (+1.8) II no 370 5.1 
PG12 2'F-ANA loop d(GGTTGGTGTGGTTGG) 59.1 (+2.9) II no 310 3.5 
PG13 2'F-ANA loop d(GGTTGGTGTGGTTGG) 51.0 (+0.9) II no 58 3.4 
PG14 2'F-ANA loop d(GGTTGGTGTGGTTGG) 50.6 (+0.8) II no 40 2.0 
P8 ssDNA control d(GTCTCTTGTGTGACTCTGGTAAC) NA NA NA NC 0.5 
Hl Hairpin control (RNA) r(GGACUUCGGUCC) NA NA NA NC NA 
a Capital and bold letter: 2'F-ANA 
b !:J.Tm is the Tm change per 2'F-ANA between any modified aptamer with the unmodified DNA aptamer (PGl, Tm = 47.4°C); NA: not applicable. 
e "Type 1" CD spectrum refers to a positive CD band at ~265 nm and a negative band at ~ 240 nm that correlates with G-anti conformation in the 
the G-quartet. "Type II'' CD refers to a CD spectrum with positive band at ~ 295 nm and a negative band at ~ 260 nm, which indicates a alternative 
anti-G and syn-G conformation in the G-quartet . CD was measured in the buffer of 10 mM Tris, pH 6.8, 25mM KCl.[28] 
d Hysterisis in Tm refers to the hysterisis existing between a heating and cooling process with 0.5°C/min temperature change during Tm 
measurements. 
e Kd was roughly estimated from the concentration (nM) where 50% of the maximum binding percentage was observed with a certain aptamer 
during the thrombin concentrations studied; NC: not ca1culated. 
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processes, again supporting an intermolecular G-quadruplex adopted by PG2 (Figure4.5) 
It is expected that PG2 can form a tetrameric G-quadruplex, as reported in the literature 
to exist in many short G-rich sequences inc1uding the anti-HIV phosphorothioate PS-
d(T 2G4 T 2) and others. (19,55·58] 
Replacement of Anti-Gs and Syn-Gs with 2'F-ANA 
The next phase of the investigation studied the effect of 2'F-araG on anti-Gs and syn-Gs 
observed in different G-quadruplexes as discussed in the Introduction. The 
conformationally biased 2'F-ANA unit(43] (i.e. more south/east than its DNA counterpart), 
featuring a fJ-face fluorine, is expected to stabilize G-quartets requiring anti-Gs to avoid 
steric interaction between guanine and the fluorine.[59] Preorganization of anti glycosidic 
conformation favored by 2'F-araG[59] (Figure 4.2) will reduce the loss of entropy during 
G-quartet assembly so as to contribute the stabilization of G-quadruplex complex. 
Conversely, replacement of syn-Gs with 2'F-araGs is expected to cause destabilization 
since 2'F-araG is forced to adopt an unfavorable glycosidic orientation or abandon its 
preferred G-quartet structure altogether. Previous examples of the stabilizing effect of 
preorganization can be seen in the application of north-conformation locked nuc1eic acid 
(LNA), used to stabilize an RNA-like structure[60] and a more compact 2'-deoxy-2'-
hydroxymethyl-homouridine (2-a-hm-dT) to stabilize a compact 2',5'-RNA hairpin loop 
structure. [61] 
H 0 H2NII~ N 0 ~ F (N~ 
N HO~N-< :NH F NJ =Z HO~ 0- N NH2 
0- ~ 
OH 
OH 
Figure 4.2: Glycosic conformation equilibrium of 
dG and 2'F-araG with south furanose sugar ring 
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KC1, at a final strand concentration of 8 )lM. The Tm data are provided in Table 1. CD 
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25mM KCI at 15°C at a final strand concentration of 8 )lM. Type l and Type II CD types 
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Figure 4.5: Heating and cooling Tm transitions of 2'F-ANA modified thrombin-binding 
aptamers (Table 1) measured at 29S nm in a buffer of la mM Tris, 2S mM KCl, pH 6.8, 
at a final strand concentration of 8 !lM in a heating/cooling rate of O.SoC/min (red fiHed 
square: heating; blue empty square: cooling). 
CD, similar to the aH DNA aptamer (PG 1) (Figure 4.3C & D). PG4 shows a c1ear Type l 
CD both without and with K+, demonstrating that the G-quadruplex adopted by PG4 
could form even in the absence of K+, thus suggesting that replacement of the loop with 
2'F-ANA further benefits the G-quadruplex formation. This is consistent with previous 
work showing that aH the thymidines in this thrombin-binding DNA aptamer adopt the 
anti orientation.[23] A concentration-independent Tm profile (Figure 4.4) and lack of 
hysteresis in heating/cooling processes both support a unimolecular G-quadruplex 
structure like the DNA control (Figure 4.S and Figure S4.1 in Supplementary Data). 
Replacement of anti-G with 2'F-ANA is therefore able to stabilize the G-quartet without 
changing the quadruplex topology. 
The results of replacement ofthe syn-Gs with 2'F-ANA also match expectations. 
Modification of the syn-Gs with 2'F-ANA (PGS) and replacement of both syn-Gs and 
loops (PG6) with 2'F-ANA result in less stable complexes compared with PG3 and PG4. 
PGS is even less stable than the original aH DNA aptamer (!1Tm = -O.SoC/ 2'F-ANA 
modification, Table 4.1), and PG6 is only as stable as the aU DNA aptamer control (t:Œm 
= O.loC/ 2'F-ANA modification, Table 4.1). CD experiments show that both PGS and 
PG6 display very low amplitude peaks at 260 nm even in the presence of K+, indicating 
little structure formed (Figure 4.3C &D and Figure S4.4 in Supplementary Data). A Tm 
vs. concentration study suggested that the Tm of PGS and PG6 is independent of 
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concentration so they likely still form unimolecular structures (Figure 4.4) but the 
formation of these structures seems kinetically slow based on the finding that major 
hysteresis is observed at a heating/cooling rate of 0.5°C/min (Figure 4.5 and Figure S4.l 
in Supplementary Data). Taken together, these results suggest that 2'F-araGs can be 
forced to adopt a syn orientation about the glycosidic bond, but it is certainly not favored. 
If the unimolecular G-quadruplex is maintained in PG5 and PG6, the defined structure is 
not present in significant quantity in solution, as indicated by the previous CD 
experiments. Furthermore, in the case where 2'F-araGs replace both syn-Gs and anti-Gs 
in the quartet (PG7), we found that 2'F-ANA brings minimal stabilization (!:lTm = OAoC/ 
2'F-ANA modification, Table 4.1). Type l CD profile (i.e. a positive CD band at -260 nm 
and a negative band at ~ 240 nm) was observed in the presence of K+ and not shown in 
the absence of K+, indicating a parallel quadruplex with aIl anti-Gs,[28] as in PG2; 
concentration dependent Tm (Figure 4.4) and significant hysteresis observed in 
heating/cooling processes (Figure 4.5) support the idea that PG7 could adopt a tetrameric 
paraUel G-quadruplex with aU anti-Gs. 
To verify whether anti-Gs can be stabilized by 2'F-ANA in other types of G-
quadruplexes, we chose two other aptamers from the literature. 
A). Anti-HIV Phosphorothioate PS-d(T2G4T2) Modified with 2'F-ANA. Both 
the phosphodiester sequence PO-d(T 2G4 T 2) and the phosphorothioate sequence PS-
d(T 2G4 T 2) are known to adopt a structure in which aIl G residues are in the anti 
conformation Y 9,50] As a result, this aptamer has a characteristic "Type l'' CD signature 
(Table 4.2 and Figures 4.6A).[28] Thermal denaturation studies at 260 nm yielded noisy 
curves. The reason for this could be the slow dissociation process of both phosphodiester 
and phosphorothioate reported in the literature.[50] Tm profiles shown in Figure 4.6B were 
obtained by plotting the maximum molar ellipticities vs. temperature based on 
temperature-dependent CD spectra (Figure S4.5, Supplementary Data). Although it is 
impossible to get accurate Tm data for these kinetically slow G-quadrup1exes, clearly our 
apparent Tm data help to confirm the significant thermal stabilization provided by the 2'F-
ANA-G units (PG 18-20, Table 4.2). Our results indicate that phosphorothioate 
modifications lead to stabilization, inconsistent with the literature finding. [42] Compared 
with the controls PG 17 (PO-DNA) and PG 18 (PS-DNA), 2'F -ANA modified sequences 
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Code Type Sequence" 
d(T2G4T2) and related sequences 
PG17 AH PO-DNA PO-d (TTGGGGTT) 
PG18 AH PS-DNA PS-d (TTGGGGTT) 
PG19 
PG20 
AH PS-2'F-ANA 
PS-2'F-ANA-G 
d(G4T4G4) and related sequences 
PS-d(TTGGGGTT) 
PS-d(TTGGGGTT) 
PG21 AH PO-DNA PO-d (GGGGTTTTGGGG) 
1 
1 
1 
1 
II 
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66.0 
73.5 [50} 
74.0 
83.0 (+1.1) 
87.0 (+3.3) 
65 [51} 
64.4 
PG22 An PO-2'F-ANA PO-d (GGGGTTTTGGGG) 1 90.0 (+2.1) 
PG23 G-syn PO-d (GGGGTTTTGGGG) 1 72.5 (+2.0) 
PG24 G-anti PO-d (GGGGTTTTGGGG) II 66.2 (+0.5) 
a Capital and bo1d 1etter: 2'F-ANA; PO: phosphate linkage; PS: phosphorothioate linkage. 
b CD type 1 & refer to the note in Table 1. 
e dT2G4T2 and re1ated sequences (PG17-20): phosphate buffered saline (PBS buffer, pH 7.2 at 
25°C), 137 mM NaC1, 2.7 mM KCl, 1.5 mM KH2P04, 8 mM Na2HP04; strand concentration: 20 
flM for both CD and Tm experiments. dG4T4G4 and related sequences (PG21-24): 10 mM sodium 
phosphate buffer, 0.1 mM EDTA, pH 7 and 200 mM NaC1; strand concentration: 10 flM. 
d dT2G4T2 and re1ated sequences (PG17-20): phosphate buffered saline (PBS buffer, pH 7.2 at 
25°C), 137 mM NaCl, 2.7 mM KC1, 1.5 mM KH2P04, 8 mM Na2HP04; strand concentration: 20 
flM; Tm data were generated from concentration-dependent CD spectra (Figure S5 and Materials 
and Method). dG4T4G4 and related sequences (PG21-24): 10 mM sodium phosphate buffer, 0.1 
mM EDTA, pH 7 and 200 mM NaCl; strand concentration: 100 flM; Tm measurements were 
conducted at 295 nm wavelength. 
e I1Tm (oC) is the Tm change / 2'F-ANA modification of PG 18-20 or PG22-24 relative to the control 
PG 18 (74.0°C) or PG21 (PG64.4°C), respectively. 
PG 19 and PG20 show large increases in molar ellipticities, indicating a better guanine-
guanine interactions within the G-tetrad structure. 
B). A Telomeric DNA d(G4T4G4) Modified with 2'F-ANA. Structural analysis 
has shown that a telomeric DNA sequence d(G4T4G4) (PG21, Table 4.2) can form a 
symmetrical dimeric quadruplex with four G-quartets and a diagonalloop in the presence 
ofNa+ (Figure1C).[25,26] The guanine conformation is 5'-d(GsGaGsGa-TTTT-GsGaGsGa)-3' 
where s denotes syn and a anti.[26,36) Several sequences, inc1uding a fully 2'F-ANA 
modified sequence (PG22), a sequence with 2'F-ANA replacing aIl syn-Gs (PG23) and a 
sequence with 2'F-ANA modifications for aIl anti-Gs (PG24), were tested (Table 4.2). 
When the anti-G residues were replaced by 2'F-ANA G residues, a modest thermal 
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stabilization of the G-quadruplex structure resulted, without disruption of the 3-D 
structure (Table 4.2, and Figures 4.7 A&B). When the syn-G residues were replaced 
(PG22 & PG23), a remarkable increase in thermal stabilization of the G-quadruplex 
structure resulted (up to 25°C; Table 4.2), with a concomitant type II-to-type l 
conformational change induced by the 2'F-ANA-G(anti) replacement (Figure 4.7A). 
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Figure 4.6: (A) CD spectra of dTzG4Tz and related sequences (PG17-20) obtained in 
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Supplementary Data); the corresponding Tm data are shown in Table 2 
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Overall, these two additional examples confirm the results obtained for the 
thrombin-binding aptamers: the modification of anti-Gs with 2'F-ANA can generally 
stabilize a G-quartet requiring anti-Gs, maintaining the overall quadruplex conformation, 
while the modification of syn-Gs with 2'F-ANA is not favored and results in a complete 
conformational switch to an alternative G-quadruplex structure, as indicated by the 
change of CD type from II to 1 for PG2, PG5, PG6, PG7, PG22 & PG23 (Table 4.1 & 4.2, 
Figure 4.3D, Figure 4.7 A and Figure S4.4 in Supplementary Data). The stabilizing 
effects of 2'F-ANA on G-quadruplexes is related to the conformational preorganization 
and the small steric effect of the fluorine atom. 2'-O-Methyl modification generates 
steric problems at the 2' position and is often shown to destabilize a unimolecular G-
quadruplex, resulting in significant conformational perturbation in both intra- and 
intermolecular G-quadruplex systems.[42] 
Replacement of Loops with 2'F-ANA 
The base conformation of thymidines in the loop region of the thrombin-binding aptamer 
d(GIG2T3T4G5G6T7GsT9GIOGlITl2TI3GI4G15) (Figure 4.1B) exc1usively prefers the anti 
orientation. [23] The literature reports that Gs shows base stacking interactions with the 
first G-quartet but the conformation of the nuc1eotide was not mentioned. [32] The 
replacement of Gs with 2'F -araG in this study resulted in an increase of 0.8 oC in Tm (PG8 
and PG9 in Table 4.1). It was expected that the replacement of anti thymidines in the 
loops with anti conformationally biased 2'F-araT should increase thermal stability. 
Thermal melting studies support this hypothesis (PG8-14, Table 4.1). Different positions 
of thymidine contribute to the stability of the G-quadruplex to different degrees (Table 
4.1 and Figure S4.2, Supplementary Data). 2'F -ANA replacements in the loops 
consisting of two thymidines (PG 12) bring a greater thermal stabilization (I1Tm = 2.9°C/ 
2'F-ANA modification, Table 4.1) than with modification in the TGT loop (PG9, I1Tm = 
1.6°C/ 2'F-ANA modification, Table 4.1). T3 and Tl2 are the most sensitive positions to 
2'F-araT modification resulting in an almost 6°C difference in Tm (PG9 vs. PGIO; PGll 
vs. PG14, Table 4.2), while the replacement of T13 and T4 with 2'F-araT is much less 
sensitive and results only in slight Tm increases of 1°C (PG9 vs. PG 11, Table 4.2) and 
O.2°C (PG 10 vs. PG 13, Table 4.2), respectively. The crystal structure of this DNA 
aptamer bound to thrombin suggests that T3 and Tl2 are different from T4 and T 13 • It 
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appears that the bases of T 3 and T 12 do not interact with any other moieties within the 
aptamer, nor do they interact with thrombin, instead, they extend out into the solvent. [32] 
Modifying T3 and T12 with 2'F-araT might change the conformation of the loops, bringing 
out stabilization to the whole G-quadruplex structure as suggested by the Tm increase. A 
detailed picture, however, is difficult to describe at this stage. The replacement of the 
central nucleotide Gs with a 2'F-araG is also less important for stabilization (PG8 vs. 
PG9, only 0.8°C Tm difference). Overall, 2'F-ANA modifications of loop 
deoxynucleotides stabilizes the formation of a unimolecular G-quadruplex (Figure 4.1B), 
supported by all CD and UV melting analysis. It was found that all loop-modified 
thrombin-binding aptamers (PG8-l4) maintain Type II CD in the presence ofK+, like the 
DNA aptamer control (Figure S4.4, Supplementary Data). Remarkably, in the absence of 
K+, a relatively strong positive peak at ~295 nm is still observed, which indicates 
significant G-quartet formation. Therefore, replacement of the loop deoxynucleotides 
with 2'F-ANA helps the formation of G-quadruplex structure. They show concentration-
independent Tm data, indicating a unimolecular structure, in agreement with a lack of 
hysteresis in heating/cooling processes (Figure 4.5 and Figure S4.1, Supplementary 
Data). 
Nuclease Resistance Induced by 2'F-ANA 
Incorporation of 2'F-ANA in oligonucleotides leads to an improvement in nuclease 
resistance.[44] This study further evaluates the nuclease resistance of fully 2'F-ANA-
modified thrombin-binding aptamers (PG 1-14, Table 4.1). The data clearly shows that 
2'F-ANA modified aptamers have enhanced half-lives in 10% FBS (in one case> 48 fold 
compared with PG1, Figure 4.8, Figure S4.6 in Supplementary Data and Table 4.1) but 
nuclease stability is found to be dependent on both the position (esp. syn-G and anti-G) 
and number of 2'F-ANA residues within the oligonucleotide backbone. For example, 
replacing anti-Gs with 2'F-ANA (PG3 and PG4) increases the half-lives to 4.8 and 9.4 h, 
respectively, while replacing syn-Gs with 2'F-ANA (PG5 and PG6) does not yield much 
gain in biostability with half-life of only 0.8 and 0.6 h, respectively, comparable to the 
DNA aptamer (PG 1) (Figure 4.8). The contrast could be justified by the previous finding 
that PG5 and PG6 only form insignificant G-quadruplex structures (Figure 4.3D) due to 
the unfavoured conformation of the perturbed syn-Gs. It is expected that a complex 
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Figure 4.8: Stability of selected FANA modified thrombin-binding aptamers (PG 1-7) and 
ssDNA control to 10% fetal bovine serum (FBS) as monitored by polyacrylamide gel 
electrophoresis (aptamer sequence in Table 4.2) 
structure should be less accessible for nuclease attack compared to dissociated or "open" 
oligonucleotides. Furthermore, the nuclease stability of PG 13 and PG 14 is enhanced over 
PG 1 by a factor of 4-7 with only four 2'F-ANA incorporated (Table 4.1). Modification of 
the loop residues of stable structures (e.g. PG4, PG8) may have a double effect since the 
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increased stability of the duplex would be combined with protection of the nuc1eotides 
most exposed to endonuc1ease attack. 
Binding Affinity of 2'F-ANA-modified Thrombin-binding Aptamers with Thrombin 
As mentioned in the introduction, the thrombin-binding aptamer is very sensitive to 
chemical modifications, which often undermine its thermal stability and/or binding 
activity.[421. Thus, a final experiment in this study was conducted using nitrocellulose 
filter binding assays to assess the effect of 2'F-ANA modifications on the thrombin 
binding affinity. Data are presented in Table 4.1 and in Figure 4.9. ssDNA (P8) and 
hairpin (Hl) controls show no binding to thrombin as expectedY21 Binding of 2'F-ANA 
aptamers to thrombin is always adversely affected by 2'F-ANA modifications on G-
quartets themselves, whether syn- or anti-Gs are modified (PG2-PG6). Sorne loop 
modifications with 2'F-ANA also disfavor thrombin binding (PG8-PG 12). However, two 
loop-modified aptamers (PG 13 and PG 14, Table 4.1) show a 4-5 fold enhancement in 
100 - - - - P8 H1 
PG1 A PG2 
90 PG3 e PG4 
0 PG6 
)lE PG8 
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)( PG10 
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• PG14 
A PG9 70 
• PG11 ~ 0 60 • PG13 en 
t: 
"C 50 
t: 
III 40 
30 
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0 
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Thrombin concentration (nM) 
Figure 4.9. Binding affinity with human thrombin assessed by nitrocellulose filter 
binding assays. 
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thrombin binding affinity. Therefore, the first 2'F-ANA modified thrombin-binding 
aptamers to combine enhanced thermal and nuc1ease stability with stronger binding 
affinity has been demonstrated. Previous structural studies by NMR and crystallography 
suggest that the loop moieties would change conformation during binding to thrombin. [32] 
The TGT loop is involved with the fibrinogen exosite and two TT loops could interact 
with the heparin exosite. It seems that 2'F-ANA-T modification of one of the TT loops 
and the two thymidines in the TGT loop enhances thrombin binding. 
Conclusions 
In the present study 2'F-ANA modified oligonuc1eotides were investigated based on a 
thrombin-binding DNA aptamer d(G2T2G2TGTG2T2G2), an anti-HIV phosphothioate PS-
d(T2G4T2), and a DNA telomeric sequence d(G4T4G4) (Table 4.1 and Table 4.2) by UV 
thermal denaturation and CD experiments. Generally, replacement of anti-Gs with 2'F-
ANA can stabilize a G-quartet requiring anti-Gs and maintain the quadruplex 
conformation, while replacement of syn-Gs with 2'F-ANA is not favored and results in 
complete conformational change of the G-quadruplexes. The data shows that appropriate 
incorporation of 2'F-ANA residues into G-quadruplexes leads to an increase in the 
melting temperature of the complex formed (/)'Tm up to ~ + 3°CI 2'F-ANA modification, 
Table 4.1 and 4.2). The structure of thrombin-binding aptamers is stabilized by the 
presence of potassium ions. Nuc1ease resistance of 2'F-ANA modified thrombin-binding 
aptamers is increased up to 48 fold in 10% FBS. Two 2'F-ANA-modified thrombin-
binding aptamers (PG13 and PGI4) show a 4-5 fold enhancement in binding affinity to 
thrombin along with increased thermal stability and nuc1ease resistance. Therefore, the 
impact of 2'F-ANA modifications on G-quartets and loop regions has been demonstrated. 
The study suggests that 2'F-ANA could have great potential in the application of 
oligonuc1eotide-based therapeutics involving the G-quadruplexes. 
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Figure S4.1: Heating and cooling Tm transitions of selected FANA modified thrombin-
binding aptamers (Table 4.1) measured at 295 nm in a heating/cooling rate ofO.5°C in a 
buffer of 10 mM Tris, 25 mM KCl, pH 6.8, at a strand concentration of 8 ~; and 
dG4T4G4 related sequences PG2l-24 (Table 4.2) in 10 mM sodium phosphate buffer, 0.1 
mM EDTA, pH 7 and 200 mM NaCl at a strand concentration of 100 f.lM. (red filled 
square: heating; blue empty square: cooIing). 
177 
1 
0.9 
0.8 
:t::: 0.7 A PG3(K+) § PG4(K+) 
" 0.6 PG5(K+) 
(J) 0 PG6(K+) 
.~ 0.5 • PG7(K+) 
CU • PG8(K+) E 0.4 A PG9(K+) 
o x PG10(K+) 
Z 0.3 le PG11(K+) 
+ PG12(K+) 
0.2 • PG13(K+) 
• PG14(K+) 
0.1 - - - . Ali FANA(K+) 
Total Tm 
-Ali DNA (K+) o +----,----,----,-----,----~ 
10 20 30 40 50 60 70 
Temperature te) 
Chapter IV 
80 
Figure S4.2: Normalized Tm of total FANA modified thrombin-binding aptamers (PG1-
14 in Table 4.1) measured at 295 nm in buffer 10 mM Tris, pH 6.8, 25 mM KC1, at a final 
strand concentration of 8 J.lM (also refer to Figure 4.3) and Tm data were presented in 
Table 4.1. 
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25mM KCl at 15°C at a final strand concentration of 8 )lM. 
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Figure S4.5. Temperature-dependent CD spectra for PG 17-20 (Table 4.2) and resulting 
Tm curves for each complex. PBS buffer, 137 mM NaCI, 2.7 mM KCI, 1.5 mM KH2P04, 
8 mM Na2HP04, pH 7.2 at 25°C; strand concentration: 20 /lM; 10 min equilibrium time 
was set at each temperature studied. The resulting Tm curves were generated by plotting 
the maximum absorbance at 265 nm wavelength (normalized) vs temperature and shown 
in Figure 6; the corresponding Tm data are shown in Table 4.2. 
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Figure S4.6: (A) Stability of FANA modified thrombin-binding aptamers (PG 1-14, Table 
4.1) to 10% fetal bovine serum (FBS) as monitored by polyacrylamide gel 
electrophoresis (time points: 0, 0.25, 0.5, 1, 2, 6, 15h, 24h). (B) Stability curve of 
aptamers to 10% FBS as monitored by PAGE; half life of these aptamers (tIl2) is 
calculated by 50% remaining line and presented in Table 4.1. 
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Table S4.1: MALDI-TOF anab sis ofthrombin-binding aptamers (PGI-PGI4) 
New Type Sequence Cale. MALDI 
code Mass 
PGI AllDNA d(GGTTGGTGTGGTTGG) 4726 4726 
PG2 A1l2'F-ANA d(GGTTGGTGTGGTTGG) 4996 5000 
PG3 2'F-ANA G-anti d(GGTTGGTGTGGTTGG) 4798 4801 
PG4 2'F-ANA G-anti& loop d(GGTTGGTGTGGTTGG) 4906 4905 
PG5 2'F-ANA G-syn d(GGTTGGTGTGGTTGG) 4798 4797 
PG6 2'F-ANA G-syn&loop d(GGTTGGTGTGGTTGG) 4906 4910 
PG7 2'F-ANA G-quartet d(GGTTGGTGTGGTTGG) 4870 4871 
PG8 2'F-ANA all-loop d(GGTTGGTGTGGTTGG) 4852 4854 
PG9 2'F-ANA loop d(GGTTGGTGTGGTTGG) 4834 4837 
PGIO 2'F-ANA loop d(GGTTGGTGTGGTTGG) 4816 4818 
PGll 2'F-ANA loop d(GGTTGGTGTGGTTGG) 4816 4818 
PGl2 2'F-ANA loop d(GGTTGGTGTGGTTGG) 4798 4792 
PGl3 2'F-ANA loop d(GGTTGGTGTGGTTGG) 4798 4798 
PGl4 2'F-ANA loop d(GGTTGGTGTGGTTGG) 4798 4796 
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Chapter V 
In Chapter IV, we demonstrated that 2'-deoxy-2'-fluoro-13-D-arabinonuc1eotides (2'F-
araN) can be introduced into the DNA aptamers leading to FANA-DNA chimeras with enhanced 
thermal stability, nuc1ease resistance and in sorne cases improved binding affinity to their 
intended prote in target (i.e., thrombin). This suggests that FANA-DNA aptamers could find use 
as therapeutic and diagnostic agents. An alternative and more practical way to generate 
chemically-modified aptamers is through Systematic Evolution of Ligands by EXponential 
enrichment (SELEX), a technique based on the enzymatic synthesis of oligonuc1eotides starting 
from chemically modified nuc1eoside S'-triphosphates and the native building blocks, namely, 
deoxyribonuc1eoside S'-triphosphates (dNTPs) or ribonucleoside S'-triphosphates (rNTPs). Due 
to the high substrate specificity exhibited by DNA (or RNA) polymerases, only a limited number 
of nuc1eoside modifications are compatible with the SELEX process. This chapter examines, for 
the first time, the ability of DNA polymerases to carry out template-directed synthesis of 2'-
deoxy-2'-fluoro-13-D-arabinonuc1eic acids (2'F-ANA). 
Reprint from Peng, c.G. and Damha, M.l. (2006) Polymerase-directed synthesis of 2'-deoxy-
2'-fluoro-13-D-arabinonuc1eic acids. Journal of the American Chemical Society. (on-line 
publication on April 10, 2007; doi:10.10211ja069100g). With permission from ACS 
Publications. 
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Chapter V. Polymerase-Directed Synthesis of 2'-Deoxy-2'-Fluoro-f3-n-Arabino-Nucleic 
Acids (2'F-ANA) 
Abstract 
We have examined the ability of 2'-deoxy-2'-fluoro-f3-D-arabinonuc1eoside S'-triphosphates (2'F-
araNTPs) to serve as substrates for various DNA polymerases, thereby rendering these modified 
nuc1eoside S'-triphosphates (NTPs) amenable to DNA aptamer selection. We adapted primer 
extension assays to screen nine DNA polymerases for their ability to incorporate aU four 2'F-
araNTPs. We found that 2'F-araNTPs are very good substrates for thermophilic DNA 
polymerases Deep Vent (3'->5' exo-) (DV), 9°Nm™ DNA polymerase (9N), Therminator™ (Th) 
and Phusion™ High Fidelity DNA polymerase (Ph), aIl of which effectively and selectively 
incorporated 2'F-araNTPs to yie1d fuIl-length products. DV, 9N and Ph were shown to synthesize 
F ANA-DNA strands on F ANA-DNA templates, and Klenow fragment DNA polymerase (3'->5' 
exo-) (KF) and Bst DNA polymerase (Bst) catalyzed FANA template-directed DNA synthesis. 
While it was not possible to synthesize an alI-FANA strand on an alI-FANA template, it was 
possible for DV, 9N and Ph polymerase to drive the formation of multiple F ANA:F ANA base 
pairs within a DNA-F ANA chimeric duplex. AlI of these results suggest that it should be 
possible to evolve F ANA-modified aptamers via SELEX. 
Introduction 
Systematic evolution of ligands by exponential enrichment (SELEX)ll,2] is a powerful 
method for generating oligonuc1eotide aptamers with therapeutic utility, particularly when 
modified nuc1eoside S'-triphosphates (NTPs) are used for the selection of aptamers with 
nuc1ease-resistant capability.l3] Two key requirements must be met for the effective utilization of 
modified NTPs in the SELEX process; that is, polymerases must recognize and incorporate the 
modified nuc1eoside S'-triphosphates as building blocks with high fidelity; and the resulting 
products must be faithfuIly amplified into cDNA libraries. In addition to the most commonly 
used 2'-fluoro and 2'-amino rNTPs,l3] only a handful of other modified rNTPsl4-7] and even fewer 
dNTPsl8] are available for aptamer selection. 
2-Fluoro-D-arabinose confers a DNA-like (South/East) conformationl9] to the 
oligonuc1eotide while rendering it more nuc1ease resistant. lJO] In addition, 2-fluoro-D-arabinose 
raises the Tm of duplexes (ca. +0.5-1 °C/nt),lll] triplexes (ca. +0.8 °C/nt),P2] and C-rich (ca. +1 
186 
ChapterV 
OC/nt, pH < 4.0),[13] and G-rich tetraplexes (ca. +2 oC/nt). (Peng, C. G.; Darnha, M.J., 
unpublished results.) Furthermore, DNA or RNA containing FANA units exhibit gene silencing 
efficacy (via rnRNA targeting) in the low nanomolar range.[14] For aU of these reasons, we 
hypothesized that F ANA-modified strands could also have considerable potential as aptamers, 
and we sought to test this hypothesis by first examining the ability of 2'-deoxy-2'-fluoro-~-D­
arabinonucleoside S'-triphosphates (2'F-araNTPs) to serve as substrates for various DNA 
polymerases, thereby rendering these modified NTPs amenable to DNA aptamer selection. To 
our knowledge, there are no reports on the biosynthesis of FANA in vitro, though 2'F-araNTP 
derivatives have been studied as potential chain terminators for antiviral and anticancer 
applications[15] and positron emission tomographyY6] 
Results and Discussion 
We adapted primer extension assays[7,17] to first screen various DNA polymerases[18] for 
their ability to incorporate 2'F-araNTPs (N = A, G, T and C, Figure 5.1). Family B polymerases 
(DV, 9N, Th, Ph) effectively incorporated aU four 2'F-araNTPs to yield fuU-Iength FANA 
products (Figure SS.2, Supporting Information), whereas family A polymerases (Bst, Taq, KF) 
O· O· O· 
1 1 1 Base 
-O-P-O-P-O-P-O~ Il Il Il 0 
o 0 0 F 
2'F-araNTP OH 
Figure 5.1: Chemical structure of 
2'F-araNTPs (N = A, G, T and C). 
and MML V generated premature products containing 
only two to four 2'F-araNTP residues (for names of 
enzymes, see note [19]). The divergence in DNA 
polymerase classification and structure(18] and NTP 
discrimination has been observed with other modified 
nucleotides, for example, ddNTPs and acyclic 
NTPs,[20] suggesting that significant differences exist in the active site of these two families (A 
and B) of enzymes. 
Performing SELEX usmg modified NTPs reqmres necessary fidelity in the 
polymerization reaction so that the selection of functional sequences can be faithfuUy maintained 
and enriched from one round to another. Thus, we next conducted "dropout assays,,[21] to assess 
apparent fidelity of 2'F-araNTP incorporation by DV and 9N. In one of these assays, 2'F-
araA TP was removed from the pool, and the ensuing synthesis assessed in comparison with a 
control reaction containing aH four 2'F-araNTPs. For comparison, dropout experiments 
containing dNTPs were run in paraUel and the results obtained are shown in Figure 5.2. FuU-
length DNA and FANA products were obtained when aU four dNTPs (group 1 and 5) and 2'F-
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Figure 5.2: Fidelity study on 2'F-araATP incorporation by DV and 9N DNA polymerases on 
DNA template PF41. Experimental details about this drop out assay are provided in the 
supporting material. Reaction conditions: 0.8 unit DV and 9N, 25 ~M triphosphates at 550C in 
30 ~L reaction volume; incubation time: 30 min. Group 1 & 5: dNTPs; 2 & 6: drop out of dATP; 
3 & 7: 2'F-araNTPs, 4 & 8: drop out of 2'F-araATP; 27mer DNA is PF39 in Table S5.l, 
Supporting Information. 
araNTPs (groups 3 and 7) were available, although sorne pausing was evident during synthesis of 
the arabinose modified oligomers. Compared with dATP, both DV and 9N exhibited excellent 
selectivity on 2'F-araATP, as demonstrated by efficient chain termination at the position where 
2'F-araATP was required (groups 4 and 8). In contrast, dropping out dATP in these assays 
(groups 2 and 6) afforded full-length in addition to premature products (Table 5.1), suggesting 
that 2'F-araATP is more strictly selected than dATP under these conditions. 
Next, we applied the same drop out experiments to the remaining three triphosphates, 
namely, 2'F-araGTP, 2'F-araCTP and 2'F-araTTP (Table 5.1; Figures S5.3-S5.4, Supporting 
Information). Again, DV and 9N demonstrated higher fidelity with respect to 2'F-araGTP 
incorporation relative to the native dGTP. Selectivity toward the pyrimidine-based 2'F-araNTPs 
was significantly less, but the same was true for the corresponding pyrimidine-containing 
dNTPs. Factors goveming fidelity of base substitutions by polymerases are complex and not 
completely understoodY2] Preferential geometry,[23] sugar pucker,[24] and topology and size of 
the polymerase-active site[23] are aIl important considerations. In addition, it has also been 
suggested that drop out essays underestimate the fidelity of base substitution because there would 
be more opportunity for NTP misincorporation when the normal competition between the correct 
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and incorrect NTP is lacking in these experiments.[21] Regardless of the mechanisms that operate, 
the selectivity for 2'F-araNTP incorporation by DY and 9N polymerases appears to be 
comparable, if not better, than that of dNTPs. 
Next, we examined Phusion DNA polymerase (Ph), an enzyme with higher processing 
capacity and fidelity compared to other thermophilic polymerases (e.g., the error rates for ph[25] 
and Dy[26] are 4.4 x 10-7 and 2.2 x 10-4, respectively). AlI four drop out experiments were 
conducted with the same DNA template PF21 (Figure 5.3), or PF41 (Figure S5.5, Supporting 
Information). For the dNTPs, syntheses stopped at the expected termination sites, yielding 
products lacking the required dNTP at the 3 '-terminus. A similar pattern was observed with 2'F-
araNTPs, although in the latter, FANA synthesis proceeded with more difficulty (Figure 5.3; 
Primer (PF20) 
DNA template (PF21) 
Expeeted produel: 
1. 2'F-araNTPs (Ali) 
2. Drop out 2'F-araCTP (AGT) 
3. Drop out 2'F-araTTP (AGC) 
4. Drop out 2'F-araATP (CTG) 
5. Drop out 2'F-araGTP (CTA) 
5' -j',TTAT(;CTGliGTG1,Ti\T-CCCTCTTCTCACCGTTT-5' 
.j. Ph, triphosphates condition 1-5 
5' _32p-TlV\TACGACTCACTATA-GGGAGAAGAGTGGCAAA-3' 
5' _32p-'r.n.ATACGACTCACTATA-GGGAGAAGAGTGG-3 1 
5'-32p-TAATACGACTCACTATA-GGGAGAAGAG-3' 
5' _32p-TAATACGACTCfI.CTATA-GGG-3 1 
5' _32P-TAATACGACTCACTATA-3 ' 
Phusion ™ High Fidelity DNA Polymerase 
dNTPs 2'F·araNTPs 
1 2 3 4 5 Lanes 6 7 8 9 10 1 
~ WIAGëJëTGlm ~ ~IAGëJëTGlm ~ 
.nll· g 
-.. .. 
PF39 
PF41 • t!I 
E-t 
--+i ••~ 
. ""';;: .... c'll'!' ... · .l'I~-+j 
- g 
Figure 5.3: Fidelity study on 2'F-araNTP incorporation by Ph on DNA template PF21. Reaction 
conditions: 0.8 unit Ph, 25 )lM triphosphate at 55°C in 30 )lL reaction volume for 30min. 1ane 1: 
dNTPs; 2: drop out dCTP (i.e. dATP, dGTP and dTTP, shorten as AGT; same coding for lane 3-
5), 1ane 6: 2'F-araNTPs; 7: drop out 2'F-araCTP (i.e. 2'F-araATP, 2'F-araGTP, 2 'F-araTTP , 
shorten as AGT; same coding for lane 8-10). Template PF41 and primer PF20 are shown; PF39 
is a 27 -nt DNA control. 
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Table 5.1. Apparent fidelity of FANA synthesis in dropout assay 
Polymerase 
% Apparent Fidelitya 
Template used Figure 
2'F-araNTP dNTP 
A: >99% >99% PF21 5.3 G: >99% >99% Ph T: >99% >99% 
C: >99% >99% 
A: >99% 1% PF41 5.2 
DY G: >99% 62% PF43 S5.3 
T: 3% 19% PF21 S5.4 
C: 50% 3% PF23 S5.4 
A: >99% 80% PF41 5.2 
9N G: 98% 84% PF43 S5.3 T: 76% 32% PF21 S5.4 
C: 43% 82% PF23 S5.4 
a Apparent fidelity is ca1culated according to the equation 1-[(% full-Iength - 2'F-araNTP)/ (% 
full-Iength + 2'F-araNTP)] at 30 min reaction time (sample equation for dNTP values); >99% 
means that the full-Iength product is not detectable in our dropout assays. 
lanes 6-10). This effect, however, was observed only in the drop out assays, that is, the reaction 
containing aIl four 2'F-araNTPs produced excellent yields of the full-Iength FANA product with 
virtually no pausing observed. We speculate that in a dropout assay, where polymerization 
activity is suboptimal, the pausing bands observed may result, at least in part, by the shuttling 
(cycling) between the strong Ph 3'-5' exonuclease and polymerase activitiesY S],[271 Similar 
results were observed with the DNA template PF41 (Figure S5.5). Of note, apparent fidelity 
among Ph, DY and 9N is correlated to 3'-5' exonuclease proofreading activity, with Ph having the 
strongest exonuclease activity and also 2'F-araNTP fidelity, and DY having no exonuclease 
activity and low 2'F-fidelity. We recently became aware of Wengel's work that Ph can 
incorporate a few LNA triphosphates in a growing DNA strand.[281 Thus, FANA and LNA NTPs 
appear to be the first examples of modified NTPs incorporated by Ph. 
We are currently testing the limits of these procedures by exploring the synthesis of (a) 
DNA-FANA on a DNA-FANA template, and (b) DNA on an alI-FANA template. Preliminary 
results obtained indicate that DY, 9N and Ph can synthesize FANA-DNA strands on FANA-
DNA templates (Figure S5.6, Supporting Information), and that KF and Bst DNA can catalyze 
FANA template-directed DNA synthesis (Figure S5.7, Supporting Information). While we have 
not been able to synthesize an alI-FANA strand on an alI-FANA template, it is possible for DY, 
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9N and Ph polymerase to drive the formation of multiple F ANA:F ANA base pairs within a 
DNA-FANA chimeric duplex (Figure S5.6; Supporting Information). 
In summary, family B thermophilic DNA polymerases such as DV, 9N and Ph can utilize 
2'F-araNTPs, or a combination of 2'F-araNTPs and dNTPs, to generate FANA or chimeric 
F ANA-DNA strands, respectively. In addition, these polymerases were shown to synthesize 
chimeric FANA-DNA strands on a chimeric FANA-DNA template. KF and Bst (family A) 
DNA polymerases were able to incorporate dNTPs on a template FANA strand. These results 
suggest that it should be possible to evolve FANA-modified aptamers via SELEX. 
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Nucleotides 
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Nucleotides. 2'-Deoxyribonucleoside 5'-triphosphates (dNTPs) were purchased from Fermentas. 
2'F-araN were synthesized by published procedures (Elzagheid, M. L, et al., Synthesis of 
protected 2'-Deoxy-2'-fluoro-~-D-arabinonucleosides. In Current Protocols in Nucleic Acid 
Chemistry, John Wiley & Sons: 2002, ppl.7.l-19). The introduction of the 5'-triphosphate 
moiety was conducted by Rasayan, Inc. (Encinitas, Califomia, USA) and 2'F-rUTP and 2'F-rCTP 
were also purchased from Rasayan, Inc. The structures of the fluorinated nucleoside 5'-
triphosphates are shown in Figure S5.l. 
o 
"l'À 
o 0 0 N 0 
Il Il 11-0 
·o-p-o-P-o-P-o 0 
1 1 1 O· 0- 0- F 
A 
NH2 C1 
o 0 0 N 0 
Il 1111-0 
-o-P-o-P-o-P-o 0 
1 1 1 0- 0- 0- F 
B 
OH OH 
C NH2 
N:(:N o 0 0 (t 1 
Il Il Il N) 
-O-P-O-P-O-P-0-p N 
1 1 1 0- 0- 0- F 
OH 
o 
Nt
O 
NH 000 (t 1 
Il Il Il N ~ 
-O-P-O-P-O-P-0-p N NH2 
1 1 1 0 
0- 0- 0- F 
OH 
Figure S5.1: Structure of 2'F-araNTPs. A: 1-(2-deoxy-2-fluoro-~-D-arabinofuranosyl)thymine 
5'-triphosphate (2'F-araTTP); B: 1-(2-deoxy-2-fluoro-~-D-arabinofuranosyl)cytosine 5'-
triphosphate (2'F -araCTP); C: 9-(2-deoxy -2-fluoro- ~-D-arabinofuranosyl)adenine 5'-triphosphate 
(2'F -araATP); D: 9-(2-deoxy-2-fluoro-~-D-arabinofuranosyl)guanine 5 '-triphosphate (2'F-
araGTP). 
2. Template and Primer Design. DNA and FANA-DNA templates and primers used in this 
study are shown in Table S5.1. The primer (PF20) is a 17nt DNA sequence 5'-
TAATACGACTCACTATA-3'. Each template strand comprises three sequence segments: a 17nt 
long primer binding sequence 5'-TATAGTGAGTCGTATTA-3', a 10nt long running start sequence 
5'-CTCTTCTCCC-3', and a variable "test sequences" to test 2'F-araNTP incorporation 
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Table S5.1. Base Seguences of Oli~onucleotide TemElates and Primer 
Code Type Sequence * N-
mer 
PF20 Primer 5'-TAATACGACTCACTATA-3' 17 
PF21 DNA tempo 5'-TTTGCC-A-CTCTTCTCCCTATAGTGAGTCGTATTA-3' 34 
PF23 DNA tempo 5'-TTTACC-G-CTCTTCTCCCTATAGTGAGTCGTATTA-3' 34 
PF31 FANA-DNA 5'-TTACCTTTCTCTTCTCCCTATAGTGAGTCGTATTA-3' 35 tempo 
PF32 DNA tempo 5'-CTCTATGTGCACGCACTCTTCTCCCTATAGTGAGTCGTATTA-3' 42 
PF33 DNA tempo 5'-TCGGTGGATCATAGACAGTACTCTTCTCCCTATAGTGAGTCGTATTA-3' 47 
PF34 FANA-DNA 5'-CTCTATGTGCACGCACTCTTCTCCCTATAGTGAGTCGTATTA-3' 42 
PF39 DNA control 5'-TAATACGACTCACTATAGGGAGAAGAG-3' 27 
PF41 DNA tempo 5'-AGAGCC-T-GAGAAGAGAGTATAGTGAGTCGTATTA-3' 34 
PF43 DNA tempo 5'-AAATGG-C-GAGAAGAGAGTA TA GTGA GTCGTA TTA-3' 34 
*Note: Bold and capitalletter: FANA units; Capital letters: DNA; Italized sequence: primer binding 
sequence and primer (17nt); Underlined sequence: a running start (1 Ont). 
Table S5.2. Polymerase Information and Reaction Buffer Conditions 
POlymerase* Short Activity Reaction buffer (xl) 
name (units//J:L) 
Thermophilic DNA polymerase (reaction temperature at 55°e in this study) 
Deep Vent (3'-+5' DV 2 20 mM Tris-HCI (pH 8.8 at 25°C), 10 mM 
exo-) DNA (NH4)zS04, 10 mM KCl, 2 mM MgS04, 
polymerase 0.1 % Triton X-lOO; 0.2 mM dNTPs 
9° Nm DNA 9N 2 Same as above 
polymerase 
Therminator DNA Th 2 Same as above 
polymerase 
Bst DNA polymerase Bst 
large fragment 
Taq DNA polymerase Taq 
Phusion High-Fidelity Ph 
DNA polymerase 
8 
5 
2 
Same as above 
Same as above 
5X Phusion™ HF Buffer; 0.2 mM dNTPs 
Mesophilic DNA polymerase (reaction temperature at 31'e in this study) 
Klenow fragment KF 5 10 mM Tris-HCl (pH 7.5 at 25°C), 5 mM MgCI2, 
(3'-+ 5' exo-) DNA 7.5 mM DTT; 0.033 mM dNTPs 
polymerase 
Reverse transcriptase (reaction temperature at 3re in this study) 
HIV-l RT HIV 27.3 50 mM Tris-HCI (pH 7.8 at 25°C), 60 mM KCl, 
(recombinant) 2.5 mM MgClz; 0.2 mM dNTPs 
Moloney Murine MM LV 10 50 mM Tris-HCI (PH 8.3 at 25°C), 50 mM KCI, 4 
Leukemia Virus RT mM MgClz, 1 OmM DTT; 0.5 mM dNTPs 
* Enzyme sources: aH from New England Biolabs (NEB) except for Ph from Finnzymes (distributed by 
NEB); HIV-I RT from Worthington Biochemical Corp. 
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(PF33), FANA template mediated DNA synthe sis (PF3l, PF34) and the fidelity of 2'F-araATP 
(PF4l), 2'F-araGTP (PF43), 2'F-araTTP (PF2l), 2'F-araCTP (PF23). Other control sequences 
(PF39, PF33) are also listed in Table S5.l. DNA sequences were obtained from commercial 
sources (Integrated DNA Technologies). Oligonucleotide FANA-DNA templates were 
synthesized according to the published procedures (Viazovkina, E. V., et al., Solid-phase 
synthesis of 2'-deoxy-2'-fluoro-/3-D-oligoarabinonucleotides (2'F-ANA) and their 
phosphorothioate derivatives. In Current Protocols in Nucleic Acid Chemistry, John Wiley & 
Sons, Inc. 2002, pp 4.15.1-22). 
3. General Procedure of Primer Extension Reaction. Primer extension assays were used to 
evaluate the polymerase activity for incorporation of 2'F -araNTPs, and for template mediated 
DNA biosynthesis. Unless otherwise noticed in this study, the conditions used in the primer 
extension assays, such as dNTP concentrations, reaction temperatures, concentration of Mg2+, 
and reaction buffers (provided by the manufacturers, except for the HIV -R T buffer which was 
prepared in-house) are shown in Table S5.2. The DNA primer (PF20) was first labeled by a 
radioactive phosphorous probe e2p) at the 5'-hydroxyl terminus according to published 
procedure (Galameau, A., et al., Assay for evaluating ribonuclease H-mediated degradation of 
RNA-antisense oligonucleotide duplexes. In Methods Mol. Biol., Totowa, NJ, United States, 
2005, 288, pp 65-80). Unlabeled DNA primer was also used to adjust the primer concentration. 
Then primer to template was mixed together with the final concentration at 100 nM for the 
primer and the template (l: 1 molar ratio). The primer and template were heated at 95°C for 5min 
and annealed at 4°C at least two hours before use. In an microtube, the mixture of 5x or 10x 
buffer, triphosphates (dNTPs or 2'F-araNTPs), water, the primer and template mixture was 
prepared according to pre-calculated reaction volume and concentrations (see buffer conditions 
in Table S5.2). Mineral oil (20 ilL) was used to pre vent evaporation. The reaction mixture was 
incubated at either 37°C or 55°C (see temperature conditions in Table S5.2) and one of the 
various enzymes tested was added to initiate the primer extension reactions. Time points were 
obtained by taking 4 ilL or 8 ilL aliquot from the reaction mixture and quenching the aliquot by 
the same volume of a stopping dye solution (98% deionized formamide, 10 mM EDTA, 1 mg/ml 
bromophenol blue and 1 mg/ml xylene cyanol). The product pattern from each time point was 
analyzed by 12% denaturing polyacryamide gel electrophoresis (PAGE) and subsequent 
autoradiography analysis. 
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5' _32p_ TAAT11CGACTCACT~4 T .. 4-.3' Primer (PF20) 
DNA tempo (PF33) 3' - ATTIU'GCTGilGTGATA'T'-CCCTC'.:'TCTCATGACAGATACTAGGTGGCT-5' 
! Polymerase. 0.2 mM 2'F-araNTPs 
Expected product S' _32p-TAATACGACTCAC'l'ATT\-GGGAGAAGAGTACTGTCTATGATCCACCGA-3' 
DV 9N Th Bst Taq Ph KF MMLV 
~~~~....:::::::::J~~~ P 30 60 30 60 30 60 30 60 30 60 30 60 30 60 30 60 
T PF'bt& 
P: full length 
product 
control, 0.2 
mM dNTPs, 
1 ~L DV; 
Others: 
0.2 mM 
2'F-araTTP 
2'F-araCTP 
2'F-araATP 
2'F-araGTP 
Figure S5.2. Incorporation of 2'F-araN units (7x 2'F-araG, 11x 2'F-araA, 6x 2'F-araT, 6x 2'F-
araC) cata1yzed by DNA po1ymerases on a DNA temp1ate PF33. Primer extension reaction 
conditions were performed with 100 nM primer/temp1ate (1:1 mo1ar ratio), 0.2 mM 2'F-
araNTPs (shown above) and 1 pL DV, 9N, Th, Bst and Taq, KF, 0.5 pL Ph and MMLV, 
respective1y in 20 pL reaction volume, at 55°C (DV, 9N, Th, Bst, Taq, Ph) or 37°C (KF and 
MMLV). Reaction progress over time was ana1yzed by 12% denaturing PAGE. Lane P is the 
product control obtained in a similar primer extension assay with 1 pL DV, 0.2 mM dNTPs at 
55°C for 30min, on the same template PF33; PF39 is a 27-nt DNA control (see Table S5.1). 
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5' _32p_ TAA'l'AC~(;A.C'1IC:AC;TA'I'A- 3
' 
3 ' - A" "nr 11 "r'''/''''G ft ,."."", -, ," JI 'r' ;"]' "AG" n r"\.,, 0.C ('CT 1\ Il 7\ 5" 1...:...:·:.....:.'-."1\.,.._.J.. .r!\,,;T.J..·0h • .l ... ~.1.-\....::"-iç·· 1:"L·-+t:;Il.J~,--, .t"ti11'~-
~ Polymerase, 2'F-araNTPs (drop-out 2'F-araGTP) 
5' _32p-TAI\.TACGACTCl\.CTNI'l\.-CTCTCTTCTC-3
' 
tn -dGTP 2'F-araNTPs -2'F-araG 
Time g: .-=::=:1 -==-::=1 -==-::=1 
p (min) ~ 1030 60 1030 60 1030 60 
+ 
cr. -dGTP 2'F-araNTPs -2'F-araG 
p 
• 
f- -==-::=1 .........-=:::1 -==-::=1 ;-., 
Z 1 0 30 60 10 30 60 10 30 60 1 ~ 8 
+ 8 
~ 
U 
U 
.C!) 
1 
U 
8 
U 
8 
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U 
8 
U 
8 
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Figure S5.3. Fidelity study on 2'F-araGTP incorporation by DV and 9N DNA polymerases on 
DNA template PF43. Reaction conditions: primer/template (1:1 molar ratio): 100 nM; 0.4 pL 
(0.8 unit) DV, 9N, 25 pM triphosphate concentration at 55°C in 30 pL reaction volume. Reaction 
time for dNTPs (group l, 5) was 30 min and others were shown above. Group 1 & 5: dNTPs; 2 
& 6: drop out dGTP (i.e. dTTP, dCTP and dATP), 3 & 7: 2'F-araNTPs, 4 & 8: drop out 2'F-
araGTP; lane P is the template PF41 as the fuU-length product control; PF39 is a 27-nt DNA 
control (see Table S5.1). AU samples were analyzed by 12% denaturing PAGE. 
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Primer (PF20) 
DNA tempo (PF21) 
5 T _32p_ TAATI1CGAè~TC.4(,"TATll- 3' 
3 1 -ll.TTil. TGCTGAGTGIl TAT-CCCTCTTCTC 0CCGTTT-5 ' 
~ Polymerase, 2'F-araNTPs (drop-out 2'F-araTTP) 
5'_32p-TAATACGACTCACTATA-GGGAGAAGAG-3' Expected product 
A 
r-----~~--~------------------------~ DY DNA pOlymerase 
2 3 
If. -dTTP 2'F-araNTPs 
t- ,.............. .,............. 
~ 0.2 05 1 2 0.2 0.5 1 2 
Tlmel'" 
4 
-2'F·araT 
.,............. 
02 0.5 1 2 
.. 1 2 1. • Il. J _1.', 
-
9N DNA pOlymerase 
5 6 7 8 
tf ·dTTP 2'F ·araNTPs ·2'F ·ara T 
'Z -=::::::l -=::::::J ~ 
;' 02 05 0.2 0.5 1 0.2 0.5 1 
.~ 
27mer 
DNA 
Primer (PF20) 
DNA tempo (PF23) 
51 _32p-TlliiTACGACTCllCTliTll-3' 
3' -ATTATGCTGAGTGATAT-CCCTCTTCTC@CCATTT-5' 
~ Polymerase, 2'F·araNTPs (drop-out 2'F·araCTP) 
5'-32P-TAATACGACTCACTATA-GGGAGAAGAG-3' Expected product 
r-~------------------.-----------~----~ 
1 9N DNA polymerase 
B 
DY DNA polymerase 
2 3 4 
If. ·deTP 2·F·araNTPs ·2'F·araC 
'Z --=:::::J --=:::::J--=:::::J :r 0.2 os 1 2 0.2 05 1 2 02 05 1 2 
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DNA 
Figure S5.4 A & B. Fidelity study on (A) 2'F-araTTP and (B) 2'F-araCTP incorporation 
by DV and 9N DNA polymerases on a DNA template (A) PF21 and (B) PF23, 
respectively. Reaction conditions: 100 nM primer/template (1:1 molar ratio); 0.4 pL (0,8 
unit) DV or 9N, 25 pM triphosphate concentration at 55 oC in 30 pL reaction volume. 
Reaction time for dNTPs (group 1, 5 in both A and B) was 30 min and others were shown 
above. In A: group 1 & 5: dNTPs; 2 & 6: drop out dTTP; 3 & 7: 2'F-araNTPs; 4 & 8: drop 
out 2'F-araTTPs; in B: group 1 & 5: dNTPs; 2 & 6: drop out dCTP; 3 & 7: 2'F-araNTPs; 4 
& 8: drop out 2'F-araCTPs; PF39 is a 27-nt DNA control (see Table SI). AH samp1es were 
analyzed by 12% denaturing PAGE. 
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Primer (PF20) 
DNA template (PF41) 
Expected product: 
1. 2'F-araNTPs (Ali) 
2. Drop out 2'F-araCTP (AGT) 
3. Drop out 2'F-araTTP (AGC) 
4. Drop out 2'F-araATP (CTG) 
5. Drop out 2'F-araGTP (CT A) 
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5 '_32p_ TAATACGACTC'ACTATA-3' 
5' -ATTil. TGCTGAG 'l'Gli TA T-G.1\GAGAAGAGTCCGAGA-5 ' 
! Phusion, triphosphates condition 1-5 
5'_32P-TAATACGACTCACTATA-CTCTCTTCTCAGGCTCT-3' 
5 '_32p-TAATACGACTCACTATA-3 , 
5'_32p-TAATACGACTCACTATA-C-3' 
S'_32p-TAATACGACTCACTATA-CTCTCTTCTC-3' 
5'_32P-TAATACGACTCACTATA-CTCTCTTCTCA-3' 
Phusion ™ High Fidelity DNA Polymerase 
dNTPs 
Figure S5.5. Fidelity study on 2'F-araNTP incorporation by Phusion High Fidelity polymerases 
on purine rich DNA template PF4l. The base sequence of the primer, DNA template and 
resulting terminated products in different dropout conditions (condition 1-5) is shown. Primer 
extension conditions: 100 nM primerltemplate (1:1 molar ratio); for dNTPs (lanes 1-5): O.4,uL 
(0.8 unit) Ph, 25 ,uM dNTP concentration; for 2'F-araNTPs (lanes 6-10): 0.8 ,uL (1.6 unit) Ph, 
0.2 mM 2'F-araNTP at 55 oC in 30,uL reaction volume for 30 min. Lane 1: dNTPs; 2: drop out 
dCTP (i.e. dATP, dGTP and dTTP, shorten as AGT, same co ding for lanes 3-5), lane 6: 2'F-
araNTPs; 7: drop out 2'F-araCTP (i.e. 2'F-araATP, 2'F-araGTP, 2'F-araTTP, shorten as AGT; 
same coding for lanes 8-10). The template PF41 and the primer PF20 are shown; PF39 is a 
27mer DNA control (see Table SI). AlI samples were analyzed by 12% denaturing PAGE. 
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Primer (PF20) 
DNA tempo (PF34) 
5' _32p_ TAA TACGACTc.:4.CTA TA- 3' 
3' -ATTiITGCTGAGTGATI~T-CCCTCTTCTC-ACGCACGTGTATCTC-5' 
Expected product 
l Polymerase, dATP, dGTP, 2'F-araITP, 2'F-araCTP 
5'_32P-TAATACGACTCACTATA-GGGAGAAGAG-TGCGTGCACATAGAG-3' 
A 
B 
1 2 3 4 5 6 
DV DV 9N 9N Ph Ph 
P -==-=::1 -==-=::1 -==-=::1 -=====::1 ~ r-=--=--... 
0,51 2 3 0,5 1 2 3 0.5 1 2 3 0,5 1 2 3 :l 2 1 053 2 1 0,5 
• 
Primer 
1 
Group 1.3,5: 0.2 mM dNTPs; Group 2,4,6: 0.2 mM dATP, dGTP, 2'F-araTTP, 2'F-araCTP 
1 2 3 4 5 6 7 8 Group 1, 3, 
HIV HIV Kf Kf Taq Taq Bst Bst 0,2 mM 
......-:::J......-:::J ..........-::1..........-::1 .-=-:'::1.-=-:'::1..........-::1 ..........-::1 dNTPs 
1 3 17 1 3 17 1 3 17 1 3 17 1 3 17 1 3 17 1 3 17 1 3 17 
Time(h) 
MI JI. 
Primer 
Group 2, 4: 
0.2 mM 
dATP,dGTP 
2'F-araTTP 
2'F-araCTP 
Group 5, 7, 
004 mM 
dNTPs 
Group 6, 8: 
004 mM 
dATP. dGTP 
2'F-araTTP 
2'F-araCTP ... 
Figure S5.6. Incorporation of 2'F-araNTPs (3x 2'F-araT and 3x 2'F-araC) units catalyzed by 
DNA polymerases on a chimeric DNA-F ANA template PF34. The identity of DNA polymerases, 
and the base sequence of the primer, chimeric DNA-FANA template (PF34), and resulting 
chimeric DNA-FANA product are shown. A: 20 pL reaction volume for aU, 2 pL enzyme used; 
B: 20 pL reaction volume for aU, 1.5 pL HIV-RT, 2 pL KF, Taq, Bst, respectively; Hl were 
formed through a chain termination assay with 0.1 mM dATP, dGTP, dCTP, dTTP + ddTTP (1:1 
molar ratio), 0.4 pL HIV-RT in 20 pL reaction volume on a DNA template PF32 with the same 
sequence as PF34 (See Table S5.1); products shown on lane H2 were formed through a chain 
termination assay with 0.1 mM dATP, dGTP, dTTP, dCTP + ddCTP (1:1 molar ratio), 0.4 pL 
HIV-RT in 20 pL reaction volume on a DNA template PF32 with the same sequence as PF34 
(See Table S5.1). 
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Primer (PF20) 5' _32p_ 'J'llATACGACTCl",CTATli- 3' 
DNA tempo (PF31) .3' -i,TTllTGCTG/1GTGA'J'AT-CCCTCTTCTC-TTTCCATT-5' 
! Polymerase, dNTPs 
Expected product S' _32p-TAATACGl,CTCACTATA-GGGP,GAAGAG-AAAGGTAA-3' 
Time (h) 0.5 1 3 0.5 1 3 0.5 1 3 0.5 3 0.5 1 3 0.5 1 
< 
< 
.... 
C) 
C) 
< 
< 
< 
p 
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Figure S5. 7. Assay to assess the activity of FANA as a template (PF31) for polymerase-directed 
DNA synthesis. The identity of the DNA polymerases, the base sequence of the primer, chimeric 
DNA-FANA template (PF31), and resulting DNA oligonucleotide product are shown. Reaction 
volume was 30 pL, and dNTP and enzyme amounts/concentrations are also shown. 
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2'-Deoxy-2'-fluoro-~-D-arabinonucleic acids (2'F-ANA) and 2'-deoxy-2'-fluoro-~­
D-ribonucleic acids (2'F-RNA) are diastereomers differing in their configuration at the 2'-
carbon of the furanose sugar ring and as such, possess distinct properties that are being 
exploited in gene silencing (siRNA, antisense aptamers). While 2'-deoxy-2'-fluoro-~-D­
ribonucleoside 5'-triphosphates (2'F-rNTPs) are among the most commonly used sugar-
modified nucleoside 5'-triphosphates for in vitro selection experiments, 2'-deoxy-2'-
fluoro-~-D-arabinonucleoside 5'-triphosphates (2'F-araNTPs) have just been applied to 
the biosynthesis of 2'F-ANA oligonucleotides (Chapter V). As a follow-up study, here 
we compare the synthesis efficiency of the two isomeric nucleoside 5'-triphosphates 
(NTPs), namely, 2'F-araNTPs and 2'-deoxy-2'-fluoro-~-D-ribonucleoside 5'-triphosphate 
(2'F-rNTPs) by Deep Vent (exo-), 9°Nm™, HIV-l reverse transcriptase (RT) and 
Moloney Murine Leukemia Virus (MMLV) RT DNA polymerases. Incorporation of 2'F-
araTTP proceeded more efficiently relative to 2'F-rUTP, while the incorporation of 2'F-
araCTP was slightly less efficient than that observed with 2'F-rCTP. Considering the 
potential advantages of both 2'F-ANA and 2'F-RNA modifications in oligonucleotide-
based gene silencing approaches, this study suggests that it should be possible to generate 
2'F-ANA/2'F-RNA-based aptamers through an in vitro selection process. 
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Chapter VI. Assessing Polymerase Activity with 2'-Deoxy-2'-fluoro-p-D-
ribonucleoside S'-Triphosphates (2'F-rNTPs) and 2'-Deoxy-2'-fluoro-p-D-
arabinonucleoside S'-Triphosphates (2 'F -araNTPs) 
Abstract 
2'-Deoxy-2'-fluoro-p-D-ribonuc1eosides (2'F-rN) and 2'-deoxy-2'-fluoro-p-D-
arabinonuc1eosides (2'F-araN) differ solely in the stereochemistry at the 2'-carbon of the 
furanose sugar ring. While 2'F-rN 5'-triphosphates (2'F-rNTPs) are among the most 
commonly used sugar-modified nuc1eoside 5'-triphosphates (NTPs) for in vitro selection, 
the epimeric 2'F-araN 5'-triphosphates (2'F-araNTPs) have only recently been applied to 
polymerase-directed biosynthesis (Chapter V). In an effort to continue characterizing the 
polymerase specificity of 2'F-araNTPs, this study assessed the ability of eight different 
DNA polymerases to incorporate three contiguous pyrimidine 2'F-araNTPs into a 
growing DNA chain. Furthermore, primer extension assays were conducted to compare, 
for the first time, the incorporation efficiency of the two isomeric NTPs, i.e., 2'F-araNTPs 
or 2'F-rNTPs, by four DNA polymerases [Deep Vent (exo-), 9°Nm™, HIV-l RT and 
MMLV-RT]. Under the conditions used, incorporation of 2'F-araTTP proceeded more 
efficiently relative to 2'F-rUTP, while the incorporation of 2'F-araCTP is slightly less 
efficient than that observed with 2'F-rCTP. Interestingly, these preferences were 
observed for aH four of the DNA polymerases tested. Considering the potential 
advantages of each 2'-deoxy-2'-fluoro-D-arabinonuc1eic acid (2'F-ANA) and 2'-deoxy-2'-
fluoro-D-ribonuc1eic acid (2'F-RNA) modifications in oligonuc1eotide-based gene 
silencing approaches, these studies suggest that it should be possible to generate 2'F-
ANA/2'F-RNA-based aptamers through an in vitro selection (SELEX) process. By 
examining the structure-activity relationship (SAR) of the ribose and arabinose sugar, this 
study also contributes to the understanding of how C2' stereochemistry and sugar pucker 
affect NTP selection (specificity) by DNA polymerases. 
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Introduction 
NTPs are extensively used as probes to elucidate mechanistic details of DNA 
biosynthesis and they represent the active form of several approved and pre-clinical 
antiviral and anticancer agentsY-3] Chemically-modified nucleoside 5'-triphosphates 
(NTPs) are also of great importance in the development of aptamers as research, 
therapeutic and diagnostic agents. [4,5] They are usually generated from the process of 
Systematic Evolution of Ligands by EXponential enrichment (SELEX)[6-8] and gained 
recognition with the recent FDA approval of Macugen®, a 2'F/2'-OMe ribose-modified 
oligonucleotide indicated for the treatment of neovascular age-related macular 
degeneration. [9] 
Modified NTPs can serve either as substrates or inhibitors of polymerases 
depending on the structural changes introduced through modifications to the base, 
phosphate and/or sugar moieties relative to the natural NTPs (i.e. deoxyribonucleoside 5'-
triphosphates (dNTPs) and ribonucleoside 5'-triphosphates (rNTPs))y] Introducing a 
fluorine (F) atom into the sugar moiety of nucleosides, particularly at C2', has a strong 
impact on the sugar ring conformational equilibrium.[lO] When the 2'-fluorine atom is 
"up" (or~) in 2'-deoxy-2'-fluoro-~-D-arabinonucleic acid (2'F-ANA), the arabinofuranose 
sugar ring predominantly puckers in the South/East (C2'/04'-endo) conformation,[1l,12] 
whereas a "down" (or a) fluorine in 2'-deoxy-2'-fluoro-~-D-ribonucleic acid (2'F-RNA) 
ste ers the ribofuranose ring into the North (C3'_endo).[13-15] These C2'-modified sugars in 
tum dictate the conformation of the corresponding oligonucleotides. 
A fluorine atom at C2' significantly impacts the thermodynamic stability and 
biological activity of duplexes. For example, oligonucleotides modified with 2'F-RNA 
units have enhanced binding affinity with mRNA (~+2 OC/nt) relative to the unmodified 
counterpartsY6-19] The incorporation of 2'F-ANA units also raises the Tm of different 
systems, i.e., duplexes (~ +1 °C/nt),[20] triplexes (~ +0.8 °C/nt),[21] C-rich tetrads (~ +1 
OC/nt, pH<4.0P2] and G-rich tetrads (~ +2 OC/nt) (Peng and Darnha, manuscript in 
preparation; Chapter IV). Pyrimidine-based 2'F-RNAs were introduced into hammerhead 
ribozymes[23] or siRNAs[24] and exhibited increased or maintained activity. Antisense 
DNA or siRNA strands containing a significant 2'F-ANA content displayed gene 
silencing efficacy in the low nanomolar range. [25,26] 
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Given that 2'-deoxy-2'-fluoro-~-D-ribonuc1eoside S'-triphosphates (2'F-rNTPs) are 
good substrates for T7 RNA pOlymerase,[27] they are among the most commonly used in 
RNA-based SELEX.[28.30] A few studies have shown that 2'F-rNTPs are also substrates 
for DNA polymerasesY1,32] Richardson et al. reported that all four 2'F-rNTPs are 
substrates of human DNA pol y, and DNA polya can accepts 2'F-rUTP, 2'F-rCTP and 
2'F-rGTP, but not 2'F_rATp.[33] Furthermore, the incorporation efficiency of 2'F-rCTP by 
pol a is 17 fold higher compared to that of 2'F-rUTp.[33] Thermostable DNA 
polymerases [Pfu (exo-), Vent (exo-), Deep Vent (exo-) and UITma] are also able to 
incorporate 2'F-rUTP and 2'F-rCTP with reasonable efficiency.[34] 
2'-Deoxy-2'-fluoro-p-D-arabinonucleoside analogues have been studied for 
antiviral and anticancer applications. The recently approved anticancer drug 
clofarabine[35] lS 2-chloro-2'F -araA. 2' -Deoxy-2' -fluoro- ~-D-arabinonuc1eoside S'-
triphosphates (2'F-araNTPs) and derivatives have long been investigated to understand 
their virotoxicity or cytotoxicity since they are involved in DNA biosynthesis by viral 
and eukaryotic DNA polymerasesY] FMAU (2'F-araT) and other 2'F-arabinonucleosides 
can be incorporated into eukaryotic as well as viral DNA, [36,37] but other studies show that 
they are preferred by viral polymerases but not the mammalian polymerases. [37,38] One of 
clofarabine's mechanisms of action, in fact, is the induction of strand breaks after 
incorporation into cellular DNA.[39] FMAU[40,41] and other 2'F-araNTPs incorporating 18F 
radionuclide (ty, = 110 min) allows for the non-invasive imaging of tumors through 
positron emission tomography (PET). The successful application of these NTPs in PET 
relies on the ability of DNA polymerase to largely (and more selectively) incorporate 
these NTP in tumor cells.l42] 2'F-araNTPs have not been extensively investigated for in 
vitro selection/amplification processes. [43] 
Our group has recently shown that thermostable DNA polymerases such as Deep 
Vent (exo-) (DV), 9''Nm™ (9N), Therminator™, and Phusion™, accept both purine and 
pyrimidine 2'F-araNTPs as substrates and are able to synthesize long (30 nt) stretches of 
2'F-ANAs with high efficiency and fidelity (Peng and Damha, manuscript submitted, 
Chapter V). In addition, these enzymes are capable of synthesizing DNA on a 2'F-ANA 
template, and can drive the formation of 2'F-ANA/2'F-ANA base pairs on chimeric 2'F-
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ANA-DNA templates (Peng and Darnha, manuseript submitted, Chapter V). This 
suggests that it should be possible to generate 2'F-ANA-based aptamers through SELEX. 
In this follow-up study, we designed a less ehallenging system to first assess the 
incorporation of three contiguous pyrimidine 2'F-araNTPs (i.e. 2'F-araTTP or 2'F-
araCTP). Then we compared for the first time the incorporation efficiency of pyrimidine 
2'F-araNTPs to that of the corresponding 2'F-rNTP stereoisomers by two retroviral DNA 
polymerases, namely, HIV-l reverse transcriptase (RT), Moloney Murine Leukemia 
(MMLV)-RT, and two thermostable DNA polymerases, namely, DV and 9N. Finally, we 
also compared the incorporation effieieney of various combinations of pyrimidine 2'F-
araNTP, 2'F-rNTP, and native rNTP along with dATP and dGTP. 
Materials and Methods 
Nucleotides. 
dNTPs were purchased from Fermentas. 2'-deoxy-2'-fluoro-I3-D-arabinonuc1eosides were 
obtained from Topigen Pharmaceuticals, Inc. (Montreal, Canada). The introduction of the 
S'-triphosphate moiety was conducted by Rasayan, Inc. (Encinitas, California, USA). 
2'F-rUTP and 2'F-rCTP were purchased from Rasayan, Ine. The structures of the 
fluorinated nuc1eoside S'-triphosphates are shown in Figure 6.1. 
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Figure 6.1: A. 1-(2-deoxy-2-fluoro-I3-D-arabinofuranosyl)thymine S'-triphosphate (2'F-
araTTP); B. 1-(2-deoxy-2-fluoro-I3-D-arabinofuranosyl)cytosine S'-triphosphate (2'F-
araCTP); C. 1-(2-deoxy-2-fluoro-I3-D-furanosyl)uracil S'-triphosphate (2'F-rUTP); D. 1-
(2-deoxy-2-fluoro-I3-D-ribofuranosyl)cytosine S'-triphosphate (2'F -rCTP) 
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Template and Primer Design 
DNA and 2'F-ANA-DNA templates and primers used in this study are shown in Table 
6.1. The primer (PF20) is a 17nt DNA sequence 5'-TAATACGACTCACTATA-3'. Each 
template strand comprises three sequence segments: a 17nt long primer binding sequence 
5'-TATAGTGAGTCGTATTA-3', a 1 Ont running start sequence 5'-CTCTTCTCCC-3',[44,45] 
and a variable DNA "test sequence". The oligomers were designed to test the 
incorporation of three 2'F-araT units on the DNA template PF22, three 2'F-araC units on 
the DNA template PF24, and six mixed 2'F-araT and 2'F-araC units on the DNA template 
PF32. DNA sequences were obtained from Integrated DNA Technologies (IDT). 
Oligonuc1eotide 2'F-ANA-DNA templates were synthesized according to a published 
procedure. [46] 
Table 6.1: Base sequence of oligonuc1eotide templates and primer 
Code Type Sequence * N-mer 
PF20 Primer 5'-TAATACGACTCACTATA-3' 17 
PF22 DNAtemp. 5'-TTTGCCAAACTCTTCTCCCTATAGTGAGTCGTATTA-3' 36 
PF24 DNAtemp. 5'-TTTACCGGGCTCTTCTCCC TA TA GTGA GTCGTATTA-3' 36 
PF32 DNAtemp. 5'-CTCT ATGTGCACGCACTCTTCTCCCTATA GTGA GTCGTATTA-3' 42 
*Note: Italized sequence: primer binding sequence and primer (J 7nt); Underlined sequence: 
a running start (lOnt) 
Primer Extension Reactions 
We adapted primer extension assays[44,45] to first screen eight DNA polymerases (Table 
6.2) for their ability to incorporate three consecutive 2'F-araT and 2'F-araC units. Enzyme 
activity and default reaction buffer conditions suggested by the manufacturers are shown 
in Table S6.1 (Supplementary Data). AIl reaction buffers were provided by the 
manufacturers except for the HIV -1 R T buffer which was prepared in-house. The DNA 
primer (PF20) was first labeled by a radioactive phosphorus probe e2p) at the 5'-hydroxyl 
terminus according to a published procedure.[47] Unlabeled DNA primer was also used to 
adjust the primer concentration. The final concentrations were 85 nM for the primer and 
255 nM for the template in the screening experiments, and 100 nM for the primer and the 
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template in the comparison studies. The primer and template were heated at 95°C for 5 
min and annealed at 4°C at least two hours before use. In a microtube, the mixture of a 
buffer, triphosphates (different combinations of four dNTPs, 2'F-araNTPs, 2'F-dNTPs 
and/or rNTPs), water, primer and template was prepared according to pre- calculated 
reaction volume and concentrations. Mineral oil (20 ilL) was used to prevent evaporation 
for assays running at 55°C. A polymerase was added to initiate the primer extension 
reaction. Time points were obtained by removing 4 ilL or 8 ilL aliquots from the reaction 
Table 6.2: Polymerase used and incorporation efficiency ofthree 2'F-araT(C)TPs 
Polymerases * Short Incorporation of Incorporation of 
name three 2'F-araTTP three 2'F-araCTP 
Thermophilic DNApolymerases (assays conducted at 55°C except otherwise noticed) 
Deep Vent (3'~5' exo-) DNA 
polymerase 
9° NmTM DNApolymerase 
Est DNA polymerase large fragment 
Taq DNA polymerase 
Phusion™ High-Fidelity DNA 
polymerase 
DV 
9N 
Est 
+++ 
Taq 
Ph ++++ 
Mesophilic DNApolymerase (assays conducted at 37'C) 
Klenow fragment DNA polymerase Kf 
(3'~ 5' exo-) 
++ 
Reverse transcriptase DNA polymerases (assays conducted at 37'C) 
HIV-l RT (recombinant) 
Moloney Murine Leukemia Virus RT 
HIV-l 
RT 
MMLV-
RT 
++++ 
+++ 
++++ 
++++ 
++++ 
++++ 
++++ 
++ 
++++ 
++++ 
* Enzyme sources: aU from New England Biolabs (NEB) except for Ph from Finnzymes 
(distributed by NEB); HIV-l RT from Worthington Biochemical Corp.; 
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mixture and quenching with an equal volume of a stopping dye solution (98% deionized 
formamide, 10 mM EDTA, 1 mg/ml bromophenol blue and 1 mg/ml xylene cyanol). The 
product pattern was analyzed by 12% denaturing polyacryamide gel electrophoresis 
(PAGE) and subsequent autoradiography analysis. 
Results 
Incorporation of Three Contiguous 2'F-araTTPs and 2'F-araCTPs 
Primer extension assays were used to assess the incorporation of three contiguous 2'F-
araTTPs on the DNA template PF22. Under the conditions used, all of the polymerases 
studied generated full-Iength products, although to different extents (Figure 6.2). Pausing 
was observed for Taq, MMLV-RT, DV, 9N and Bst. Remarkably, the thermophilic 
enzymes DV, 9N and Taq were able to incorporate three 2'F-araTTPs even at 37°C 
(Section A in Figure 6.2). Ph could afford full-Iength products without any pausing at 
55°C. 
Primer (PF20) 5' _321?_ ::lV,TllCCllCTC:K'7'ATIl-3 , 
DNA temp, (PF22) 3' -f\TTATUCTC;:,G';"CATAl'-CCCTCTTCTC-,~Af;-CCG'I"l'T-5' 
l Polymerase, dATP, dGTP, dCTP, 2'F-araTTP 
Expected product 5' _32P-TJ:..ATACGAC"l'CACTATA-GGGAGAAGAG-TTT-GGCAAA- 3' 
Figure 6.2: DNA-template directed polymerization of three contiguous 2'F-araTs by 
DNA polymerases. A: all reactions at 37°C, 20 ilL rcaction volume, 1 ilL polymerase, 
dNTPs and 2'F-araTTP concentrations: 0.2 mM for Taq, DV, 9N, HIV-l RT; 0.5 mM for 
MMLV, 0.033 mM for Kf; B: reactions at 55°C, 20 ilL reaction volume, 2 )lL Bst and 0.4 
ilL Ph, 0.2 mM triphosphates; P: full-Iength product control; H: products formed through 
a chain termination assay with 0.1 mM dATP, dGTP, dTTP, dTTP+ddTTP (1:1 molar 
ratio), 0.4 ilL HIV-I RT in 20 )lL reaction volume, on the same template PF22 
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The same primer extension assays were used to assess the incorporation of three 
2'F-araC units on the DNA template PF24 (Figure S6.1, Supplementary Data). MMLV-
RT, Kf and HIV-I RT aIl gave full-Iength products (Section A). Thermophilic enzymes 
DV and Taq could incorporate three consecutive 2'F-araCTPs at 37°C, however, the rate 
of polymerization was significantly slower and sorne premature products (pausing) were 
observed. 9N and Bst failed to generate full-Iength products at 37°C (section A) but were 
able to incorporate three 2'F-araCTPs and gave the expected full-Iength products at 
higher temperature (55°C) (Section B & C). The high-fidelity enzyme Ph also easily 
provided a full-Iength product at 55°C. Overall, aIl the DNA polymerases tested were 
able to incorporate three 2'F-araTTPs and 2'F-araCTPs into a DNA strand and afforded 
full-Iength products. 9N and DV could incorporate 2'F-araTTP better than 2'F-araCTP 
(Table 6.2). 
Incorporation Efficiency of2'F-araTTP vs 2'F-rUTP 
Once the conditions of the primer extension assays were established, the incorporation 
efficiencies of 2'F-araTTP and 2'F-rUTP by HIV-I RT and MMLV-RT on the DNA 
template PF22 were compared. As shown in Figure 6.3A, 2'F-araTTP was an excellent 
substrate ofHIV-1 RT and its incorporation proceeded more efficiently compared to 2'F-
rUTP and rUTP. Interestingly, different pausing patterns were observed. In the absence 
of 2'F-modifed NTPs, the expected full-Iength DNA product was obtained from DNA-
primed (PF20) biosynthesis on the DNA template PF22. Addition of an equivalent 
amount of the dideoxynuc1eoside 5'-triphosphate (ddTTP) led to the formation of three 
new bands resulting from chain termination directly opposite the d(AAA) residues 
present in the template strand (lane H; Figure 6.3). These bands served as "markers" 
facilitating the identification of products formed in the 2'F-modifed NTPs-based assays. 
The replacement of dTTP with either 2'F-rUTP or rUTP strongly inhibited RT-catalyzed 
synthesis of full-Iength product, as evidenced by the appearance of significant amounts of 
products resulting from chain termination after incorporation of one or two rNTPs. Even 
the incorporation of the first rUTP or 2'F-rUTP unit proceeded with difficulty as 
evidenced by the band patterns observed after 5 min. These truncated products 
represented more than 94% of the total polymerization products even after lh incubation 
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with the enzyme. In sharp contrast, polymerization in the presence of 2'F -araTTP 
provided a significant amount of the full-length product after 30 min. However, the 
appearance of a significant amount of two shorter products, 5'-[DNA primer]-2'F-
ara(TpTpT)-dGG-3' and 5'-[DNA primer]-2'F-ara(TpTpT)-dGGC-3', were observed 
during the first 5-20 min of reaction. This suggests that while the arabinose units do not 
cause significant chain termination as observed with both 2'F-rUTP and rUTP, the 
efficiency of subsequent steps, particularly the addition of subsequent dNTPs, IS 
somewhat hindered following incorporation of2'F-araTTPs (delayed pausing). 
Primer (PF20J ';' ~np_ ';'"<,V_2' .. 't~Y;,::,.':·:,,;',;<::A~·/," 3' 
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100 
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------- ------
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Figure 6.3: Efficiency of incorporation of 2'F-
araTTP vs 2'F-rUTP through the DNA template 
PF22 (A), and 2'F-araCTP vs 2'F-rCTP through 
the DNA template PF24 (B) mediated by HIV-I 
RT DNA polymerization. (C) is a plot of time-
course of full-Iength product (%). Reactions 
conducted at 37°C in a 40 ilL reaction volume, 
with 0,66 ilL (18 units) enzyme; triphosphate 
concentrations were shown; products shown on 
lane H were formed through a chain termination 
assay with 0.1 mM dATP, dGTP, dCTP, 
dTTP+ddTTP (1:1 molar ratio) on the temp1ate 
PF22 (A), or 0,1 mM dATP, dGTP, dTTP, 
dCTP+ddCTP (1: 1 molar ratio) on the template 
PF24 (B), respectively; 0.4 ilL HIV-l RT in 20 
ilL reaction volume at 37°C. P: full-Iength 
product control. 
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Table 6.3: The order of incorporation efficiency of2'F-araT(C)TP vs 2'F-rU(C)TP 
Polymerases Or der of efficiency of incorporation a Figures 
HIV-I RT dTTP > 2'F-araTTP > 2'F-rUTP > UTP 
dCTP ~ 2'F-rCTP ~ 2'F-araCTP > CTP 
MMLV-RT dTTP> 2'F-araTTP > 2'F-rUTP > UTP 
dCTP ~ 2'F-rCTP ~ 2'F-araCTP > CTP 
DV dTTP ~ 2'F-araTTP > 2'F-rUTP 
dCTP ~ 2'F-rCTP ~ 2'F-araCTP 
9N dTTP ~ 2'F-araTTP > 2'F-rUTP 
dCTP ~ 2'F-araCTP ~ 2'F-rCTP 
6.3A 
6.3B 
S6.2; S6.3 
6.5 
6.4A 
6.4B 
S6.4A 
S6.4B 
ChapterVI 
a incorporation efficiency is evaluated by the percentage of full-Iength products from 
primer extension assays. 
Similar results were obtained with MMLV-RT. This enzyme was able to 
incorporate 2'F-araTTP more efficiently than 2'F-rUTP and rUTP (Figure S6.2 and S6.3, 
Supplementary Data). Similarly, pausing was observed after the first incorporation of 
2'F-araTTP, and before the first incorporation of 2'F-rUTP and rUTP. By analyzing the 
second incorporations of modified triphosphates in Figure S6.3, it is c1ear that 2'F-
araTTP is the best substrate ofMMLV-RT. 
We also wished to compare the efficiency of incorporation of 2'F-araTTP and 2'F-
rUTP by thermostable polymerases DV and 9N, as these enzymes were previously found 
to be the most effective at polymerizing 2'F-ANA strands (Peng and Darnha, manuscript 
submitted; Chapter V). With DV, incorporation of 2'F-araTTPs proceeded efficiently 
giving after 5 min nearly quantitative yield of full length product. Accumulation of an 
intermediate band corresponding to 5'-[DNA primer]-2'F-ara(TpTpT)-dG-3' was 
observed in the first 2 min (Figure 6.4A). With 2'F-rUTP, however, abrupt pausing was 
observed after the first and second 2'F-rUTP incorporation, yielding only 20% of the 
desired full-Iength product after 9.5h (Figure 6.4A). The same trends were observed with 
9N DNA polymerase (Figure S6.4A, Supplementary Data). Incorporation efficiencies of 
2'F-araTTP and dTTP were comparable and ca. 100% full-Iength products were generated 
within 2 min and without pausing, whereas the reaction with 2'F-rUTP paused after one 
214 
ChapterVI 
incorporation producing little of the expected full-length product (ca. 20% after one 
hour). 
Incorporation Efficiency of 2'F -araCTP vs 2'F -rCTP 
The same primer extension assays were used to evaluate the efficiency of DNA-template 
(PF24) directed incorporation of the cytosine NTPs by HIV-l RT and MMLV-RT. The 
incorporation of 2'F modified CTPs seemed to be more complicated than what was 
previously shown with 2'F modified TTPs (Figure 6.3B and Figure 6.5). Generally, in 
contrast to what was observed for the thymine NTPs, the incorporation efficiency of 2'F-
araCTP by HIV-l RT and MMLV-RT is comparable to or slightly less efficient than that 
Primer (PF20) "! _Up~ ;'A.·\T/;, Y;>·\'~~~·.·;':"iA-:·/'i-;: .. • Pnmer (PF20) ',' _ltp_ ;'J'.,',:::/, ':,~/~. 'T~""C;A:'i)-Y 
DNA tempo (PF22) Y -.~\:,~·}!,::·';::<'T:;Y":'.:;!"\·r . .:!-T-SSS:S::.~~S2:2-;::;.:,A-':: '.G':':';:- -'? ONA tempo (PF24) .~' -A '; :'/;;'«". >(:A,,··>'~A;:1.~'-,'(J;ff;-::·~:<:1.'(>-GG;:;'-C,-";N:«?1'~5t 
l Polymerase, dATP. dGTP, dCTP. 2"F-araTTP 1 Polyroo",..,. dATP. dGTP, dATP, 2'F ..... CTP 
Expacted product ~. -uP~'r/l.A,[AC::;A(:1(;AZ'=rltrA"';~:::GA(;M&} .. S""'TH<~:';(?~;·J>~ ;.' Expecled product '>' ~·)2p-·r.'\.~,;:A(\::..~ç:r:~\,-:'!'':~T;i-CCG1~GAA.CAG-CCC-CCCAA.;-)' 
1: 0.2 mM dNTPs: Group 2: 0.2 mM dATP, dGTP. dCTP' 2"F-araTTP: 
3: 0.2 mM dATP. dGTP, dCTP. 2'F-rUTP 
dNTPs: Group 2: 0.2 mM dATP. dGTP, dTTP, 2'F-
0,2 mM dATP, dGTP, dTTP. 2'F-rCTP 
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Figure 6,4: Efficiency of incorporation of 2'F-
araTTP vs 2'F-rUTP through the DNA template 
,,~ ........ - .... --""I--------""'PF22 (A), and 2'F-araCTP vs 2'F-rCTP through the 
DNA template PF24 (B) mediated by DV DNA 
=8: ~V':raTTP :::;::~~~aCTP polymerization. (C) is a plot of time-course of full-
-~ 2'F-rUTP -+-2'F-rCTP length product (%). Reactions conducted at 55°C in 
a 60 ilL reaction volume, with l.5 ilL (3 units) 
C Deep Vent (exo-) DNA polymerase enzyme; triphosphate concentrations were shown; 
_ -t!r ___ ~ ___ - -6 products shown on lane H were fonned through a 
~ ~ chain tennination assay with 0,1 mM dATP, dGTP, 
o __ ~-;-----,----,---~---,---; dCTP, dTTP+ddTTP (1: 1 molar ratio), 0.4 ilL HIV-
o 10 20 30 40 50 60 1 RT in 20 ilL reaction volume on the template 
Time (min) PF22 at 37°C; products shown on lane M were 
fonned through a chain tennination assay with 0.2 
mM dATP, dGTP, dTTP, dCTP+ddCTP (1: 1 molar 
ratio), 0.4 ilL MMLV-RT in 20 ilL reaction volume 
on the template PF24 at 37°C. P: full-length 
product control. 
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observed with 2'F-rCTP but better than rCTP. Remarkably, 2'F-rCTP behaved very 
differently from rCTP, e.g, little or no pausing was observed with these enzymes. On the 
other hand, assays with rCTP and either HIV-1 RT and MMLV-RT showed significant 
pausing before the first rCTP incorporation, as observed earlier with rUTP. 
Binding of 2'F-araCTP at the active site of MMLV-RT appears to occur more 
readily over its isomeric counterpart 2'F-rCTP since pausing was observed after the first 
2'F-araCTP incorporation but before the first 2'F-rCTP incorporation (Figure 6.5). Further 
elongation beyond the 2'F-araC unit, however, seemed very difficult and mainly 
premature products (ca. 90%) were observed after 60 minutes; in contrast, once 2'F-rCTP 
was incorporated, synthesis proceeded readily giving rise to almost 100% of full-Iength 
product (Figure 6.5). 
DV and 9N were able to incorporate 2'F-araCTP as well as 2'F-rCTP under the 
conditions studied here (Figure 6.4B and Figure S6.4B in Supplementary Data). 
Primer (PF20) 5~ _321'_ r:AA;'liC3!:.C-:C)h7,llTA'~'~' 
DNA temp, (PF24) 'i' -,' "?A :\'CC 'Ghm'(;,"T,~>Ç":C:':"::rTC::";; - :"\;',:;-CC:;C:":",' -:, • 
l Pœyme~e.dATP,dGTP,dATP,rF~raCTP 
Expected product )'" ",stP-1'AA1'A'::::CAC-'l'Cl\GTi'\ l'l~~'C~_)JAGA/,.GAl~~CCC-G:;(;/,)'v\ ~3 ' 
3: 
01",1\4 
rCTP '04 
~ e..-
1> 
::J 
." 
~ 
Cl. 
5 
Cl 
t: 
QI 
~ 
::J 
IL 
100 l 
90 1 
1 
80 " 
70 c 
60 
50 
40 
30 
20 
10 
0 
0 5 
-dCTP 
_2'F~raCTP 
....... 2·F·rCTP 
.... rCTP 
10 15 20 25 30 35 40 
Time(min) 
Figure 6.5. Efficiency of incorporation of 2'F-araCTP vs 2'F-rCTP through DNA 
template PF24 mediated by MMLV-RT DNA polymerization. Right figure is a plot of 
time-course offull-Iength product (%). Reactions conducted at 37°C, in a 40 ilL reaction 
volume, with 0.6 ilL (12 units) enzyme; triphosphate concentrations were shown; 
products shown on lane H were formed through a chain termination assay with 0.1 mM 
dATP, dGTP, dTTP, dCTP+ddCTP (1: 1 molar ratio) on the template PF24, 0.4 ilL HIV-1 
RT in 20 ilL reaction volume at 37°C. P: full-length product control. 
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In summary, incorporation of 2'F-araTTP proceeded more efficiently relative to 
2'F-rUTP, while the incorporation of 2'F-araCTP is slightly less efficient than that 
observed with 2'F-rCTP. While the substrate specificity towards the 2'F-rUTP and rUTP 
pair were similar, a surprisingly different specificity towards the corresponding cytosine 
pair (i.e. 2'F-rCTP and rCTP) was observed. The order of incorporation efficiency of 2'F 
modified pyrimidine NTPs is summarized in Table 6.3. 
Incorporation Efficiency of Pairs of Modified Triphosphates 
Next, we conducted primer extension assays on the DNA template PF32 in order to 
synthesize chimeric (ribo/arabino/deoxy) oligonuc1eotides with 9N, DV and HIV-l RT 
polymerases. The monomers consisted of dATP, dGTP and one of five different 
pyrimidine pairs: 2'F-araTTPI2'F-araCTP (Group 3 in Figure 6.6), 2'F-araTTP/2'F-rCTP 
(Group 4), 2'F-rUTPI2'F-araCTP (Group 5), 2'F-rUTP/2'F-rCTP (Group 6), and 
rUTP/rCTP (Group 7). Control reactions with the native dNTPs and rNTPs were carried 
out as well (Group 1 and 2 in Figure 6.6). 
Incorporation efficiency was measured either as the percentage of full-length 
products, or the number of nuc1eotides incorporated if no full-length products were 
obtained. With 9N and DV, incorporation efficiencies followed the same trend (Table 
6.3). Interestingly, HIV-l RT produced opposite results for Groups 3, 4, 6 (Table 6.4). 
Generally, dNTPs are the best and rNTPs are the worst substrates and the combination of 
2'F modified NTPs showed different incorporation efficiencies. The results are 
summarized in Table 6.4 and possible explanations for these results are discussed below. 
Discussion 
Previous studies showed that only thermophilic polymerases, namely, DV, 9N, Th and 
Ph, can generate full-length products of 2'F-ANA with an four 2'F-araNTPs (Chapter V; 
Peng and Darnha, manuscript submitted). The present study showed that all these DNA 
incorporated three pyrimidine 2'F-araNTPs into a growing DNA strand and afforded full-
length products (Table 6.2). These results contrast with those reported by Chaput and 
Szostak on DNA-template directed synthesis of a-L-threofuranosyl nuc1eic acids 
(TNA).[44] Among the various DNA polymerases studied, only DV carried out TNA 
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Primer (PF20) S' _32p_ T~',,1Tj"'C(;ACTC1,eTA:'I,-, 3' 
DNA tempo (PF32) :3' - !1TTi> T,3CT(,,;GTGA TA T-SOSO;:TÇ.}Jyrc-ACGCACGTG7/\ TC1'C- 5' 
l dATP, dGTP. 2'F.araTIP, 2'F·araCTP 
Expected product 5' _32p-T/\ATACGP..CTCACTATA-GGGAGAAGAG-'1'GCGTGCACA'1'AGAG-3' 
100 l --dNTPs -9-rNTPs 
i _2'F-araTIP/2'F-araCTP ~2'F-rUTP/2'F-araCTP 
-+-2'F-araTIP/2'F-rCTP --&-2'F-rUTP/2'F-rCTP 
- 80 --+- rUTP/rCTP ê 
-
U 
:l 
"C 60 !:! 
c.. 
J: 
œ 40 
r::: 
CI) 
~ 
~ 20 
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Time (time) 
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Figure 6.6. DNA template (PF32)-mediated DNA polymerization assay catalyzed by 9N 
DNA polymerase comparing the efficiency of incorporation of dATP, dGTP in the 
presence ofvarious pyrimidine NTP combinations, namely: 2'F-araTTP/2'F-araTTP; 2'F-
araTTPI2'F-rCTP; 2'F-rUTPI2'F-rCTP; and rUTP/rCTP. Reactions were carried out at 
55°C; 40 ilL reaction volume, 9N enzyme (2 ilL; 4 units); 0.2 mM triphosphates; 
products shown on lane Hl were formed through a chain termination assay with 0.1 mM 
dATP, dGTP, dCTP, dTTP+ddTTP (1: 1 molar ratio), 0.4 ilL HIV-1 RT in 20 ilL reaction 
volume on the same template PF32; Bottom figure is a plot of time-course of full-length 
product (%) 
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Table 6.4: The order of efficiency of incorporation of different triphosphates pairs 
Polymerase 
9N 
DV 
HIV-l RT 
Order of efficiency of incorporation 
aH four dNTPs (Group 1) > 
2'F-araTTP/2'F-araCTP (Group 3) ~ 
2'F- araTTP/2'F-rCTP (Group 4) > 
2'F-rUTP/2'F-rCTP (Group 6) > 
2'F-rUTP/2'F-araCTP (Group 5) ~ 
rUTP/rCTP (Group 7»> 
aH four rNTPs (Group 2) 
aH four dNTPs (Group 1) ~ 
2'F-araTTP/2'F-araCTP (Group 3) ~ 
2'F-araTTP/2'F-rCTP (Group 4) > 
2'F-rUTP/2'F-rCTP (Group 6) > 
2'F-rUTP/2'F-araCTP (Group 5) > 
rUTP/rCTP (Group 7) > 
aH four rNTPs (Group 2) 
aH four dNTPs (Group 1»> 
2'F-rUTP/2'F-rCTP (Group 6) > 
2'F-araTTP/2'F-rCTP (Group 4) > 
2'F-araTTP/2'F-araCTP (Group 3) > 
2'F-rUTP/2'F-araCTP (Group 5) ~ 
rUTP /rCTP (Group 7) > 
aH four rNTPs (Group 2) 
Figures 
Figure 6.6 
Figure S6.5; 
Supp1ementary 
data 
Figure S6.6. 
Supp1ementary 
data 
synthesis. However incorporation efficiency was poor and at least 1 day incubation was 
necessary in order for these enzymes to couple three contiguous TNA residues. [44] 
Incorporation of 2'F-araTTP proceeded more efficiently relative to 2'F-rUTP, but 
the opposite trend was observed for the 2'F-araCTP/2'F-rCTP pair (Table 6.3). 
Furthermore, when comparing polymerization patterns, 2'F-rUTP behaved like rUTP, but 
the same was not true for the cytosine pair, 2'F-rCTP and rCTP. Below we attempt to 
rationalize these results. 
Co-crystallization of HIV -1 R T with a double-stranded DNA template-primer 
(binary comp1ex: RT-dsDNA),[48] and with dsDNA and dNTP (ternary complex: RT-
dsDNA-dNTP)[49] suggest that the dsDNA adopts an A-like (north) structure near the 
polymerase active site which gradually converts to the B-form conformation (south) as 
this DNA region moves away from polymerase active site. Therefore it is expected that 
incoming NTPs with an A-like conformation should be favored for binding at the active 
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site. Other factors such as steric interactions between incoming NTPs and the polymerase 
amino acid residues also help dictate the specificity of NTP binding. For instance, 
models based on crystal structures suggest that Phe155 in MMLV-RT (or Tyr-1l5 in 
HIV -1 R T) acts as a "steric gate" that discriminates between the 2'H of a dNTP and the 
2'OH group of an NTP.l49-51 ] The elegant work of Marquez and others with 
conformationally biased NTP analogues and HIV-I RT fully support this hypothesis.[52,53] 
In order to explain the contrasting inhibitory behavior of aFddATP and (the more potent) 
pFddATP they conducted molecular dynamics simulations on these NTPs and showed 
that aFddATP had unfavorable steric interaction with Tyr115 (HIV-I-RT) (analogous to 
the interaction of 2'-OH of rNTPs with Tyr115), even though aFddATP adopts the 
favored north-conformation for binding at the polymerase active site[52] (Figure 6.7). Our 
observation that incorporation of 2'F-araTTP proceeds more efficiently than that of 2'F-
rUTP is consistent with the previous studies, [52] suggesting that when the fluorine is on 
the same face of the ring as the 5' carbon (i.e. P-F) as in 2'F-araTTP, the steric interaction 
with Tyr115 in HIV-I RT is avoided. 2'F-araTTP, however, must pay an energy penalty 
since it must switch to the north conformation in order to bind at the active site of RT. 
Such conformation is possible and precedented for arabinonucleosides[54] The more 
flexible dTTP thus shows the highest efficiency of incorporation. 
Nucleoside analogs that do not block DNA synthe sis at the point of incorporation, 
but only after additional incorporations of normal dNTPs have been also termed "delayed 
chain terminators", which have been shown to be relatively resistant to excision by HIV-I 
RT mutant, one of HIV-I RT's drug-resistance mechanisms.[55] The noticeable delayed 
pausing we have observed with 2'F-araNTPs may be due to the inclusion of three 
contigous 2'F-araT in the dsDNA. This likely induces an unfavorable conformational 
change in the RT-primer-template complex, which should result in a diminished rate of 
dNTP incorporation or, in the dissociation of RT from the primer-template duplex 
resulting in abortive products. The pausing observed before the incorporation of2'F-rUTP 
or rUTP (Figure 6.3A) indicates that 2'F-rUTP or rUTP has difficulty in binding at the 
active site of RT, consistent with the proposaI of steric gate control. Similar pausing 
patterns are observed for 2'F-rUTP and rUTP, consistent with the fact that 2'F-rUTP is a 
mimic of rNTPs and are both excellent substrates for T7 RNA polymerase. [27] 
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Figure 6.7: Static view of the dNTP binding site of RT in complex with north and south 
aFddATP in (A) and I3FddATP in (B) (adapted from Mu, Marquez, et al. 2000[52]) 
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Similar results are obtained for MMLV-RT, DV and 9N (Table 6.3). One can 
speculate that these enzymes could use the same discrimination mechanism 
(conformational preference and steric gate) to distinguish between dTTP, 2 'F -ara TTP, 
2'F-rUTP and rUTP during incorporation. Our finding that the incorporation efficiency of 
2'F-araTTP is higher than that of2'F-rUTP by HIV-I RT, MMLV-RT, DV and 9N is not 
surprising since 2'F-araTTP is a dTTP mimic (and thus favored by DNA polymerases), 
while 2'F-rUTP is a rUTP mimic, which should be more favored by RNA polymerases. 
Surprisingly, a more complex pattern of incorporation efficiency was observed 
among the cytosine series, dCTP, 2'F-araCTP, 2'F-rCTP and rCTP in the primer 
extension reactions catalyzed by HIV-l RT and MMLV RT. Based on the pausing 
patterns observed, binding of 2'F-araCTP at the active site of MMLV-RT seemed to be 
more advantageous over its ribose counterpart, 2'F-rCTP (Figure 6.5). This is again 
consistent with steric gate control for NTP binding. [52] The further elongation observed, 
however, indicates that other factors play important roles in single base incorporation, 
aside from the steric gate factor and conformational bias of sugar pucker. Previous 
studies on the fidelity of base incorporation have shown that the rate-limiting step could 
be different among multiple molecular checkpoints involved in DNA polymerase-
directed polymerization. [56,57] Our experiments simply measure the overall result of all 
possible factors governing base incorporations. The factors governing the specificity and 
efficiency of base incorporation by DNA polymerases are complex and not completely 
understoodJ58] Preferential geometry'p] sugar pucker,[53] topology and size of the 
polymerase active site[l] are aU important considerations. In our screening experiments, 
we found that the efficiency of incorporation of 2'F-araCTP < 2'F-araTTP in same primer 
extension conditions with sorne DNA polymerases (e.g. DV and 9N). For 2'F-rCTP, the 
literature has shown that the incorporation rate of 2'F-rCTP is much higher than that of 
2'F-rUTP by human polymerases a and y.[33] We expect that the observed incorporation 
efficiency of 2'F-rCTP 2 2'F-araCTP is the superposition of two factors: first, the overall 
incorporation efficiency of 2'F-rCTP may be higher than 2'F-rUTP by HIV-l RT and 
MMLV-RT; second, the incorporation efficiency of 2'F-araCTP is lower than that of 2'F-
araTTP. Why 2'F-rCTP differs from rCTP remains an unsolved question in this work and 
requires further study. 
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Delayed pausing was often observed with the incorporation of 2'F-araTTP and 
2'F-araCTP (Figure 6.3, 6.4, 6.5, Figure S6.2 in Supplementary Data). These results are 
somewhat consistent with studies previously reported by our group, in which a DNA 
primer strand containing a single 3'-arabinocytidine unit (araC; in this case the 2'-
substituent is an OH group) was found to serve as a primer ofDNA synthesis. However, 
significant pausing of HIV-l RT was observed after extension with 4 x dNTP units. [59] 
The order of the incorporation efficiency of the NTP mixtures shown in Table 6.4 
is an overall effect of the incorporation efficiencies of individual modified NTPs (Table 
6.3). The first modified NTP incorporated is either 2'F-araTTP or 2'F-rUTP, so the rate 
limiting step could be the incorporation of the first NTP. This seems to be the case for 9N 
and DV. For example, the order of incorporation efficiency Group 3 ::::; Group 4 > Group 6 
> Group 5 (Table 6.4) can be explained by the general trend of incorporation efficiency 
2'F-araTTP > 2'F-rUTP and 2'F-rCTP ~ 2'F-araCTP. The other combinations of rNTPs 
(Group 2 and Group 7) were not favored by 9N in this primer extension assay, consistent 
with the poor incorporation ofrNTPs by DNA polymerases (Table 6.3). 
The order of incorporation efficiency by HIV-I RT is less predictable by the 
previous results of incorporation of pyrimidine 2'F-araNTPs vs 2'F-rNTPs. As shown in 
Table 6.4 and Figure S6.6 (Supplementary Data), 2'F-rUTP/2'F-rCTP (Group 6) 
incorporation is higher than that of 2'F-araTTP/2'F-rCTP (Group 4), therefore it suggests 
that the efficiency of incorporation of 2'F-rUTP is higher than that of 2'F-araTTP, not 
consistent with the pervious finding in Figure 6.3A. However, if we compare 2'F-
araTTP/2'F-araCTP (Group 3) and 2'F-rUTP/2'F-araCTP (Group 5), the order of 
efficiency of incorporation tells us that 2'F-araTTP is better incorporated than 2'F-rUTP, 
consistent with the finding from Figure 6.3A. The efficiency of incorporation of 2'F-
araTTP/2'F-rCTP (Group 4) > 2'F-araTTP/2'F-araCTP (Group 3) is consistent with the 
finding that 2'F-rCTP is a better substrate than 2'F-araCTP (Figure 6.3B). This 
complication of the efficiency of incorporation by HIV-I RT indicates that the rate-
limiting step in HIV-l RT should be different from DV and 9N. The incorporation of2'F 
modified CTPs seems more important in determining the yield of the full-Iength 
products. 
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Conclusion 
2'F-araTTP and 2'F-araCTP are substrates of aIl the DNA polymerases tested in the 
present study. DV and 9N were the most efficient at incorporating 2'F-araTTP and 2'F-
araCTP and afforded good yields of fulliength chimeric 2'F-ANAIDNA products. Our 
comparative studies of the efficiency of incorporation of 2'F-araNTPs vs 2'F-rNTPs by 
four DNA polymerases demonstrate that, under the conditions used, incorporation of2'F-
araTTP proceeded much more efficiently relative to 2'F-rUTP, while the incorporation of 
2'F-araCTP was only slightly less efficient than that observed with 2'F-rCTP (Table 6.3). 
Generally, dNTPs were found to be better substrates than rNTPs; 2'F-rUTP behaves 
much like rUTP but 2'F-rCTP is strikingly different from rCTP. Furthermore, we 
demonstrate that mixtures of 2'F-araNTPs and 2'F-rNTPs can be used to generate 2'F-
r/2'F-ara-oligonucleotides through template-directed DNA polymerization reactions. The 
2'F-araTTP and 2'F-rCTP pair gave excellent results with the DNA polymerases tested. 
Considering the potential advantages of 2'F-ANA and 2'F-RNA modifications in 
oligonuc1eotide-based gene silencing approaches, our studies suggest that it should be 
possible to generate chimeric 2'F-ANA/2'F-RNA/DNA aptamers through an in vitro 
selection (SELEX) process. 
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Table 86.1: Polymerase information and default primer extension assay conditions 
Polymerase Activity Reaction buffer (xl) 
(units/IlL) 
Thermophilic DNA polymerase (reaction temperature at 55°C in this study) 
DV 
9N 
Th 
Bst 
Taq 
Ph 
2 
2 
2 
8 
5 
2 
20 mM Tris-HCl (pH 8.8 at 25°C), 10 mM (NH4)zS04, 10 mM 
KCl, 2 mM MgS04, 0.1 % Triton X-100; 0.2 mM dNTPs 
Same as above 
Same as above 
Same as above 
Same as above 
5X Phusion™ HF Buffer; 0.2 mM dNTPs 
Mesophilic DNA polymerase (reaction temperature at 37°C in this study) 
KF 5 10 mM Tris-HCl (pH 7.5 at 25°C), 5 mM MgC12, 7.5 mM 
DTT; 0.033 mM dNTPs 
Reverse transcriptase (reaction temperature at 37°C in this study) 
HIV 27.3 
MMLV 10 
50 mM Tris-HCl (PH 7.8 at 25°C), 60 mM KCl, 2.5 mM 
MgCb; 0.2 mM dNTPs 
50 mM Tris-HCl (pH 8.3 at 25°C), 50 mM KCI, 4 mM MgClz, 
1 OmM DTT; 0.5 mM dNTPs 
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Primer (PF20) 5' _32p_ Til.A'I'ACGACTCl,CTll'tA-3
' 
DNA tempo (PF24) 3 ' -ATTATGCTGAGTGilTAT-CCCTCTTCTC-GGG-CCATTT-5' ! Polymerase. dATP, dGTP. dATP, 2'F·araCTP 
Expected product S' _32p-TAATACGACTCACTATA-GGGAGl\AGAG-CCC-GGCAAA-3' 
Taq MMLV DV Bst 9N HIV Kf Taq DV 9N Bst Ph 
.............-: .............-:.............-: ............-:: ............-:: ............-::.....:::::::::: P P .L:I-d.L:I 
10254570102545 70102545 70102545701025457010254570102545 
Time(mîn} ,41.-
Figure S6.1: DNA-template directed polymerization of three contiguous 2'F-araC 
nuc1eotide units catalyzed by DNA polymerases on a DNA-template PF24. A: reactions 
at 37 oC, 20 ~L reaction volume, 0.5 ~L enzyme, dNTPs and 2'F-araCTP: 0.01 mM for 
MMLV and 0.05 mM for HIV; reactions at 37 oC, 20 ~L reaction volume, 1 ~L enzyme, 
dNTP and 2'F-araCTP: 0.033 mM for Kf and 0.5 mM for MMLV; B: reactions at 55 oC, 
40 ~L reaction volume, 2 ~L enzyme added, 0.2 mM triphosphates; C: reactions at 55 oC, 
20 ~L reaction volume, 2 ~L Bst and 0.4 ~L Ph., 0.2 mM triphosphates; products shown 
on lane H were formed through a chain termination assay with 0.1 mM dATP, dGTP, 
dTTP, dCTP+ddCTP (1:1 molar ratio), 0.4 ~L HIV-1 RT in 20 ~L reaction volume, on the 
same template PF24. 
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Figure S6.2. Efficiency of incorporation of 2'F-araTTP vs 2'F-rUTP through DNA 
template PF22 mediated by MMLV-RT DNA polymerization. Right figure is a plot of 
time-course of full-Iength product (%). Reactions conducted at 37°C, in a 60 ilL reaction 
volume, with 1 ilL (20 units) enzyme; triphosphate concentrations were shown; products 
shown on lane H were formed through a chain termination assay with 0.1 mM dATP, 
dGTP, dCTP, dTTP+ddTTP (1:1 molar ratio) on the template PF22, 0.4 ilL HIV-1 RT in 
20 ilL reaction volume at 37°C. P: full-length product control. 
Primer (PF20) 5' _32P-TAiiTACG/1CTCilC"I'!WA-3' 
DNA tempo (PF22) 3' -A TTkTGCTGAG'!'G/lTA T-S:5:i"1'CT'TC'l'C-AAA-CCG'l'TT-5 ' 
! Polymerase. dATP, dGTP, dCTP, 2'F-araTTP 
Expected product 5' _32P-TAA'l'ACGACTCACTATA-GGGAGAAGAG-TTT-GGCAAA-3' 
Groupl.01 100 l 
mMdNTPs 90 1 
'V" Group 2.3,4: 80 -
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--;:' dGTP.dCTP ,e , L 601 
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Figure S6.3: Efficiency of incorporation of 2'F-araTTP vs 2'F-rUTP through DNA 
template (PF22)-mediated MMLV-RT DNA polymerization. The base sequence of the 
primer, DNA template (PF22) and resulting chimeric DNA-2'F-ANA oligonuc1eotide 
product is shown. Reactions conducted at 37°C in a 40 ilL reaction volume with 0.6 ilL 
(12 units) enzyme, triphosphate concentrations shown; products shown on lane H were 
formed through a chain termination assay with 0.1 mM dATP, dGTP, dCTP, 
dTTP+ddTTP (1: 1 molar ratio), 0.4 ilL HIV-I RT (8 units) in 20 ilL reaction volume on 
the same template PF22 at 37°C.; (B):Time-course products with the 2nd incorporations of 
2'F-araTTP, 2'F-dUTP or UTP (%) based on gel (A). 
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Figure S6.4: Efficiency of incorporation of 
2'F-araTTP vs 2'F-rUTP through DNA temp1ate 
PF22 (A), and 2'F-araC vs 2'F-rC through DNA 
template PF24 (B) mediated by 9N DNA 
polymerization. (C) is a plot of time-course of 
full-Iength product (%), Reactions conducted at 
55°C in a 60 ilL reaction volume, with 3 ilL (6 
units) 9N DNA pol; triphosphate 
concentrations were shown; products shown on 
lane H were formed through a chain 
termination assay with 0.1 mM dATP, dGTP, 
dCTP, dTTP+ddTTP (1:1 molar ratio), 0.4 ilL 
:1 20 LI.. tr ~- - tr - - - -6 - - - --1'; HIV-1 RT in 20 ilL reaction volume on the template PF22 at 3rc. ; products shown on 
lane M were formed through a chain 0 
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40 50 60 termination assay with 0.2 mM dATP, dGTP, 
dTTP, dCTP+ddCTP (1: l molar ratio), 0.4 JlL 
MMLV-RT in 20 ilL reaction volume on the 
template PF24 at 37°C. P: full-Iength product 
controL 
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Primer (PF20) 5' _32p_ TA1;]"AC,:;.h.L·i,,~·)\C:'TATA-,~' 
DNA tempo (PF32) .l' -ATl'AT::<:'1'CA:;TCArAT-CC~;':'CTTCTC-AC(;CACG'I'GTATC'l'C-5' 
l dATP. dGTP, 2'F-araTTP. 2'F-araCTP 
Expected product 
1 
:) 1 _32P-T"J:.J ... Tt'V.:C:\CTCAC'rA'l'A -GGGAGAAG;V.~ -TGCGTGCAChT!'l.GAG- 3 1 
2 3 
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Figure S6.5: DNA template (PF32)-mediated DNA polymerization catalyzed by DV 
DNA polymerase comparing the efficiency of incorporation of dATP, dGTP in the 
presence ofvarious pyrimidine NTP combinations, namely: 2'F-araTTP/2'F-araTTP; 2'F-
araTTP/2'F-dCTP; 2'F-dUTP/2'F-dCTP; and UTP/CTP. Reactions were carried out at 
55°C; 40 f.lL reaction volume, 9N enzyme (2 f.lL; 4 units); 0.2 mM triphosphatess; 
products shown on lane H were formed through a chain termination assay with 0.1 mM 
dATP, dGTP, dCTP, dTTP+ddTTP (1:1 molar ratio), 0.4 f.lL HIV-1 RT in 20 f.lL reaction 
volume on the same template PF32; The bottom figure is a plot of time-course of full-
length product (%). 
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Primer (PF20) s 1 _32p-l'AATk~(~rY"?\ :';,·,~7'A Tlo- y 
DNA temp, (PF32) 3' -liTTA L~~'TC;1,C;l'G/]AI'-CCCTC'rTCTC-ACGCACGTGTATCTC-5' 
l dATP. dGTP. 2'F·araTTP, 2'F·araCTP 
Expected product ') 1 -32p-?AAT1\C:;P·,CIT1\CT fIT }\-GGCN;:;JI.loGF,G-TGCGTGCI',CAT1\GAG-3 t 
1 2 3 
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Figure 86.6: DNA template (PF32)-mediated DNA polymerization catalyzed by HIV-l 
RT DNA polymerase comparing the efficiency of incorporation of dATP, dGTP in the 
presence ofvarious pyrimidine NTP combinations, namely: 2'F-araTTP/2'F-araTTP; 2'F-
araTTPI2'F-dCTP; 2'F-dUTPI2'F-dCTP; and rUTP/rCTP, Reactions at 37°C, 40 I-lL 
reaction volume, 1 I-lL (27,3 units) HIV-l RT (except for 0.4 I-lL for the first lane); 0.2 
mM TPs (except for 0.1 mM dNTPs in the first land); H control: 0,1 mM dATP, dGTP, 
dTTP+ddTTP (1:1), dCTP+ddCTP (1:1), HIV-l RT, the same template PF32 at 37°C for 
15min; The bottom figure is a plot oftime-course offull-length product (%). 
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Chapter VII. Contributions to Knowledge 
7.1. Summary and Conclusions 
Chapter VII 
In an effort to develop novel oligonucleotide analogues as potential therapeutics 
and/or diagnostic reagents, specifically for their use as antisense and aptamer based 
technologies, the chemical synthesis of two C2'-modified oligonucleotides containing 
1-(2-deoxy-2-a-C-hydroxymethyl-~-D-ribofuranosyl)thymine and 2'-deoxy- 2'-fluoro-
~-D-arabinonucleosides were investigated. These were generated either through 
solid-phase or DNA polymerase-mediated oligonucleotide synthesis. 
The 3'- and 2'-O-phosphoramidite derivatives of 1-(2-deoxy-2-a-C-
hydroxymethyl-~-D-ribofuranosyl)thymine (or 2'-a-hm-dT, abbreviated as "H") were 
synthesized and incorporated into otherwise unmodified DNA, RNA and 2',5'-RNA 
chains. Thermal denaturation data showed that "H" units had a stabilizing as weIl as a 
destabilizing effect on duplexes depending on the phosphodiester connectivity (3',5" 
or 2',5') of the H units, and the nature of the accepting oligonucleotide strand (RNA, 
DNA vs 2',5'-RNA). Consistent with previous findings, 3',5'-linked H units were 
found to significantly destabilize DNA:RNA hybrids and DNA:DNA duplexes (the 
strand containing a few H units is in italics). The incorporation of 3',5'-linked H into 
RNA:RNA duplexes was found to be less destabilizing. It was also shown that 
2',5'-linked H had a small destabilizing effect on 2',5'-RNA:RNA and RNA:RNA 
duplexes, and in fact, they were shown to stabilize 2',5'-RNA hairpins when 
incorporated within their constituent 2',5'-linked tetraloop. These results were 
rationalized in terms of the "compact" and "extended" conformations of nucleotides. 
A series of branched RNAs (Y -shaped) related to yeast pre-mRNA splicing 
intermediates were synthesized incorporating both natural (i.e. ribose) and non-natural 
(i.e. "H" and acyclic nucleoside) branchpoints in order to examine the effect of sugar 
and phosphodiester configuration on hydrolytic efficiency of the yeast debranching 
enzyme (yDBR). Selective hydrolysis of the 2',5'-phosphodiester bond by yDBR 
was evident only in the wild-type ribo-A and ribo-U branched RNA. On the other 
hand, the branchpoint analogs were resistant to enzyme hydrolysis even after a 60 min 
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incubation period, suggesting that the length of the 2',5'-internucleotide linkage 
(extended in the case of "H") dramaticaIly affects debranching efficacy. Moreover, 
these studies have indicated a concentration dependant inhibition of wild-type Y -RNA 
debranching in the presence of H-containing branched RNA, such that a 50% 
reduction in debranching efficiency was observed at a concentration of 70 nM of 
inhibitor. The strength of the inhibition depended on the nature of the 2'-nucleotide 
residue. In this regard, a 2'-cytidine had the best inhibitory activity. Such an 
inhibitor would signify a potential choice for enzyme co-crystaIlization and X-ray 
analysis of the yDBR active site structure. 
2'-Deoxy-2'-fluoro-~-D-arabinonucleic acid (2'F-ANA) has been developed in 
the Damha group for antisense and siRNA -mediated gene silencing. This thesis 
explored, for the first time, the potential of this promising modification in aptamer 
applications. Specifically, the impact of the 2'F-ANA modification on stability and 
conformation of the weIl known thrombin-binding aptamer d(G2 T 2G2 TGTG2 T 2G2), 
the anti-HIV phosphorothioate sequence PS-d(T2G4T2), and a DNA telomeric 
sequence d(G4T4G4) were investigated. UV thermal melting (Tm) and circular 
dichroism (CD) experiments revealed that 2'F-ANA can stabilize G-quartets and 
maintain the quadruplex conformation provided only the anti-deoxyguanosines are 
replaced with 2'F-ANA residues. Replacement of syn-deoxyguanosines with 
2'F-ANA resulted in a dramatic switch to an alternative and in sorne cases very stable, 
quadruplex conformation. The data also showed that incorporation of 2'F-ANA 
residues into thrombin-binding DNA stabilizes the complex (t:Œm up to - + 3°Cl 
2'F-ANA modification). The 2'F-ANA modification also increased the half-life in 
10% fetal bovine serum (FBS) up to 48 fold. Two 2'F-ANA-modified 
thrombin-binding aptamers (PG 13 and PG 14) showed enhanced binding affinity to 
thrombin nearly four fold, as assessed by a nitrocellulose fil ter binding assay. PG 13 
and PG 14 also exhibited increased thermal stability (_1°C increase in Tm) and 
nuclease resistance (4-7 fold). Therefore, these studies have opened new 
perspectives for the biological application of 2'F-ANA as aptamer oligonucleotides. 
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This thesis work also examined the polymerase-directed synthesis of 2'F-ANA 
oligonucleotides. A primer extension assays was adapted to screen several DNA 
polymerases for their ability to incorporate aIl four 2'F-araNTPs (N = A, G, T and C) 
and found that these monomers are very good substrates for commonly used 
thermophilic DNA polymerases. Remarkably, the selectivity (fidelity) for 2'F-araNTP 
(N= purines) incorporation by DV and 9N polymerases was comparable, if not better, 
than that of the native dNTPs. Selectivity toward the pyrimidine-based 2'F-araNTPs 
was significantly less, but the same was true for the corresponding 
pyrimidine-containing dNTPs. DV, 9N and Ph polymerases catalyzed synthesis of 
chimeric FANA-DNA strands on FANA-DNA templates, whereas Klenow fragment 
DNA polymerase (3'->5' exo-) (KF) and Bst DNA polymerase (Bst) were able to 
catalyze 2'F-ANA template-directed DNA synthesis. While it was not possible to 
synthesize an all-2'F-ANA strand on an aIl-2'FANA template, it was possible for DV, 
9N and Ph polymerases to drive the formation of multiple FANA:FANA base pairs 
within a DNA-FANA chimeric duplex. AlI of these results suggest that it should be 
possible to evolve FANA-modified aptamers using in vitro selection. 
FinaIly, this thesis provided the first comparison study of incorporation 
efficiency of the two isomeric NTPs (i.e. 2'F-araNTPs and 2'F-rNTPs) by 
thermophilic and retroviral DNA polymerases (DV, 9N, HIV-l RT, and MMLV RT). 
Under our primer extension conditions, incorporation of 2'F-araTTP proceeded more 
efficiently than 2'F-rUTP, while the incorporation of 2'F-araCTP is slightly less 
efficient than that observed with 2'F-rCTP. Considering the potential advantages of 
2'F-ANA and 2'F-RNA modifications in oligonucleotide-based gene silencing 
approaches, our study suggests that it should be possible to generate 
2'F-ANAI2'F-RNA-based aptamers through an in vitro selection process such as 
SELEX. By examining the structure-activity relationship (SAR) of the ribose and 
arabinose sugars, these studies contributed to the understanding of how C2' 
stereochemistry and sugar pucker affect NTP selection (specificity) by DNA 
polymerases. 
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As a direct result of the studies described herein, the following have been 
recently published, or are currently in preparation for submission in the near 
future: 
1. Peng, c.G. and Darnha, M.J. Assessing polymerase activity with 
2'-deoxy-2'-fluoro-~-D-ribonucleoside 5 '-triphosphates (2'F-rNTPs) and 
2'-deoxy-2'-fluoro-~-D-arabinonucleoside 5'-triphosphates (2'F-araNTPs), 
manuscript in preparation for Biochemistry. 
2. Peng, c.G., Mangos M. and Damha, M.J. Yeast debranching enzyme (yDBR) 
inhibition by novel branched RNAs, manuscript in preparation for Bioorganic & 
Medicinal Chemistry Letters. 
3. Peng, C.G. and Damha, M.J. G-quadruplex induced stabilization by 
2'-deoxy-2'-fluoro-~-D-arabinonucleic acids (2'F-ANA), manuscript submitted to 
Nucleic Acids Research (Manuscript NAR-00988-2007). 
4. Peng, C.G. and Damha, M.J. (2007) Polymerase-directed synthesis of 
2'-deoxy-2'-fluoro-~-D-arabinonucleic acids. Journal of the American Chemical 
Society, 129,5310-5311 
5. Peng, c.G. and Damha, M.J. (2006) DNA polymerase recognition of 
2'-deoxy-2'-fluoroarabinonucleoside 5'-triphosphates (2'F-araNTPs). Nucleosides, 
Nucleotides and Nucleic Acids (Conference Proceedings; in press) 
6. Peng, c.G. and Darnha, M.J. (2005) Synthesis and hybridization studies of 
oligonucleotides contammg 1-(2-deoxy-2-a-C-hydroxymethyl-~-D-ribo-
furanosyl)thymine (2'-a-hm-dT). Nucleic Acids Research, 33(22), 7019-7028. 
The results disclosed in this thesis have led to the following provisional patents 
being filed: 
1. Darnha, M.J. and Peng, C.G. (2006) 2'-Deoxy-2'-Fluoro- fJ-D-Arabinonucleoside 
5'-Triphosphates and Their Use in Enzymatic Nucleic Acid Synthesis. V.S. 
Provisional Patent Application VS 60/839,417. 
2. Damha, M.J. and Peng, c.G. (2005) Aptamers Comprising Arabinose Modified 
Units. V.S. Provisional Patent Application VS 60/722,973. 
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2'F-araNTPs and 2'F-riboNTPs. The XVII International Roundtable on 
Nucleosides, Nucleotides and Nucleic Acids (IRTXVII), Bern, Switzerland, 
September 3-7. 
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of novel oligonucleotide structures containing modified 2',5'-RNA. 231 st ACS 
National Meeting, Atlanta, GA, USA, March 26-30. (oral presentation) 
3. Peng, c.G. (2006) Synthesis, characterization and applications of modified 
2',5'-RNA and FANA modified aptamers. Organic Seminar, Chemistry 
Department, McGill University, Montreal, Jan. 13. (oral presentation) 
4. Peng, c.G. and Damha, M.J. (2005) Synthesis of 2'-deoxy-2'-a-C-hydroxymethyl 
2',5'-linked RNA. 16th Quebec-Ontario Minisymposium in Synthetic and 
Bio-Organic Chemistry, Sainte-Adele, Canada, Nov. 11-13. 
5. Peng, c.G. and Damha, M.J. (2005) Synthesis of a "taller" 2',5'-linked ribonucleic 
acid: 2'-a-C-hydroxymethyl 2',5'-linked RNA. 14th Conversation in Nuc1eic Acid 
StructurelBiology at SUNY, Albany, USA, June 14-18. 
6. Peng, c.G. and Damha, M.J. (2004) Synthesis and binding properties of 
2'-a-C-hydroxymethyl-2',5'-linked RNA. 87th CSC Annual meeting, London, 
Canada, May 29-June 1. (oral presentation) 
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ABSTRACT 
We report the first investigation of oligoribonuc-
leotides containing a few 1-(2-deoxy-2-a-C-hydroxy-
methyl-~-D-ribofuranosyl)thymine units (or 2'-hm-dT, 
abbreviated in this work as 'H'). Both the 2'-CH20-
phosphoramidite and 3'-O-phosphoramidite derivat-
ives of H were synthesized and incorporated into both 
2',5'-RNA and RNA chains. The hybridization proper-
ties ofthe modified oligonucleotides have been stud-
ied via thermal denaturation and circular dichroism 
studies. While 3',5'-linked H was shown previously 
to significantly destabilize DNA:RNA hybrids and 
DNA:DNA duplexes (modification in the DNA strand; 
A Tm'" -3°C/insert), we find that 2',5'-linked H have a 
smaller effect on 2,5-RNA:RNA and RNA:RNA 
duplexes (A Tm = -O.3°C and -1.2°C, respectively). 
The incorporation of 3',5'-linked H into 2,5-RNA: 
RNA and RNA:RNA duplexes was found to be more 
destabilizing (-O.7°C and -3.6°C, respectively). 
Significantly, however, the 2',5'-linked H units confer 
marked stability to RNA hairpins when they are incor-
porated into a 2',5'-linked tetraloop structure 
(ATm = +1.5°C/insert). These results are rationalized 
in terms of the compact and extended conformations 
of nucleotides. 
INTRODUCTION 
Our group has had a long-standing research interest in the 
physicochemical and biochemical properties of 2',S'-linked 
ribonucleic acids (2',5'-RNA, Figure 1) (1,2). These regioi-
somers of standard (i.e. 3',5'-linked) RNA are not only inter-
esting from a structural point of view, but also have potential 
use in the down-regulation of gene expression (3,4). For 
instance, 2' ,5' -RNAs are able to associate with complementary 
single-stranded RNA (ssRNA) (3) as weil as duplex DNA (5) 
and, as such, can potentially be used to down-regulate gene 
expression via the antisense and antigene approaches 
(Figure 1) (4,6-8). It is also well-documented that annealing 
two normal RNA strands is more favorable than annealing a 
2',S'-RNA strand with a normal RNA strand (1,3,8,9). Fur-
thermore, mutually complementary 2',S'-RNA strands have 
the ability to associate, but exhibit a transition temperature 
(Tm) that is considerably lower than those of the corresponding 
RNA:RNA or RNA:2' ,5' -RNA duplexes. A comparison of the 
Tm values of various duplexes of mixed base composition 
revealed the following order of duplex thermal stability: 
RNA:RNA > DNA:DNA ~ DNARNA > RNA:2' ,5' -RNA> 
2',5'-RNA: 2',S'-RNA > DNA 2',S'-RNA (undetected) (1). 
Molecular modeling and circular dichroism (CD) studies of 
these duplexes revealed that RNA: 2' ,5' -RNA hybrids adopt a 
continuous A-type helix structure similar to that of native 
RNA Cl), but have smaller interstrand phosphate-phosphate 
distances (by '" 1 À). This may account, at least in part, for the 
lower thermal stability of RNA:2',S'-RNA relative to RNA: 
RNA and RNADNA helices (1). 
As part of our ongoing study of these systems, we now 
present an investigation of 2',5'-RNA chains containing one 
or more 1-(2-deoxy-2-a-C-hydroxymethyl-~-D-ribofurano­
syl)thymine (2' -a-hm-dT; abbreviated in this work as 'H', 
Figure 1 and Scheme 1). We anticipated that lengthening 
the sugar-phosphate backbone by one methylene unit would 
not only diminish putative P-P repulsions in 2',S'-RNA:RNA 
duplexes, but wou Id also provide a 'compact' nucleotide con-
formation favoring tighter RNA binding (Figure 2) (10,11). 
This interesting modification was first studied by Schmit et al. 
(12) and reviewed more recently by Freier and Altmann (13). 
Schmit et al. (12) reported that 3',5'-linked H units (3',5'-H) 
significantly destabilize DNA:RNA hybrids and DNA:DNA 
duplexes (modification in the DNA strand; I1T m = -2.9°C). 
Destabilization owing to the 2' -a-hydroxymethyl and other 
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Scheme 1. Structures of 2'-a-hm-dT (H) and ils phosphoramidile derivatives 8 and Il. 
2' -u alkyl groups was explained by the tendency of these 
substituents to shift the conformational equilibrium of the 
sugar toward the C2'-endo pucker and away from the C3'-
endo pucker found in RNA, 2'-O-alkyl RNA and 2'F-RNA 
duplexes (12,13). To the best of our knowledge, neither 2',5'-
linked H units (2' ,5'-H) nor incorporation into RNA have ever 
been examined. The present study revea1ed that 2',5'-H units 
have a modest destabilizing effect on 2',5'-RNA:RNA 
(/lT ru = -o. 3°C) and RNA:RNA duplexes (/lT ru = -1.2°C), 
whereas 3',5' -H units are significantly more destabilizing 
(-0.7°C and -3.6°C, respective1y), consistent with the results 
of Schmit et al. (12). In contrast, we find that 2',5'-H units 
confer significant stability to RNA hairpins, particularly when 
they are placed in the loop structure (/lT ru = + 1.s°C). 
MATERIALS AND METHODS 
General reagents 
AlI reactions were carried out in oven-dried glassware under a 
N2 atmosphere. Dichloromethane (CH2CI2) and acetonitrile 
(CH)CN) were dried by refluxing and distilling over calcium 
hydride (CaH2) under a N2 atmosphere. Tetrahydrofuran 
(THF) was dried by refluxing over sodium and benzo-
phenone under a N2 atmosphere and collected before use. 
Anhydrous methanol (MeOH), pyridine (py), N-ethyl-N,N-
diisopropylamine (DIPEA), N,N-dimethylformamide (DMF) 
and 2,6-lutidine were obtained from Aldrich. The following 
chemicals were used as received from Aldrich: p-anisyl-
chlorodipenylmethane (MMTr-Cl), benzoyl chloride (Bz-
Cl), tert-butyldimethylsilyltriflate (TBDMSOTf), tert-
butyldimethylsilylchloride (TBDMSCl), 4,5-dicyano-
imidazole (DCI), 4-dimethylaminopyridine (DMAP), 1,1,1, 
3,3,3-hexamethyldisilazane (HMDS), 10 wt% palladium on 
carbon powder (10% Pd/C), triethylamine tris(hydrofluoride) 
(TREAT HF), D-ribose, silver nitrate (AgN03), 1.0 M tin (IV) 
tetrachloride solution in dichloromethane (SnCI4), thymine. 
~-cyanoethyl-N,N-diisopropylchlorophosphorarnidite and 
other solid-phase synthe sis reagents and regular nuc1eoside 
monomers were purchased from ChemGenes Corp. 
(Ashland, MA). 
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Figure 2. The C2' - and C3' -endo sugar puckers are favored in 2',5' -linked RNA and 3' .5' -linked RNA, respectively (10, II). The intraresidue P-P distance determines 
the 'compact' or 'extended' backbone structure (II). Lengthening by an extra carbon C2' (H) removes the gauche effect between the ring oxygen and 02', which is 
expected to reinforce the C2'-endo or compact conformation for 2',5'-linked H units. 
Methyl 2-a-benzoyloxymethyl-2-deoxy-3,S-di-O-(2,4-
dichlorobenzyl)-a-n-ribofuranoside (2) 
Compound (1) was obtained following slight modifications of 
the procedure described by Martin [(14); Supplementary 
Data]. Under a N2 atmosphere, 1.5 ml (1.78 g, 12.7 mmol) 
BzCl was added to a solution ofl (4.83 g, 9.73 mmol) in 75 ml 
dry pyridine. The resulting solution was kept stirring at room 
temperature for 4 h. The reaction progress was monitored by 
TLC. When the reaction was complete, the reaction mixture 
was concentrated under reduced pressure, and then washed 
with saturated NaHC03 and brine. The aqueous phase was 
extracted with CH2Cl2 three times. The combined organic 
layers were evaporated to dryness to afford 2 in quantitative 
yield (5.84 g). Rf (Si02) = 0.86 (2:1 EtOAc/hexane); 0.70 
(1:2 EtOAc/hexane); IH NMR (400 MHz, CDCI3, Ô): 7.98-
7.09 (m, llH, ArH), 5.11 (d, 3h2 = 5.2 Hz, IR, Hl), 4.73-
4.55 (m, 6H, benzyl CH2 and CH2-C2), 4.4-4.43 (m, IR, H4), 
4.08 (dd, 3h2, 313-4 = 5.2, 2.4 Hz, IR, H3), 3.54-3.64 (AB 
dd,215.5' = 22.4 Hz, 314.5+5, = 4.4, 5.2 Hz, 2H, H5 and H5'), 
3.45 (s, 3H, OCH3), 2.74-2.67 (m, IR, H2). ESI-MS for 
C2sH26Cl406 [MNa+] calcd 621.05, found 621.1. 
1-[2-a-Benzoyloxymethyl-2-deoxy-3,S-di-O-(2, 
4-dichlorobenzyl)-n-ribofuranosyl]thymine (3) 
Under a N2 atmosphere, a mixture of dry thymine (1.35 g, 
10.7 mmol), ammonium sulfate (0.136 g, 1.029 mmol) and 
HMDS (2.87 ml, 13.8 mmol) in anhydrous CH3CN (41 ml) 
was refluxed at 100°C for 4 h until the reaction mixture was 
clear. The reaction mixture was cooled to room temperature 
and added to a solution of 2 (2.47 g, 4.12 mmol) in dry CH3CN 
(19.5 ml) followed by 1.0 M SnCl4 in CH2C12 (4.12 ml, 4.12 
mmol). The resulting solution was warmed to 50°C and left 
stirring for an additional 12 h. After the reaction was complete, 
the reaction mixture was cooled to room temperature, washed 
with saturated NaHC03 (50 ml) and filtered. The filtrate was 
extracted three times with the same volume of CH2Ch and the 
organic layer was washed with brine, dried over Na2S04 and 
evaporated to yield a white foam. Purification by silica gel 
column chromatography with EtOAc/hexane (2:1, v/v) 
afforded the title compound in 72% yield (2.06 g, 
~:a = 5:1). Rf (Si02) = 0.6 (2:1 EtOAc/hexane); IH NMR 
of ~-isomer (400 MHz, CDCI3, Ô): 7.97-7.19 (m, 12H, ArH 
and H-6), 6.35 (d, 311'.2' = 8.8 Hz, IR, Hl'), 4.74, 4.47 (2dd, 
2JcH2_C2' = 12 Hz, 31cH2_c2'. H2' = 7.6,7.2 Hz, 2H, CH2"C2'), 
4.69-4.56 (m, 4H, benzyl CH2), 4.38 (br, m, IR, H4'), 4.31-
4.28 (m, IR, H3'), 3.9, 3.7 (2 dd, 215, 5" = 10.8 Hz, 
314'.5'+5" = 3.2, 2.4 Hz, 2H, H5' and H5/1),' 2.99-2.92 (m, 
IR, H2'), 1.64 (d, 4JcH3_C5.H6 = 1.2 Hz, 3H, CH3-C5). ESI-
MS for C32H2sCl4N207 [MNa+] ca1cd 717.39, found 717.0. 
1-(2-a.-C -Benzoyloxymethyl-2-deoxy-~-n­
ribofuranosyl)thymine (4) 
To a solution of 3 (1.065 g, 1.53 mmol) in dry MeOH (50 ml) 
was added 10% Pd/C (0.39 g, 0.37 mmol). The resulting mix-
ture was kept shaking under 40-50 psi H2 at room temperature 
for 6 h. The mixture was filtered and evaporated to dryness, 
and the residue was purified by silica gel column chromato-
graphy (eluent 40:1 to 15:1 CH2CI2IMeOH) to separate the a 
and ~-isomers. The desired ~-isomer was obtained in 71 % 
yield (0.41 g). Rf (Si02) = 0.51 (6:1 CH2CI2IMeOH); 0.31 
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(10:1 CH2C12IMeOH); IH NMR (400 MHz, DMSO-d6 , 8): 
11.22 (s, IR, N-H), 7.78-7.41 (m, 5H, Bz), 7.7 (s, IR, 
H-6), 6.14 (d, 311'2' = 8.8 Hz, IR, Hl'), 5.52 (d, 310H 
, " 3 • H3 = 4.8 Hz, IH, HO-C3), 5.1 (t, 10H HS'+HS" = 5.2 Hz, 2 . 3 IH, HO-C5'), 4.57, 4.26 (2dd, 1cH2-c2 = 11.6 Hz, 1cH2-c2. 
H2' = 5.6,8.8 Hz, 2H, CHr C2'), 3.88 (br, IR, H4'), 3.54-3.64 
(AB, dd, 215,.s" = 17.7, 314'.s'+5" = 5.2, 4.8 Hz, 2H, H5' and 
H5"), 2.72-2.29 (m, IR, H2'), 1.74 (s, 3H, CHr C5). Four 
NOESY cross peaks identified the p-isomer: H1'-H4', H2'-
H6', 2'-CHr H4', H5'-H6. ESI-MS for CIgH20N207 [MNa+] 
ca1cd 399.13, found 399.1. Isolated a-isomer, IH NMR (500 
MHz, acetone-d6, 8): 10.11 (s, IR, N-H), 8.02-7.46 (m, 5H, 
Bz), 7.9 (s, IR, H-6), 6.55 (d, 311, 2' = 7.5 Hz, IR, Hl'), 5.13 
(d, 310H. H3' = 3.5 Hz, IH, Ho-ch, 4.66 (m, IR, H3'), 4.52-
4.3 (m, 2H, CHr C2'), 4.48 (m, IR, H4'), 4.19 (br, IR, HO-
C5'), 3.66 (br, 2H, H5' andH5"), 3.33 (m, IR, H2'), 1.82 (s, 3H, 
CH3-C5). ESI-MS for a CIsH20N207 [MNa+] ca1cd 399.13, 
found 399.1. 
1-[2-a-C -benzoyloxymethyl-2-deoxy -5-0-(4-
methoxytrityl)-(3-D-ribofuranosyl]thymine (5) 
Compound 4 (0.555 g, 1.47 mmol) and AgN03 (0.375 g, 2.21 
mmol) were dissolved in dry pyridine (10 ml). The flask was 
purged with N2 and a solution of MMTrCI (0.683 g, 2.21 
mmol) in dry pyridine (5 ml) was added. After stirring for 
6 h at room temperature, the reaction was worked up by evap-
orating most of the pyridine and taking up the residue in 
CH2Clz (20 ml). The solution was washed with saturated 
NaHC03 (20 ml), dried, filtered, and finally evaporated to 
yield the crude product. Purification by silica gel column chro-
matography with 0.5% NEt3 in CH2ClzIMeOH (49:1 to 15:1, 
v/v) afforded the title compound as a white solid (687 mg; 72% 
yield). Rf (Si02) = 0.66 (10:1 CH2CI2IMeOH); IH NMR 
(400 MHz, pyridine-ds, 8): 12.12 (s, IR, N-H), 6.95-5.75 
(m, 19H, ArH), 6.73 (d, 41cH3_cs H6 = 1.2 Hz, IR, H6), 3 , . 5.94 (d, 11'.2'= 12 Hz, IH, Hl ), 4.12-3.83 (m, 3H, CHz-
C2' and H3'), 3.43 (br, m, IR, H4'), 2.48 (s, 3H, OCH3), 
2.45 (m, 2H, H5' and H5"), 2.3 (m, IR, H2'), 0.5 (s, 3H, 
CH3-C5). IH NMR (400MHz, DMSO-d6, 8): 11.26 (s, IR, 
N-H), 7.81-6.88 (m, 19H, ArH), 7.44 (s, IR, H6), 6.2 
(d, II' 2' = 8.8 Hz, IR, Hl'), 5.62 (d, 3 h' OH = 5.2 Hz, 
• 2 . 3 
IH, OH), 4.7, 4.31 (2dd, 1cH2-c2' = 11.2 Hz, 1cH2-c2', 
H2' = 5.2, 8.4 Hz, 2H, CHz-C2'), 4.43 (m, IR, H3'), 4.0 
(br m, IR, H4'), 3.73 (s, 3H, OCH3), 3.27, 3.16 (2dd, 
21s' s" = 10.4 Hz, 314, S'+5" = 6.4, 3.2 Hz, 2H, H5' and 
H5,i), 3.01-2.94 (m, IH, H2'), 1.3 (s, 3H, CHr C5). ESI-
MS for C3gH36N20g [MNa+] ca1cd 671.25, found 671.2. 
1-[2-a-C -benzoyloxymethyl-3-0-tert-
butyldimethylsilyl-2-deoxy-5-0-(4-methoxytrityl) 
-(3-D-ribofuranosyl]thymine (6) 
To a solution of 5 (205 mg, 0.316 mmol) in dry CH2Cl2 was 
added 2,6-lutidine (0.15 ml, 1.26 mmol) under a N2 atmo-
sphere. tert-Butyldimethysilyl triflate (TBDMOTf; 0.218 ml, 
0.948 mmol) was then added dropwise with stirring at room 
temperature to yield a clear yellow solution. After stirring at 
40°C for 12 h, saturated NaHC03 (12 ml) was added. The 
aqueous phase was separated and washed several times with 
CH2CI2. The combined CH2CI21ayers were dried over Na2S04 
and evaporated to dryness. Purification by silica gel column 
chromatography with 0.5% NEt3 in CH2CI2:MeOH (100:1 to 
20:1, v/v) afforded 6 in 72% yield (0.173 g). When the silyla-
tion reaction was conducted at room temperature for 4 h, the 
yield of the title compound increased to 83%. Rf 
(Si02) = 0.64 (15:1 CH2CI2IMeOH); IH NMR (500 MHz, 
DMSO-d6, 8): 11.33 (s, IR, N-H), 7.83-6.88 (l9H, ArH), 
7.5 (s, IR, H6), 6.12 (d, 31l',2' = 8.5 Hz, IR, Hl'), 4.57, 
4.3 (2m, 2H, CHz-C2'), 4.55 (m, IR, H3'), 3.97 (m, IR, 
H4'), 3.71 (s, 3H, OCH3), 3.24 (m, 2H, H5' and H5"), 3.0 
(m, IR, H2'), 1.42 (s, 3H, CHr C5), 0.8 (s, 9H, (-Bu-Si), 0.02, 
-0.06 (2s, 6H, (CH3h-Si). IH NMR (400 MHz, acetone-d6, 
8): 9.94 (s, IR, N-H), 7.96-6.91 (l7H, ArH), 7.61 (s, IR, H6), 
6.35 (d, 3.1 1'.2' = 8.8, IR, Hl'), 4.78-4.42 (m, 3H, H3' 
and CHr C2'), 4.15 (br, m, IR, H4'), 3.79 (s, 3H, OCH3), 
3.44 (m, 2H, H5' and H5"), 3.18 (m, IH, H2'), 1.44 (s, 3H, 
CHr C5), 0.92 (s, 9H, (-Bu-Si), 0.14, -0.08 (2s, 6H, 
(CH3h-Si). ESI-MS for C44HsoN20gSi [MNa+] ca1cd 
785.33, found 758.3. 
1-[3-0-tert-butyldimethylsilyl-2-deoxy -2-a -C-
hydroxymethyl-5-0-(4-methoxytrityl)-(3-D-
ribofuranosyl]thymine (7) 
A saturated solution of NaOMe in MeOH (4 ml) was added to 
6 (0.337 g, 0.442 mmol) at room temperature. After stirring for 
2-3 h, the reaction mixture was washed with saturated 
NaHC03 (10 ml). The aqueous phase was separated and 
washed several times with CH2Clz, The combined CH2Clz 
layers were dried over Na2S04, filtered and evaporated to 
dryness. Purification by silica gel column chromatography 
with 0.5% NEt3 in CH2CI2IMeOH (100:1 to 15:1, v/v) 
afforded 7 in quantitative yield (290 mg). Rf (Si02) = 0.43 
(15:1 CH2CI2IMeOH); IH NMR (400 MHz, DMSO-d6): 
811.30 (s, IR, N-H), 7.47 (s, IR, H6), 7.40-6.89 (m, 14H, 
ArH), 5.93 (d, 311 '.2' = 7.6 Hz, IR, Hl'), 4.57 (d, 310H.H3'= 
4.8 Hz, IR, OH); 4.45 (br m, IR, H3'), 3.90 (br, IR, H4'), 3.73 
(s, 3H, OCH3), 3.68, 3.45 (2m, 2H, CH2-C2'), 3.19 (m, 2H, H5' 
and H5"); 2.53 (m, IR, H2'), 1.51 (s, 3H, CHr C5), 0.82 (s, 9H, 
t-Bu-Si), 0.05, -0.04 (2s, 6H, (CH3h-Si). ESI-MS for 
C37H46N207Si [MNa+] ca1cd. 681.31, found 681.2. 
1-[2-a -C -( «(3-cyanoethyl-N,N-
diisopropylphosphoramidic)-hydroxymethyl)-2-
deoxy-5-0-(4-methoxytrityl)-(3-D-ribofuranosyl] 
thymine (8) 
N-ethyl-N,N-diisopropylamine (0.276 ml, 0.205 g, 1.58 mmol) 
was added to a solution of 7 (0.29 g, 0.44 mmol) in dry THF 
(3 ml) under a nitrogen atmosphere. The reaction was initiated 
by addition of p-cyanoethyl-N,N-diisopropy1chlorophosphor-
amidite via syringe (0.125 g, 0.118 ml, 0.528 mmol). After 2 h, 
the reaction mixture was passed through a 2 cm layer of silica 
gel (pre-neutralized with 1 % NEt3), and the desired compound 
eluted by washing with ice cold hexane followed by CH2CI2. 
Evaporation of the solution afforded the title compound as a 
nice white foam (353 mg, 97% yield). Rf (Si02) = 0.63 (2: 1 
EtOAc/hexane); 31 p NMR (200 MHz, CDCI3, 8): 148.90, 
148.24. ESI-MS for C46H63N40gPSi [MNa+] calcd 881.42, 
found 881.2. 
1-[2-Deoxy-2-a-C -hydroxymethyl-S-O-( 4-
methoxytrityl)-(3-n-ribofuranosyl]thymine (9) 
A saturated solution of NaOMe in MeOH (2 ml) was added to 
S (0.208 g, 0.321 mmol) and the resulting mixture stirred at 
room temperature for 2 h. The reaction mixture was then 
washed with brine (5 ml) followed by CH2Cl2 (20 ml). The 
combined CH2Cl2 layers were dried over Na2S04, filtered and 
evaporated to dryness. Purification by silica gel flash column 
chromatography with 0.5% NEt3 in CH2Cl2/MeOH (15: 1, v/v) 
afforded 9 in quantitative yield (175 mg). Rf (Si02) = 0.26 
(15:1 CH2Cl2/MeOH); IHNMR (400 MHz, acetone-d6, ô): 7.6 
(d, 41cH3_cs.H6 = 1.2 Hz, IR, H6), 7.52-6.91 (m, 14H, ArH), 
6.21 (d, 3l l , 2' = 8.4 Hz, IR, Hl'), 4.65 (br, m, IR, H3'), 4.1-
, 2 3 
4.12 (m, IR, H4'), 3.98, 3.79 (2dd, lCH2-c2' = 11.2 Hz, .leH2-
r2'. H2' = 10.0, 6.8 Hz, 2H, CHr C2'), 3.42-3.35 (AB, dd, 
ls' 5" = 9.6 Hz, 3 l4' 5'+S" = 4.0, 3.2 Hz, 2H, H5' and H5"), 
, " 1 
2.64-2.71 (m, IR, H2), 1.49 (s, 3H, CHr C5). H NMR (500 
MHz, DMSO-d6 , ô): 1l.3 (s, IR, N-H); 7.47 (s, IR, H6); 7.39-
6.89 (m, 14H, ArH); 5.97 (d, 311, 2' = 8.5 Hz, IR, Hl'), 5.3 (d, 
31oH, H3' = 5.5 Hz, IR, 3-0H);'4.54 (bs, IR, C2'-C-OH); 4.3 
(bs, IR, H3'); 3.91 (m, IR, H4'); 3.73 (s, 3H, OCH3); 3.74-
3.43 (2m, 2H, CHr C2'); 3.2, 3.12 (2dd, 21s' S" = 10.5 Hz, 
314'.5'+s" = 4.5, 3.0 Hz, 2H, H5' and H5"), '2.45 (m, IH, 
H2'), 1.4 (s, 3H, CH3-C5); ESI-MS for C31H32N207 
[MNa+] calcd 567.22, found 567.2. 
1-[2-a-C -tert-butyldimethylsilyloxymethyl-2-deoxy -S-
0-( 4-methoxytrityl)-(3-D-ribofuranosyl]thymine (10) 
To a solution of 9 (0.186 g, 0.342 mmol) in dry pyridine (3 ml) 
under a N2 atmosphere was added AgN03 (0.067 g, 0.393 
mmol) followed by TBDMSCI (59 mg, 0.393 mmol). After 
stirring for 12 h at room temperature, the reaction was con-
centrated and the residue taken up in CH2Ch. The solution was 
washed with saturated NaHC03 (10 ml), dried, filtered, and 
finally evaporated to yield the cru de product. Purification by 
silica gel column chromatography with 0.5% NEt3 in CH2Cl2/ 
MeOH (100:1 to 15:1, v/v) afforded the title compound in 66% 
yield (148 mg). Rf (Si02) = 0.64 (15:1 CH2CI2/MeOH); IH 
NMR (300 MHz, DMSO-d6 , ô): 11.25 (s, IR, N-H); 7.47 (s, 
IR, H6); 7.39-6.87 (m, 14H, ArH); 6.08 (d, 311 ',2' = 8.7 Hz, 
IR, Hl'); 5.32 (d, 31oH, H-3' = 4.8 Hz, IR, OH); 4.31(br m, IR, 
H3'); 3.98-3.64 (m, 2H, CHr C2'); 3.73 (s, 3H, OCH3); 3.23, 
3.13 (2dd, 314',s'+s" = 4.2, 3 Hz, 2H, H5' and H5"); 2.57 
(m, IR, H2'); l.37 (s, 3H, CH3-C5); 0.79 (s, 9H, t-Bu-Si); 
0.01- -0.04 (t, 6H, (CH3hSi); ESI-MS for C37H46N207Si 
[MNa+] calcd 681.31, found 681.2. 
1-[2-a-C -tert-butyldimethylsilyloxymethyl-3-0-(I3-
cyanoethyl-N,N-diisopropylphosphoramidic)-2-deoxy-
S-0-(4-methoxytrityl)-I3-D-ribofuranosyl]thymine (11) 
~-Cyanoethyl-N,N-diisopropylchlorophosphoramidite (32 /-lI, 
0.034 g, 0.145 mmol) was slowly added to a solution of 10 
(0.148 g, 0.121 mmol) and N-ethyl-N,N-diisopropylamine 
(76 /-lI, 0.056 g, 0.436 mmol) in dry THF (1.2 ml) under a 
N2 atmosphere. After stirring for 2.5 h, the crude mixture was 
passed through a 2 cm layer of silica gel (pre-neutralized with 
1 % NEt3), and the desired compound eluted by washing with 
ice cold hexane followed by CH2Ch. Evaporation of the solu-
tion afforded the title compound as a nice white foam (101 mg, 
52% yield). Rf (Si02) = 0.46 (2:1 EtOAc/hexane); 31p NMR 
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(200 MHz, CDCI3): Ô 151.7, 150.3; ESI-MS for 
C46H63N40SPSi [MNa+] calcd 881.42, found 881.2. 
Solid-phase synthesis of oligonucleotides 
Oligonucleotide syntheses were carried out on a 1 /-lmol scale 
using an Applied Biosystems DNAIRNA 381A synthesizer as 
described previously (1,3,15). Solutions of phosphoramidites 
8 and 11 in acetonitrile (0.09 M) were allowed to react with the 
solid support for an extended coupling time of 30 min using 
DCI in acetonitrile (O. SM) as catalyst. These conditions 
afforded >99% coupling efficiency. Deprotection was conduc-
ted by addition of(i) conc. aq. ammonialethanol (3:1, v/v, 1 ml, 
48 h, room temperature) followed by evaporation; 
(ii) TEA.3HF (100-200 /-lI, 48 h, room temperature) followed 
by evaporation. Typically, 40-80 OD units (A260) of the oli-
gonucleotides were obtained at this point. Oligonucleotides 
were purified by anion-exchange high-performance liquid 
chromatography (HPLC) (Protein Pak DEAE-5PW column-
Waters; 7.5 mm x 7.5 cm), desalted by size-exclusion chro-
matography on Sephadex 0-25 matrix, and characterized by 
MALDI-TOF mass spectrometry (Kratos Kompact-III instru-
ment; Kratos Analytical Inc., NY). Purity of the isolated oli-
gonucleotides was >95%. 
UV thermal denaturation studies 
UV thermal denaturation data were obtained on a Varian 
CARY 1 spectrophotometer equipped with a Peltier temper-
ature controller (Varian, Mulgrave, Australia). Oligomers and 
complementary targets were mixed in equimolar ratios in 
140 mM K+, 1 mM Mg2+ and 5 mM Na2HP04 buffer, 
pH 7.2, which is representative of intracellular conditions 
(16). The total strand concentration was 2.6 /-lM. Samples 
were heated ta 90°C for 5 min, cooled slowly to room tem-
perature, and refrigerated (4°C) overnight before measure-
ments. Prior to the thermal run, samples were degassed by 
placing them in an ultrasound bath for 1 min. Denaturation 
curves were acquired at 260 nm at a rate of heating of 
0.5°C/min. The data were analyzed with the software provided 
by Varian Canada and converted to Microsoft Excel. Tm values 
were calculated as the maximum ofthe first-derivative plots of 
absorbance versus temperature and have an uncertainty of 
± 1 oC. Hyperchromicity values (i.e. changes in relative absorb-
ance) were calculated using the formula: H = (A, - Aj)/Ah , 
where H is the hyperchromicity, At is the absorbance at any 
given temperature (t), Ai is the initial absorbance reading, and 
Ah is the absorbance at the highest temperature. 
Circular dichroism spectra 
CD spectra (200-350 nm) were collected on a Jasco J-71O 
spectropolarimeter at a rate of 100 nmlmin using fused quartz 
cells (Hellma, 165-QS). Measurements were carried out in 140 
mM K+, 1 mM Mg2+ and 5 mM Na2HP04 buffer, pH 7.2 (15) 
at a duplex concentration of 2.6 /-lM. The temperature was 
controlled by an external circulating bath (VWR Scientific) at 
constant temperature (5°C). The data were processed on a PC 
computer using J-700 Windows software supplied by the 
manufacturer (JASCO, Inc.). To facilitate comparisons, the 
CD spectra were background subtracted, smoothed and cor-
rected for concentration so that molar ellipticities could be 
obtained. 
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Scheme 3. Synthesis of 11. (i) NaOMe, MeOH, room temperature, 2 h, 100%; (ii) TBOMSCI, AgNO" py, room temperature, ovemight, 66%; (iii) iPr2NEt, 
(iPr2N)(OCH2CH2CN)pCI, THF, room temperature, 2.5 h, 52%. 
RESUL TS AND DISCUSSION 
Monomer synthesis 
Schemes 2 and 3 show the synthesis of 2'-a-hm-dT (abbrevi-
ated in this work as 'H') and its conversion to the 2'-CH20- (8) 
and 3'-O-phosphoramidites (11), using a synthetic strategy 
analogous to that described previously by Schmit (17) and 
Li and Piccirilli (18). We protected the C2'-CH2-OH moiety 
of O-glycoside 1 (14) as the benzoyl ester rather than as 
Schmit's acetyl ester, since we found that the latter was not 
stable under the conditions of the subsequent hydrogenolysis 
reaction (Scheme 2). Coupling of 2 with bis(trimethylsi-
lyl)thymine in the presence of SnCl4 catalyst gave anomeric 
nucleosides 3 in good yield with a ~/a stereoselectivity of 5: 1. 
It is interesting to note that the Pla stereoselectivity was found 
to be higher for the C2-CHr OAc derivative (10: 1), in agree-
ment with Schmit's findings (12,17). Separation of the anom-
ers by column chromatography was achieved after removal 
of the 2,4-dichlorobenzyl protecting groups, to provide the 
desired ~-anomer in 71% yield from 3. The anomeric 
configuration of 4 was unequivocally established using 
NOESY NMR, which displayed strong Hl'-H4', H2'-H6', 
2'-CHr H4', and H5'-H6 cross peaks. Reprotection of 
hydroxyl groups with MMTrCI followed by TBDMSOTf 
gave 6 in good yields (19). Attempts to carry out the silylation 
reaction with TBDMSCI (DMF/imidazole or AgN03/py) 
proved to be problematic (20). Lastly, we converted 6 to 
the 2'-CH20-phosphoramidite derivative 8 via consecutive 
debenzoylation and phosphitylation reactions (Scheme 2). 
To access the 3'-O-phosphoramidite derivative, nucleoside 
5 was treated with NaOMe to give diol 9 quantitatively. Con-
secutive silylation with TBDMSCI (AgNOipy) and phos-
phitylation reactions then afforded the desired compound 11 
in moderate yield (52%) (Scheme 3). 
Oligonucleotide synthesis 
To investigate the effect of 2' ,5'- and 3' ,5'-linked H units on 
the stability of duplexes, monomers 8 and 11 were incorpor-
ated into various oligonucleotide sequences by conventional 
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Table 1. Thennal denaturation data (Tm) of duplexes 
No. Designation Oligonucleotide Tm' (/)"Tm)" 
DNA RNA 2',5'-RNA 
2',5'-RNA containing 2',5'-H (H) and 3',5'-H (!!)' 
1 2,5RNA 5'-rGUC GUG UGU GUG ACU CUG GUA AC-2' br" 61.6 41.3 
II 2',5'-H 5'-rGUC UGU HGU GUG CUG GUA AC-2' br 60.7 (-0.9) 40.5 (-0.8) 
III 2'-5'-Hx2 5'-rGUC UGH HGU GUG ACU CUG GUA AC-2' br 60.6 (-0.5) 40.0 (-0.7) 
IV 2',5'-Hx3 5'-rGUC UGH HGH GUG ACU CUG GUA AC-2' br 60.5 (-0.3) 39.1 (-0.6) 
V 2',5'-rA 5'-rGUC UGU AGU GUG ACU CUG GUA AC-2' br 56.8 (-4.8) 37.3 (-3.5) 
VI 2',5'-rA x2 5'-rGUC UGA AGU GUG ACU CUG GUA AC-2' br 54.3 (-3.7) 34.0 (-3.7) 
VII 2',5'-rA x3 5'-rGUC UGA AGA GUG ACU CUG GUA AC-2' br 48.0 (-4.5) 28.0 (-4.3) 
VIII 3',5'-H 5'-rGUC UGU HGU GUG ACU CUG GUA AC-2' br 58.0 (-3.6) 37.4 (-3.9) 
RNA containing 2',5'-H (H) and 3',5'-H (H) 
IX RNA 5'-rGUC UGU UGU GUG ACU CUG GUA AC-3' 65.0 78.4 57.1 
X 2',5'-H 5'-rGUC UGU HGU GUG ACU CUG GUA AC-3' 62.0 (-3.0) 77.2 (-1.2) 52.8 (-4.3) 
XI 3',5'-H 5'-rGUC UGU HGU GUG ACU CUG GUA AC-3' 63.0 (-2.0) 77.7 (-0.7) 54.1 (-3.0) 
XII 2',5'-rU 5'-rGUC UGU UGU GUG ACU CUG GUA AC-3' 62.0 (-3.0) 78.0 (-0.4) 54.1 (-3.0) 
XIII 3',5'-rA 5'-rGUC UGU AGU GUG ACU CUG GUA' 61.1 (-3.9) 74.1 (-4.3) 51.1 (-6.0) 
DNA control 
XIV DNA 5' -dGTC TGT TGT GTG ACT CTG GT A AC-3' 68.0 69.0 br 
UT m in oC, deviation ±1 oC; complementary DNA sequence 5'-dGUU ACC AGA GUC ACA CAA CAG AC-3'; complementary RNA sequence, 5'-rGUU ACC AGA 
GUC ACA CAA CAG AC-3'; complementary 2' ,S'-RNA sequence, 5'-GUU ACC AGA GUC ACA CAA CAG AC-2'; buffer, 140 mM K+, 1 mM Mg2+ and 5 mM 
Na2HP04, pH = 7.2. 
b /),.T m' the Tm change per one modified nucleotide or mismatch relative to entries 1 or IX. 
c2',5'-H is shown as H; 3',5'-H as H; 2',5'-rA as A, 3',5'-rA as A; 2',5'-rU as U in the sequence. 
dBroad transition. - -
phosphoramidite chemistry (Table 1) (1,15,20). 4,5-
Dicyanoimidazole (DCI) was used to activate the phosphor-
amidites (15) and provided average coupling efficiencies of 
99% as monitored by the release of the monomethoxytrityl 
(MMT) cation (Materials and Methods). Deprotection condi-
tions of oligonucleotides were similar to those employed in 
RNA synthesis (20). Oligonucleotides were purified by anion-
exchange HPLC and their identity verified by MALDI-TOF 
mass spectrometry (Supplementary Data). The HPLC chroma-
tograms showed that 2' ,5'-RNA oligomers elute more rapidly 
relative to 3' ,5'-RNA oligomers of the same base composition 
(Supplementary Data). 
Hybridization studies (Tm and CD analysis) 
The binding affinity of various mixed backbone oligonuc-
leotides with one to three H units to complementary single-
stranded DNA (ssDNA), ssRNA and 2',5'-ssRNA targets was 
evaluated in a buffer designed to simulate intracellular con-
ditions (Table 1). The oligomers, 23 nt in length, were com-
plementary to portions of the U5 region of HIV-l genomic 
RNA. Oligomers containing 2',5'-H substitutions (II-IV, X), 
3',5'-H substitutions (VIII, XI) or mismatched bases (V-VII, 
XIII) were prepared in order to ascertain Watson-Crick pair-
ing of the H residues. As a comparison, the hybridization 
properties of unmodified 2',5'-RNA (1), RNA (IX) and 
DNA (XIV) sequences were also measured, along with a 
3' ,5'-linked oligomer containing a single 2' ,5'-linked uridine 
residue (XII). Thermal dissociation data (Tm, t..T m) for the 
complexes formed are presented in Table 1 and representative 
melting and CD curves are shown in Figure 3. The key obser-
vations can be summarized as follows. 
2' ,5'-H substitutions in the 2' ,5'-RNA strand. Both 2',5'-
RNA:RNA and 2',5'-RNA: 2',5'-RNA duplexes can accom-
modate a single 2' ,5'-H residue with a small 10ss of stability 
(t..T m '" -0.8-0.9°C). This destabilization is significantly 
smaller than that created by a mismatch at the same position 
(t..Tm '" -4°C ), suggesting that 2',5'-H residues in these 
duplexes retain classical base-pairing interactions. When the 
number of 2',5'-H units is increased to three (e.g. hybrid 
IV:RNA) the depression in Tm is only -O.3°C/modification, 
suggesting a stabilizing effect by the nearly contiguous 2' ,5'-H 
residues (Figure 3A). A nearly superimposable CD signature 
of the singly and triply substituted hybrids (II:RNA and 
IV:RNA) with control duplex I:RNA was observed, strongly 
suggesting that the 2' ,5'-H inserts do not perturb the global 
morphology of the duplexes (Figure 3C). The affinity towards 
RNA targets is likely to be dependent upon the ratio and 
intrastrand placement of normal (2',5'-rN) and 2',5'-H units, 
and based on the above results, a smaller thermal destabiliza-
tion is to be expected upon increasing the number of consec-
utive H residues. In fact, based on the observed trend from one 
to three inserts, a fully-modified strand constructed from 2' ,5'-
H units might possibly have a binding affinity to RNA targets 
comparable with that of 2' ,5'-RNA. 
The mode st destabilization induced by 2' ,5'-H units is 
remarkable in view of the one bond chain extension introduced 
at each of these residues compared with 2',5'-RNA (Figure 1 
and Scheme 1). In addition to the energy (electrostatic) con-
siderations described above, these phenomena may be 
explained by the anticipated conformation of the 2',5'-H 
units (Figure 2). Yathindra and coworkers (10,11) have 
shown that the sugars of 2',5'-linked RNA favor a C2'-endo 
conformation, which renders the backbone to be 'compact' 
and of almost equivalent length to that found in the native 
RNA (i.e. C3'-endo). With the C3'-endo sugar, the 3'-hydroxyl 
group would sterically interfere with the 2'-D-phosphate link-
ages. The same 'compact' conformation is expected for 2',5'-
H residues, since a strong 04'-C4'-C3'-03' gauche effect (and 
lack of an opposing 04'-Cl'-C2'-02' gauche effect) would 
reinforce the C2'-endo pucker (Figure 2). Hence, oligonuc-
leotides that are pre-organized in a 'compact' (or RNA-like) 
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Figure 3. Buffer: 140 mM K+, 1 mM Mg2+ and 5 mM Na2HP04, pH 7.2. Oligonuc1eotides were hybridized to complementary RNA (A and C) Thermal melting 
curves and CD profile, respectively, of 2' ,S'-RNA with 2' ,S'-H, 3' ,S'-H and mismatch 2',S' -rA. (B and D) Thermal melting curves and CD profile, respectively, of 
RNA with 2',5'-H, 3',S'-H, 2',5'-rU and mismatch 3',S'-rA. 
conformation are expected to bind to 'compact' RNA strands, 
and bind weakly, if at ail, to 'extended' oligonucleotide targets 
(e,g, ssDNA), Such conformational compatibility or spatial 
'matching' probably accounts for the ability of oligonuc-
leotides 1 through VDI to maintain a stable association 
with complementary RNA, but not with ssDNA (Table 1) (1), 
2',S'-H substitutions in the RNA strand and 3',5' -H substitu-
tions in the 2',5' -RNA strand, The destabilizing effect of 2',5'-
H units appears to be greater when incorporated into RNA 
strands (i1T m > -lOC/modification), regardless of whether the 
target is complementary RNA or 2',5'-RNA (Sequence X, 
Table 1). Similarly, the presence of 3',5'-H within 2',5'-
RNA leads to reduced duplex stability, with an equal destabil-
ization observed when targeting both RNA and 2',5'-RNA 
(Sequence VID, Table 1), Consistent with this notion, the 
singly-substituted hybrids VDI:RNA and X:RNA showed a 
blue shift in the CD band at 270 nm, whereas hybrids D:RNA 
and XI:RNA displayed nearly the same CD profile as the 
corresponding unmodified controls (Figure 3C and D), As 
pointed out previously (l,II), these observations may reflect 
the major disruption in the normal helical structure induced by 
the abrupt displacement of the backbone from the periphery 
towards the interior of the helix (2' -CH20P to 3' -OP) and vice 
versa (3' -OP to 2' -CH20P). 
3',5' -H substitutions in the RNA strand. Regarding the effects 
of 3' ,5' -H units within an RNA strand on hybridization affinity 
for complementary RNA, a significantly less pronounced 
decrease in duplex stability was observed in RNA:RNA 
duplexes (i1Tm = -0,7°C) than for Schmit's DNA:RNA 
hybrids (3',5'-H in the antisense DNA strand; i1T m 
-3°C) (12). It may be speculated that this is caused, at 
least in part, by the narrower minor groove width of 
DNA:RNA hybrids (compared with RNA:RNA) leading to 
more unfavorable interactions involving the large 2'-CHz-
OH group. A much larger decrease in binding affinity was 
observed for the RNA strand containing a mismatch, confirm-
ing the contribution of the thymine base of 3' ,5' -H to binding 
(XID:RNA versus XI:RNA; Table 1). 
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Stabilization of hairpin structures by 2' ,S'-H units 
We next tumed our attention towards RNA 'hairpins' and 
studied the effect of incorporating single or multiple 2' ,5'-H 
units into the loop of these structures (Figure 4A and Table 2). 
We have shown previously that hairpin Pl retains an A-form 
conformation, displays ample resistance against nucleases, 
and inhibits the RNase H activity of HIV RT (15,21,22). 
The ribonucleotide residues in the Joop are connected by 
2' ,5'-phosphodiester linkages and collectively fold into a dis-
tinct rigid structure that is unlike the native 3' ,5'-tetraloop 
structure (15). In view of the anticipated compact conforma-
tion of 2',5' -H residues (Figure 2), it was of interest to discover 
how these units would influence the stability of the hairpin. 
This was particularly intriguing given that a recent study by 
Denisov et al. (22) showed that the 2' ,5'-rUCCG Joop 
residues of hairpin Pl adopt a U5(extended)-U6(compact)-
C7(compact)-G8(extended) conformation. Therefore, we anti-
cipated that substitution at position 6 would be better tolerated 
Table 2. Thermal denaturation data of RNA hairpins with modified 2' ,5'-linked 
loops 
ID Designation Hairpin loop Tm' (dTm)" 
PI RRR 5'-GGAC(UUCG)GUCC-3' 64.7 
P2 RR(Hs)R 5'-GGAC(HUCG)GUCC-3' 63.7 (-1.0) 
P3 RR(H6)R 5'-GGAC(UHCG)GUCC-3' 66.2 (+1.5) 
P4 RR(Hs.6)R 5'-GGAC(HHCG)GUCC-3' 65.1 (+0.2) 
·Underlined residues are connected via 2',5'-phosphodiester linkages. 
bTm was measured at the wavelength of 260 nm in 0.01 M Na2HP04 and 
0.1 mM Na2EDTA, pH 7.0; oligonucIeotide concentration ~4.5 ~M. Values 
represent the average of at least five independent measurements. Error in 
Tm is within ±I oc. 
cdT,m the Tm change per one 2',5'-H(represented as Hin the sequence). 
than one at position 5, particularly if the compact conforma-
tion of the 2' ,5'-H unit was preserved at both loop positions. 
Indeed, we found that a 2' ,5'-H unit at position 6 (P3) increases 
hairpin stability, with an increase in Tm of + 1.5°C relative to 
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the parent hairpin Pl (Table 2). This stabilization is nearly 
offset by the incorporation of a second 2' ,5'-H unit at position 
5 (P4, !l.T m = +Ü.2°C), which may again be rationalized on the 
basis of a very strong preference of the 2',5'-H unit for a 
compact (C2'-endo) conformation. In view of this, it is not 
surprising that a single 2' ,5'-H substitution at position 5 (P2), 
where an extended nucleotide conformation is preferred, is 
destabilizing (!l.T m = -1.0°C). Regarding the CD profiles, 
the solution conformations of all hairpins are similar to that 
of the control Pl, with only slight variations in the intensity of 
the bands. The hairpins containing 2',5'-H units at position 5 
(P2 and P4) were found to present a reduction in the positive 
CD band at 260 nm (Figure 4D) relative to Pl and P3, con-
sistent with the expected conformational change at this posi-
tion, i.e. extended 2',5'-rU-+compact 2',5'-H. 
CONCLUSIONS 
In summary, we have studied the behavior of oligoribonuc-
leotides (2',5'-RNA and RNA) containing H units toward 
complementary RNA, 2',5' -RNA and DNA. The data obtained 
demonstrated a destabilization effect upon substituting a rU 
with H, regardless of whether H was 2' ,5' or 3' ,5'-linked. This 
destabilization was minimized when the 2',5'-H and 3',5'-H 
were incorporated into 2',5'-RNA and RNA strands, respect-
ively (!l.T m < -1.0°C). It is expected that longer oligomers 
containing this modification, particularly if they contain 2',5'-
linkages, will show adequate thermal stability, significant 
nuclease stability (23) and binding to mRNA targets. 
In spite of the drop in thermal stability observed when 
2' ,5'-H units are incorporated into RNA duplexes, a significant 
increment in stability was observed when they were incorpor-
ated into hairpin loops (!l.T m = + 1.5°C). These results and 
those described above lend strong support to the notion of 
• compact' l'extended' 2',5'/3' ,5'-backbone structure and its 
effect on hybrid stability (11). The ability of hairpins contain-
ing stabilizing 2',5'-H units to inhibit HIV RT in vitro will be 
the subject of a separate publication. 
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Table 1. Apparent Fidelity of FANA Synthesis in Dropout Assays 
% apparent fidelity' 
poIymerase 2'F·araNTP dNTP template used figure 
Ph A: >99% >99% PF21 3 
G: >99% >99% 
T: >99% >99% 
C: >99% >99% 
DV A: >99% 1% PF41 2 
G: >99% 62% PF43 S3 
T: 3% 19% PF21 S4 
C: 50% 3% PF23 S4 
9N A: >99% 80% PF41 2 
G: 98% 84% PF43 S3 
T: 76% 32% PF21 S4 
C: 43% 82% PF23 S4 
" Apparent fidelity is calculated according to the equation 1 - [(% full· 
length-2'F-araNTP)I (% full-length+2'F-araNTP)] at 30 min reaction time 
(sample equation for dNTP vaIues); >99% means that the full-Iength product 
is not detectable in our dropout assays. 
Prîmer (Pf20) 
ONA templale (PF21) 
S' -lIP-~Al.::-A,Y; • .'I.C~\:AC-r:\,j·].- J' 
:.' ~ }L:'r .... !.n?~l'\ù;$l·,;;/ .. J.~!d .. , CC(':T:~1'r:'tCt· . .(C-;;':··!,·:· -' 
ExQ8Cf!d prpducf ! Ph. tripho.ph ••• condition 1~ 
1_ 2'F .. araNTPs (Ail) '). -:u-P-TA..:"TA~~r:;AL:T{.'AC':'':'TA-~- ~. 
2. Drop out 2"F·.ntCTP (AGT) :" _:12P-·!'AATA::'·GAC'l'::dV:·:-!,'1'J'.-GGGAGII~- j' 
3, Drop out TF ...... TTP (AGe) i) 1_U:P-'I',·t:~TP,CG?GTCÙ(,"':'Nrli-~MUlG- 3' 
•. Orop our 2"F-araATP (eTG) S '_l2p-'I'AATA:'::-C?.CTC:AC:'AT,;-GQG-3· 
S, Drop out 2'F·.",OTP (CTA) ';' -"p-~"A~ACCAC"'Cl,c:'l·Sl,- 3 ' 
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---~ 
Figure 3. Fidelity study on 2'F-araNTP incorporation by Ph on DNA tem-
plate PF21. Reaction conditions: 0.8 unit Ph, 25,uM triphosphate at 55 oc 
in 30 ,uL of reaction volume for 30 min. Lane l, dNTPs; lane 2, drop out 
dCTP (Le., dATP, dGTP, and dTTP, shorten as AGT; same coding for 
lanes 3-5), lane 6, 2'F-araNTPs; lane 7, drop out 2'F-araCTP (i.e .. 2'F-
araATP, 2'F-araGTP, 2'F-araTTP, shorten as AGT; same coding for lanes 
8-10). Template PF41 and primer PF20 are shown; PF39 is a 27-nt DNA 
controL 
thennophilic polymerases (e.g., the error rates for Ph25 and Dy26 
are 4.4 x 10-7 and 2.2 x 10-4, respectively). Ali four dropout 
experiments were conducted with the same DNA template PF21 
(Figure 3), or PF41 (Figure S5, Supporting Infonnation). For the 
dNTPs, syntheses stopped at the expected tennination sites, yielding 
products lacking the required dNTP at the 3'-tenninus. A similar 
pattern was observed with 2'F-araNTPs, although in the latter, 
FANA synthesis proceeded with more difficulty (Figure 3; lanes 
6-10). This effect, however, was observed only in the dropout 
assays, that is, the reaction containing all four 2'F-araNTPs produced 
excellent yieJds of the full-length FANA product with virtually no 
pausing observed. We speculate that in a dropout assay, where 
polymerization activity is suboptimal, the pausing bands observed 
may resuIt, at least in part, by the shuttling (cycling) between the 
strong Ph 3'-5' exonuclease and polymerase activities. 1R•27 Similar 
results were observed with the DNA template PF41 (Figure S5). 
Of note, apparent fidelity among Ph, DY, and 9N is correlated to 
3'-5' exonuclease proofreading activity, with Ph having the strongest 
exonuclease activity and also 2'F-araNTP fidelity, and DY having 
no exonuclease activity and low 2'F-fideJity. We recently became 
aware of Wengel's work that Ph can incorporate a few LNA 
triphosphates in a growing DNA strand.2R Thus, FANA and LNA 
NTPs appear to be the first examples of modified NTPs incorporated 
by Ph. 
COMMUNICATIONS 
We are currently testing the Iimits ofthese procedures by explor-
ing the synthesis of (a) DNA-FANA on a DNA-FANA template 
and (b) DNA on an ali-FANA template. Preliminary results obtained 
indicate that DY, 9N, and Ph can synthesize FANA-DNA strands 
on FANA-DNA templates (Figure S6, Supporting Infonnation), 
and that KF and Bst DNA can catalyze FANA template-directed 
DNA synthesis (Figure S7, Supporting Infonnation). While we have 
not been able to synthesize an ali-FANA strand on an ali-FANA 
template, it is possible for DY, 9N, and Ph polymerase to drive 
the fonnation ofmultipJe FANA-FANA base pairs within a DNA-
FANA chimeric duplex (Figure S6; Supporting Infonnation). 
In summary, family B thermophilic DNA polymerases such as 
DY, 9N, and Ph can utilize 2'F-araNTPs, or a combination of 2'P-
araNTPs and dNTPs, to generate FANA or chimeric FANA-DNA 
strands, respectiveJy. In addition, these polymerases were shown 
to synthesize chimeric FANA-DNA strands on a chimeric FANA-
DNA template. KF and Bst (family A) DNA polymerases were 
able to incorporate dNTPs on a template FANA strand. These results 
suggest that it should be possible to evolve FANA-modified 
aptamers via SELEX. 
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